"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B1,US 10021212 B1,003-832-328-210-513,2018-07-10,2018,US 201514671675 A,2015-03-27,US 201514671675 A;;US 201462088427 P,2014-12-05,Distributed file systems on content delivery networks,"A method, article of manufacture, and apparatus for accessing a distributed file system using a content delivery network is discussed. An IO request for an object is received at a metadata server comprising metadata mapping a plurality of objects to an object store. An object identifier associated with the object and a CDN domain associated with the object store are determined. A URL is generated from the object identifier and the CDN domain. The URL is then returned to the client.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/003-832-328-210-513,Granted Patent,yes,46,12,6,15,0,H04L67/1097;;G06F16/182;;H04L67/561;;H04L67/1097;;G06F16/182;;G06F16/1827;;G06F12/0833;;G06F12/121;;G06F2212/62;;H04L67/561,G06F15/16;;H04L29/08,,12,0,,,"U.S. Appl. No. 14/671,740, filed Mar. 27, 2015, Rajiv Desai, et al.;;U.S. Appl. No. 14/673,071, filed Mar. 30, 2015, Rajiv Desai, et al.;;U.S. Appl. No. 14/864,399, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/864,425, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/865,333, filed Sep. 25, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,424, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,480, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,520, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 15/199,599, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/199,617, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/199,624, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/388,805, filed Dec. 22, 2016, Shrinand Javadekar, et al.",ACTIVE
2,US,A1,US 2018/0322141 A1,058-963-773-746-83X,2018-11-08,2018,US 201816031775 A,2018-07-10,US 201816031775 A;;US 201514671675 A;;US 201462088427 P,2014-12-05,DISTRIBUTED FILE SYSTEMS ON CONTENT DELIVERY NETWORKS,"A method, article of manufacture, and apparatus for accessing a distributed file system using a content delivery network is discussed. An IO request for an object is received at a metadata server comprising metadata mapping a plurality of objects to an object store. An object identifier associated with the object and a CDN domain associated with the object store are determined. A URL is generated from the object identifier and the CDN domain. The URL is then returned to the client.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/058-963-773-746-83X,Patent Application,yes,0,4,6,15,0,H04L67/1097;;G06F16/182;;H04L67/561;;H04L67/1097;;G06F16/182;;G06F16/1827;;G06F12/0833;;G06F12/121;;G06F2212/62;;H04L67/561,G06F17/30,,0,0,,,,ACTIVE
3,US,A1,US 2020/0026690 A1,133-321-220-201-630,2020-01-23,2020,US 201916588009 A,2019-09-30,US 201916588009 A;;US 201615080437 A;;US 201514755789 A,2015-06-30,GLOBAL DATA DEDUPLICATION ACROSS MULTIPLE DISTRIBUTED FILE SYSTEMS,"A write request is transmitted from a client to a metadata server (“MDS”), wherein the write request comprises an object identifier associated with a data object. An object store location is received for an object store from the MDS. A metadata request is transmitted to the object store using the object store location, wherein the metadata request includes the object identifier. A metadata response is received from the object store. Determine the metadata response contains an object designator. A count associated with a mapping between the object identifier and the object designator is incremented, wherein the mapping resides on an object version manager shared with a second MDS.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2016-03-24);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/133-321-220-201-630,Patent Application,yes,8,1,3,7,0,G06F16/1748;;G06F16/182;;G06F16/1748;;G06F16/182,G06F16/174;;G06F16/182,,0,0,,,,ACTIVE
4,US,A1,US 2020/0301912 A1,140-697-405-697-07X,2020-09-24,2020,US 202016899199 A,2020-06-11,US 202016899199 A;;US 201615080448 A;;US 201514755789 A,2015-06-30,DATA DEDUPLICATION ON A DISTRIBUTED FILE SYSTEM USING CONDITIONAL WRITES,"A write request is transmitted from a client to a metadata server (“MDS”), wherein the write request comprises an object identifier associated with a data object. An object store location for an object store is received from the MDS. A conditional write request is transmitted to the object store using the object store location, wherein the conditional write request includes the object identifier and the data object. A metadata response is received from the object store. The metadata response is determined to contain an object designator. A commit request is transmitted to the MDS, wherein the commit response includes the object designator.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2016-03-24);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/140-697-405-697-07X,Patent Application,yes,13,0,3,7,0,G06F16/1748;;G06F16/2379;;G06F16/2379;;G06F16/1748,G06F16/23;;G06F16/174,,0,0,,,,ACTIVE
5,US,B2,US 10353873 B2,062-921-783-896-849,2019-07-16,2019,US 201816031775 A,2018-07-10,US 201816031775 A;;US 201514671675 A;;US 201462088427 P,2014-12-05,Distributed file systems on content delivery networks,"A method, article of manufacture, and apparatus for accessing a distributed file system using a content delivery network is discussed. An IO request for an object is received at a metadata server comprising metadata mapping a plurality of objects to an object store. An object identifier associated with the object and a CDN domain associated with the object store are determined. A URL is generated from the object identifier and the CDN domain. The URL is then returned to the client.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/062-921-783-896-849,Granted Patent,yes,68,5,6,15,0,H04L67/1097;;G06F16/182;;H04L67/561;;H04L67/1097;;G06F16/182;;G06F16/1827;;G06F12/0833;;G06F12/121;;G06F2212/62;;H04L67/561,G06F15/16;;G06F16/182;;H04L29/08,,12,0,,,"U.S. Appl. No. 14/671,740, filed Mar. 27, 2015, Rajiv Desai, et al.;;U.S. Appl. No. 14/673,071, filed Mar. 30, 2015, Rajiv Desai, et al.;;U.S. Appl. No. 14/864,399, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/864,425, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/865,333, filed Sep. 25, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,424, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,480, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,520, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 15/199,599, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/199,617, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/199,624, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/388,805, filed Dec. 22, 2016, Shrinand Javadekar, et al.",ACTIVE
6,US,B2,US 11809377 B2,119-540-990-506-652,2023-11-07,2023,US 201916588009 A,2019-09-30,US 201916588009 A;;US 201615080437 A;;US 201514755789 A,2015-06-30,Global data deduplication across multiple distributed file systems,"A write request is transmitted from a client to a metadata server (“MDS”), wherein the write request comprises an object identifier associated with a data object. An object store location is received for an object store from the MDS. A metadata request is transmitted to the object store using the object store location, wherein the metadata request includes the object identifier. A metadata response is received from the object store. Determine the metadata response contains an object designator. A count associated with a mapping between the object identifier and the object designator is incremented, wherein the mapping resides on an object version manager shared with a second MDS.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2016-03-24);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/119-540-990-506-652,Granted Patent,yes,24,0,3,7,0,G06F16/1748;;G06F16/182;;G06F16/1748;;G06F16/182,G06F16/174;;G06F16/182,,0,0,,,,ACTIVE
7,US,A1,US 2019/0340158 A1,091-614-047-524-141,2019-11-07,2019,US 201916511252 A,2019-07-15,US 201916511252 A;;US 201816031775 A;;US 201514671675 A;;US 201462088427 P,2014-12-05,DISTRIBUTED FILE SYSTEMS ON CONTENT DELIVERY NETWORKS,"A method, article of manufacture, and apparatus for accessing a distributed file system using a content delivery network is discussed. An IO request for an object is received at a metadata server comprising metadata mapping a plurality of objects to an object store. An object identifier associated with the object and a CDN domain associated with the object store are determined. A URL is generated from the object identifier and the CDN domain. The URL is then returned to the client.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/091-614-047-524-141,Patent Application,yes,10,3,6,15,0,H04L67/1097;;G06F16/182;;H04L67/561;;H04L67/1097;;G06F16/182;;G06F16/1827;;G06F12/0833;;G06F12/121;;G06F2212/62;;H04L67/561,G06F16/182;;H04L29/08,,0,0,,,,ACTIVE
8,US,B1,US 10706042 B1,013-493-516-386-419,2020-07-07,2020,US 201615080448 A,2016-03-24,US 201615080448 A;;US 201514755789 A,2015-06-30,Data deduplication on a distributed file system using conditional writes,"A write request is transmitted from a client to a metadata server (“MDS”), wherein the write request comprises an object identifier associated with a data object. An object store location for an object store is received from the MDS. A conditional write request is transmitted to the object store using the object store location, wherein the conditional write request includes the object identifier and the data object. A metadata response is received from the object store. The metadata response is determined to contain an object designator. A commit request is transmitted to the MDS, wherein the commit response includes the object designator.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2016-03-24);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/013-493-516-386-419,Granted Patent,yes,18,0,3,7,0,G06F16/1748;;G06F16/2379;;G06F16/2379;;G06F16/1748,G06F16/23;;G06F16/174,,0,0,,,,ACTIVE
9,US,B2,US 11726986 B2,010-566-776-409-627,2023-08-15,2023,US 202016899199 A,2020-06-11,US 202016899199 A;;US 201615080448 A;;US 201514755789 A,2015-06-30,Data deduplication on a distributed file system using conditional writes,"A write request is transmitted from a client to a metadata server (“MDS”), wherein the write request comprises an object identifier associated with a data object. An object store location for an object store is received from the MDS. A conditional write request is transmitted to the object store using the object store location, wherein the conditional write request includes the object identifier and the data object. A metadata response is received from the object store. The metadata response is determined to contain an object designator. A commit request is transmitted to the MDS, wherein the commit response includes the object designator.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2016-03-24);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/010-566-776-409-627,Granted Patent,yes,25,0,3,7,0,G06F16/1748;;G06F16/2379;;G06F16/2379;;G06F16/1748,G06F16/23;;G06F16/174,,0,0,,,,ACTIVE
10,US,B1,US 10430384 B1,145-851-182-053-641,2019-10-01,2019,US 201615080437 A,2016-03-24,US 201615080437 A;;US 201514755789 A,2015-06-30,Global data deduplication across multiple distributed file systems,"A write request is transmitted from a client to a metadata server (“MDS”), wherein the write request comprises an object identifier associated with a data object. An object store location is received for an object store from the MDS. A metadata request is transmitted to the object store using the object store location, wherein the metadata request includes the object identifier. A metadata response is received from the object store. Determine the metadata response contains an object designator. A count associated with a mapping between the object identifier and the object designator is incremeneted, wherein the mapping resides on an object version manager shared with a second MDS.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2016-03-24);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/145-851-182-053-641,Granted Patent,yes,17,3,3,7,0,G06F16/1748;;G06F16/182;;G06F16/1748;;G06F16/182,G06F16/00;;G06F16/174;;G06F16/182,,0,0,,,,ACTIVE
11,US,B2,US 10795866 B2,152-773-001-922-397,2020-10-06,2020,US 201916511252 A,2019-07-15,US 201916511252 A;;US 201816031775 A;;US 201514671675 A;;US 201462088427 P,2014-12-05,Distributed file systems on content delivery networks,"A method, article of manufacture, and apparatus for accessing a distributed file system using a content delivery network is discussed. An IO request for an object is received at a metadata server comprising metadata mapping a plurality of objects to an object store. An object identifier associated with the object and a CDN domain associated with the object store are determined. A URL is generated from the object identifier and the CDN domain. The URL is then returned to the client.",EMC IP HOLDING CO LLC,DESAI RAJIV,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/152-773-001-922-397,Granted Patent,yes,109,0,6,15,0,H04L67/1097;;G06F16/182;;H04L67/561;;H04L67/1097;;G06F16/182;;G06F16/1827;;G06F12/0833;;G06F12/121;;G06F2212/62;;H04L67/561,G06F15/16;;G06F12/0831;;G06F12/121;;G06F16/182;;H04L29/08,,2,0,,,"What is Data Deduplication?—Definition from Techopedia, https://www.techopedia.com/definition/1067/data-deduplication (Year: 2014).;;What is Data Deduplication?—Definition from Techopedia, https://www.techopedia.com/definition/13725/inline-deduplication (Year: 2014).",ACTIVE
12,US,B2,US 11221993 B2,103-368-682-779-904,2022-01-11,2022,US 201916587997 A,2019-09-30,US 201916587997 A;;US 201615199599 A;;US 201514671740 A;;US 201462088427 P,2014-12-05,Limited deduplication scope for distributed file systems,"A method, article of manufacture, and apparatus for limited deduplication scope on a distributed file system is discussed. A write request is received from a client at the metadata server (“MDS”), where the write request comprises a data object identifier and a preferred object store identifier. The MDS determines whether a preferred object store associated with the preferred object store identifier contains a copy of a data object associated with the data object identifier. A write URL comprising the data object identifier and a object store location associated with the preferred object store is transmitted to the client when the preferred object store does not contain the copy of the data object.",EMC IP HOLDING CO LLC,DESAI RAJIV;;TOLIA NIRAJ,,https://lens.org/103-368-682-779-904,Granted Patent,yes,120,0,3,15,0,G06F16/1748;;G06F16/182;;G06F16/2379;;G06F16/1748;;G06F16/182;;G06F16/2365;;G06F16/2379,G06F16/174;;G06F16/182;;G06F16/23,,19,1,011-606-605-919-817,10.1145/1456469.1456471,"What is Inline Deduplication?—Definition from Techopedia, https://www.techopedia.com/definition/13725/inline-deduplication (Year: 2014).;;U.S. Appl. No. 14/671,675, filed Mar. 27, 2015, Rajiv Desai.;;U.S. Appl. No. 14/673,071, filed Mar. 30, 2015, Desai, et al.;;U.S. Appl. No. 14/864,399, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/864,425, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/865,333, filed Sep. 25, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,424, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,480, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,520, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 15/199,617, filed Jun. 30, 2016, Desai, et al.;;U.S. Appl. No. 15/199,624, filed Jun. 30, 2016, Desai, et al.;;U.S. Appl. No. 15/388,805, filed Dec. 22, 2016, Shrinand Javadekar, et al.;;U.S. Appl. No. 16/031,775, filed Jul. 10, 2018, Rajiv Desai.;;U.S. Appl. No. 16/511,252, filed Jul. 15, 2019, Rajiv Desai.;;Mark W. Storer et al, “Secure Data Deduplication”, ACM 2008, 10 pages. (Year: 2008).;;U.S. Application Filed on Jun. 30, 2016, by Desai et al., U.S. Appl. No. 15/199,599.;;US. Appl. filed Mar. 27, 2015, Rajiv Desai, et al., U.S. Appl. No. 14/671,740.;;What is Data Deduplication?—Definition from Techopedia, https://www.techopedia.com/definition/1067/data-deduplication (Year: 2014).;;What is Data Deduplication?—Definition from Techopedia, https://www.techopedia.com/definition/13725/inline-deduplication (Year: 2014).",ACTIVE
13,US,A1,US 2020/0026689 A1,075-121-545-112-320,2020-01-23,2020,US 201916587997 A,2019-09-30,US 201916587997 A;;US 201615199599 A;;US 201514671740 A;;US 201462088427 P,2014-12-05,LIMITED DEDUPLICATION SCOPE FOR DISTRIBUTED FILE SYSTEMS,"A method, article of manufacture, and apparatus for limited deduplication scope on a distributed file system is discussed. A write request is received from a client at the metadata server (“MDS”), where the write request comprises a data object identifier and a preferred object store identifier. The MDS determines whether a preferred object store associated with the preferred object store identifier contains a copy of a data object associated with the data object identifier. A write URL comprising the data object identifier and a object store location associated with the preferred object store is transmitted to the client when the preferred object store does not contain the copy of the data object.",EMC IP HOLDING CO LLC,DESAI RAJIV;;TOLIA NIRAJ,,https://lens.org/075-121-545-112-320,Patent Application,yes,0,4,3,15,0,G06F16/1748;;G06F16/182;;G06F16/2379;;G06F16/1748;;G06F16/182;;G06F16/2365;;G06F16/2379,G06F16/174;;G06F16/182;;G06F16/23,,0,0,,,,ACTIVE
14,US,A1,US 2018/0239778 A1,017-103-284-491-197,2018-08-23,2018,US 201815961634 A,2018-04-24,US 201815961634 A;;US 201514675451 A,2015-03-31,USER DRIVEN DATA PRE-FETCH,"Techniques to provide access to file system information are disclosed. In various embodiments, an indication that a user input associated with creating a local copy of a file system object has been received is received at a file system client. The file system client determines that a user-driven pre-fetch option has been set with respect to the file system object. The file system client pre-fetches content data associated with the file system object, based at least in part on the determination that the pre-fetch option has been set with respect to the file system object.",MAGINATICS LLC,DESAI RAJIV;;KAMRA VAIBHAV,MAGINATICS LLC (2015-03-31);;EMC CORPORATION (2019-07-22),https://lens.org/017-103-284-491-197,Patent Application,yes,10,2,3,3,0,H04L67/06;;H04L67/1097;;G06F16/172;;H04L67/5681;;H04L67/1097;;G06F16/172;;G06F16/183;;H04L67/06;;H04L67/5681,G06F17/30;;H04L29/08,,0,0,,,,ACTIVE
15,US,B1,US 10951705 B1,040-657-637-265-565,2021-03-16,2021,US 201615199617 A,2016-06-30,US 201615199617 A;;US 201514671740 A;;US 201462088427 P,2014-12-05,Write leases for distributed file systems,"A method, article of manufacture, and apparatus for providing a write leases in a distributed file system is discussed. A lease break is received for a file at a client from a metadata server (“MDS”), wherein the client has a write lease for the file. A write buffer is flushed on the client to an object store, wherein the write buffer comprises data objects comprising the file. A metadata request is transmitted from the client to the MDS in connection with flushing the write buffer. A lease extension is received for the write lease from the MDS.",EMC IP HOLDING CO LLC,DESAI RAJIV;;KAMRA VAIBHAV,EMC CORPORATION (2016-07-19);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/040-657-637-265-565,Granted Patent,yes,131,3,1,15,0,G06F16/13;;G06F16/1774;;G06F16/183;;H04L67/1097;;H04L67/1097;;H04L43/10,G06F16/182;;H04L12/26;;H04L29/08,,5,1,011-606-605-919-817,10.1145/1456469.1456471,"U.S. Appl. No. 16/511,252, filed Jul. 15, 2019, Rajiv Desai.;;What is Data Deduplication?—Definition from Techopedia, https://www.techopedia.com/definition/1067/data-deduplication (Year: 2014).;;What is Data Deduplication?—Definition from Techopedia, https://www.techopedia.com/definition/13725/inline-deduplication (Year: 2014).;;Mark W. Storer et al, “Secure Data Deduplication”, ACM 2008, 10 pages. (Year: 2008).;;What is Inline Deduplication?—Definition from Techopedia, https://www.techopedia.com/definition/13725/inline-deduplication (Year: 2014).",ACTIVE
16,US,B1,US 9984088 B1,178-220-658-233-741,2018-05-29,2018,US 201514675451 A,2015-03-31,US 201514675451 A,2015-03-31,User driven data pre-fetch,"Techniques to provide access to file system information are disclosed. In various embodiments, an indication that a user input associated with creating a local copy of a file system object has been received is received at a file system client. The file system client determines that a user-driven pre-fetch option has been set with respect to the file system object. The file system client pre-fetches content data associated with the file system object, based at least in part on the determination that the pre-fetch option has been set with respect to the file system object.",MAGINATICS LLC,DESAI RAJIV;;KAMRA VAIBHAV,MAGINATICS LLC (2015-03-31);;EMC CORPORATION (2019-07-22),https://lens.org/178-220-658-233-741,Granted Patent,yes,19,5,3,3,0,H04L67/06;;H04L67/1097;;G06F16/172;;H04L67/5681;;H04L67/1097;;G06F16/172;;G06F16/183;;H04L67/06;;H04L67/5681,G06F17/30;;H04L29/08,,0,0,,,,ACTIVE
17,US,B1,US 10430385 B1,041-613-710-139-023,2019-10-01,2019,US 201615199599 A,2016-06-30,US 201615199599 A;;US 201514671740 A;;US 201462088427 P,2014-12-05,Limited deduplication scope for distributed file systems,"A method, article of manufacture, and apparatus for limited deduplication scope on a distributed file system is discussed. A write request is received from a client at the metadata server (“MDS”), where the write request comprises a data object identifier and a preferred object store identifier. The MDS determines whether a preferred object store associated with the preferred object store identifier contains a copy of a data object associated with the data object identifier. A write URL comprising the data object identifier and a object store location associated with the preferred object store is transmitted to the client when the preferred object store does not contain the copy of the data object.",EMC IP HOLDING CO LLC,DESAI RAJIV;;TOLIA NIRAJ,EMC CORPORATION (2016-07-19);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/041-613-710-139-023,Granted Patent,yes,73,3,3,15,0,G06F16/1748;;G06F16/182;;G06F16/2379;;G06F16/1748;;G06F16/182;;G06F16/2365;;G06F16/2379,G06F16/17;;G06F16/174;;G06F16/182;;G06F16/23,,13,1,011-606-605-919-817,10.1145/1456469.1456471,"Mark W. Storer et al, “Secure Data Deduplication”, ACM 2008, 10 pages. (Year: 2008).;;U.S. Appl. No. 14/671,675, filed Mar. 27, 2015, Rajiv Desai.;;U.S. Appl. No. 14/673,071, filed Mar. 30, 2015, Rajiv Desai, et al.;;U.S. Appl. No. 14/864,399, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/864,425, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/865,333, filed Sep. 25, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,424, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,480, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,520, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 15/199,617, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/199,624, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/388,805, filed Dec. 22, 2016, Shrinand Javadekar, et al.;;U.S. Appl. No. 16/031,775, filed Jul. 10, 2018, Rajiv Desai.",ACTIVE
18,US,B2,US 10891259 B2,154-341-352-559-984,2021-01-12,2021,US 201815961634 A,2018-04-24,US 201815961634 A;;US 201514675451 A,2015-03-31,User driven data pre-fetch,"Techniques to provide access to file system information are disclosed. In various embodiments, an indication that a user input associated with creating a local copy of a file system object has been received is received at a file system client. The file system client determines that a user-driven pre-fetch option has been set with respect to the file system object. The file system client pre-fetches content data associated with the file system object, based at least in part on the determination that the pre-fetch option has been set with respect to the file system object.",MAGINATICS LLC,DESAI RAJIV;;KAMRA VAIBHAV,MAGINATICS LLC (2015-03-31);;EMC CORPORATION (2019-07-22),https://lens.org/154-341-352-559-984,Granted Patent,yes,23,0,3,3,0,H04L67/06;;H04L67/1097;;G06F16/172;;H04L67/5681;;H04L67/1097;;G06F16/172;;G06F16/183;;H04L67/06;;H04L67/5681,G06F16/172;;G06F16/182;;H04L29/08,,0,0,,,,ACTIVE
19,CN,A,CN 1997966 A,004-344-585-108-222,2007-07-11,2007,CN 200580023031 A,2005-07-01,US 58648604 P,2004-07-06,Method and system for concurrent excution of mutiple kernels,An approach for concurrently running multiple kernels using a common interrupt handler and an optional common scheduler is provided. Techniques are also provided to switch execution among the kernels. Execution and interrupt preemption among kernels in shown using interrupt mask levels. Techniques are also provided for the sharing of resources between tasks running on different kernels.,EMBEDIO INC,RAJPUT DESAI RAJIV S JASWINDER,,https://lens.org/004-344-585-108-222,Patent Application,no,0,4,2,9,0,,G06F9/46;;G06F13/24,,0,0,,,,INACTIVE
20,US,B1,US 10803020 B1,088-037-909-613-493,2020-10-13,2020,US 201514755789 A,2015-06-30,US 201514755789 A,2015-06-30,Data deduplication on a distributed file system,"A method, article of manufacture, and apparatus for deduplicating data on a distributed file system is discussed. Metadata requests are made to an object store to determine whether the store already contains a data object. If the object store does contain the data object, a commit request is sent to a metadata server. If the object store does not contain the data object, the data object is transmitted to the object store.",EMC IP HOLDING CO LLC,DESAI RAJIV;;ROSENBLUM NATHAN E,EMC CORPORATION (2015-07-13);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/088-037-909-613-493,Granted Patent,yes,16,2,1,7,0,G06F16/1748;;G06F16/1748;;G06F16/182;;G06F16/182,G06F16/174;;G06F16/182,,0,0,,,,ACTIVE
21,EP,A2,EP 1789874 A2,166-437-497-995-121,2007-05-30,2007,EP 05768081 A,2005-07-01,US 2005/0023525 W;;US 58648604 P;;US 16954205 A,2004-07-06,METHOD AND SYSTEM FOR CONCURRENT EXCUTION OF MUTIPLE KERNELS,,EMBEDIO INC,DESAI RAJIV S;;JASWINDER SINGH RAJPUT,,https://lens.org/166-437-497-995-121,Patent Application,yes,0,0,7,9,0,G06F9/46;;G06F9/4843;;G06F9/4843;;G06F9/4812;;G06F9/4812;;G06F9/4825;;G06F9/4825;;G06F13/24,G06F9/46;;G06F13/24,,1,0,,,See references of WO 2006014354A3,DISCONTINUED
22,KR,A,KR 20070083460 A,194-110-579-305-092,2007-08-24,2007,KR 20077001072 A,2007-01-16,US 16954205 A;;US 58648604 P,2004-07-06,METHOD AND SYSTEM FOR CONCURRENT EXECUTION OF MULTIPLE KERNELS,An approach for concurrently running multiple kernels using a common interrupt handler and an optional common scheduler is provided. Techniques are also provided to switch execution among the kernels. Execution and interrupt preemption among kernels in shown using interrupt mask levels. Techniques are also provided for the sharing of resources between tasks running on different kernels.,EMBEDIO INC,DESAI RAJIV S;;JASWINDER SINGH RAJPUT,,https://lens.org/194-110-579-305-092,Patent Application,no,0,6,7,9,0,G06F9/46;;G06F9/4843;;G06F9/4843;;G06F9/4812;;G06F9/4812;;G06F9/4825;;G06F9/4825;;G06F13/24,G06F9/46;;G06F13/24,,0,0,,,,DISCONTINUED
23,CN,C,CN 100576175 C,099-587-228-740-599,2009-12-30,2009,CN 200580023031 A,2005-07-01,US 58648604 P,2004-07-06,Method and system for concurrent execution of multiple kernels,An approach for concurrently running multiple kernels using a common interrupt handler and an optional common scheduler is provided. Techniques are also provided to switch execution among the kernels. Execution and interrupt preemption among kernels in shown using interrupt mask levels. Techniques are also provided for the sharing of resources between tasks running on different kernels.,EMBEDIO INC,DESAI RAJIV S;;RAJPUT JASWINDER SINGH,,https://lens.org/099-587-228-740-599,Granted Patent,no,0,0,2,9,0,,G06F9/46;;G06F13/24,,0,0,,,,INACTIVE
24,HK,A1,HK 1104102 A1,014-431-123-534-102,2008-01-04,2008,HK 07108854 A,2007-08-14,US 2005/0023525 W;;US 58648604 P;;US 16954205 A,2004-07-06,METHOD AND SYSTEM FOR CONCURRENT EXECUTION OF MUTIPLE KERNELS,,EMBEDIO INC,DESAI RAJIV S;;JASWINDER SINGH RAJPUT,,https://lens.org/014-431-123-534-102,Patent Application,no,0,0,7,9,0,G06F9/46;;G06F9/4843;;G06F9/4843;;G06F9/4812;;G06F9/4812;;G06F9/4825;;G06F9/4825;;G06F13/24,G06F/,,0,0,,,,PENDING
25,WO,A3,WO 2006/014354 A3,083-240-259-792-304,2006-04-20,2006,US 2005/0023525 W,2005-07-01,US 58648604 P;;US 16954205 A,2004-07-06,METHOD AND SYSTEM FOR CONCURRENT EXCUTION OF MUTIPLE KERNELS,An approach for concurrently running multiple kernels using a common interrupt handler and an optional common scheduler is provided. Techniques are also provided to switch execution among the kernels. Execution and interrupt preemption among kernels in shown using interrupt mask levels. Techniques are also provided for the sharing of resources between tasks running on different kernels.,DESAI RAJIV S;;JASWINDER SINGH RAJPUT,DESAI RAJIV S;;JASWINDER SINGH RAJPUT,,https://lens.org/083-240-259-792-304,Search Report,yes,4,0,7,9,0,G06F9/46;;G06F9/4843;;G06F9/4843;;G06F9/4812;;G06F9/4812;;G06F9/4825;;G06F9/4825;;G06F13/24,G06F9/46;;G06F13/24,,0,0,,,,PENDING
26,US,A1,US 2006/0010446 A1,134-514-893-383-894,2006-01-12,2006,US 16954205 A,2005-06-29,US 16954205 A;;US 58648604 P,2004-07-06,Method and system for concurrent execution of multiple kernels,An approach for concurrently running multiple kernels using a common interrupt handler and an optional common scheduler is provided. Techniques are also provided to switch execution among the kernels. Execution and interrupt preemption among kernels in shown using interrupt mask levels. Techniques are also provided for the sharing of resources between tasks running on different kernels.,DESAI RAJIV S;;RAJPUT JASWINDER S,DESAI RAJIV S;;RAJPUT JASWINDER S,EMBEDIO INC (2006-10-10),https://lens.org/134-514-893-383-894,Patent Application,yes,16,38,7,9,0,G06F9/46;;G06F9/4843;;G06F9/4843;;G06F9/4812;;G06F9/4812;;G06F9/4825;;G06F9/4825;;G06F13/24,G06F9/46,718/100,0,0,,,,DISCONTINUED
27,WO,A2,WO 2006/014354 A2,081-829-494-499-211,2006-02-09,2006,US 2005/0023525 W,2005-07-01,US 58648604 P;;US 16954205 A,2004-07-06,METHOD AND SYSTEM FOR CONCURRENT EXCUTION OF MUTIPLE KERNELS,An approach for concurrently running multiple kernels using a common interrupt handler and an optional common scheduler is provided. Techniques are also provided to switch execution among the kernels. Execution and interrupt preemption among kernels in shown using interrupt mask levels. Techniques are also provided for the sharing of resources between tasks running on different kernels.,DESAI RAJIV S;;JASWINDER SINGH RAJPUT,DESAI RAJIV S;;JASWINDER SINGH RAJPUT,,https://lens.org/081-829-494-499-211,Patent Application,yes,0,0,7,9,0,G06F9/46;;G06F9/4843;;G06F9/4843;;G06F9/4812;;G06F9/4812;;G06F9/4825;;G06F9/4825;;G06F13/24,G06F9/46,,0,0,,,,PENDING
28,CN,A,CN 106021256 A,026-529-608-555-105,2016-10-12,2016,CN 201511000869 A,2015-12-28,US 201514675425 A,2015-03-31,De-duplicating distributed file system using cloud-based object store,"Techniques to provide a de-duplicating distributed file system using a cloud-based object store are disclosed. In various embodiments, a request to store a file comprising a plurality of chunks of file data is received. A determination to store at least a subset of the plurality of chunks is made. The request is responded to at least in part by providing an indication to store two or more chunks comprising the at least a subset of the plurality of chunks comprising the file as a single stored object that includes the combined chunk data of said two or more chunks.",EMC CORP,JULIO LOPEZ;;THOMAS MANVILLE;;RAJIV DESAI;;NATHAN ROSENBLUM,,https://lens.org/026-529-608-555-105,Patent Application,no,3,2,6,6,0,G06F16/1752;;G06F16/1752;;G06F16/174;;G06F16/182,G06F17/30,,0,0,,,,ACTIVE
29,EP,A4,EP 3278538 A4,118-075-637-923-749,2018-10-10,2018,EP 16773630 A,2016-02-12,US 201514675439 A;;US 2016/0017772 W,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,,EMC CORP,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,,https://lens.org/118-075-637-923-749,Search Report,no,1,0,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/62;;G06F3/06;;G06F17/30;;H04L29/06,,2,1,005-246-924-562-073,10.1109/cloud.2013.123,"RASHID FATEMA ET AL: ""Secure Enterprise Data Deduplication in the Cloud"", 2013 IEEE SIXTH INTERNATIONAL CONFERENCE ON CLOUD COMPUTING, IEEE, 28 June 2013 (2013-06-28), pages 367 - 374, XP032525388, DOI: 10.1109/CLOUD.2013.123;;See also references of WO 2016160144A1",ACTIVE
30,WO,A1,WO 2016/160144 A1,001-153-975-503-972,2016-10-06,2016,US 2016/0017772 W,2016-02-12,US 201514675439 A,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,"Techniques to provide secure cloud-based storage of data shared across file system objects and clients are disclosed. In various embodiments, a primary encryption key is determined for an object associated with a plurality of component chunks of file system data. The primary encryption key is used to generate for each of said component chunks a corresponding chunk key, based at least in part on the primary encryption key and data comprising or otherwise associated with the chunk. The respective chunk keys are provided to a file system client configured to create and store the object at least in part by encrypting each chunk included in the plurality of component chunks using the chunk key provided for that chunk to generated encrypted chunk data, and combining the encrypted chunk data to create and store the object.",EMC CORP,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,,https://lens.org/001-153-975-503-972,Patent Application,yes,3,7,14,14,0,G06F21/6218;;G06F21/6272;;G06F3/0608;;G06F3/0641;;G06F21/6227;;G06F2221/2107;;G06F16/1748;;G06F16/137;;G06F16/183;;G06F21/602;;G06F16/134;;G06F16/137;;G06F16/183;;G06F21/6218;;G06F21/6272;;G06F3/0608;;G06F3/0641;;G06F21/6227;;G06F2221/2107;;G06F16/1748;;G06F21/602,H04L29/06,,0,0,,,,PENDING
31,US,B2,US 10191914 B2,023-072-960-202-134,2019-01-29,2019,US 201514675425 A,2015-03-31,US 201514675425 A,2015-03-31,De-duplicating distributed file system using cloud-based object store,"Techniques to provide a de-duplicating distributed file system using a cloud-based object store are disclosed. In various embodiments, a request to store a file comprising a plurality of chunks of file data is received. A determination to store at least a subset of the plurality of chunks is made. The request is responded to at least in part by providing an indication to store two or more chunks comprising the at least a subset of the plurality of chunks comprising the file as a single stored object that includes the combined chunk data of said two or more chunks.",EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/023-072-960-202-134,Granted Patent,yes,28,15,6,6,0,G06F16/1752;;G06F16/1752;;G06F16/174;;G06F16/182,G06F17/30,,1,1,005-246-924-562-073,10.1109/cloud.2013.123,"RASHID FATEMA; MIRI ALI; WOUNGANG ISAAC: ""Secure Enterprise Data Deduplication in the Cloud"", 2013 IEEE SIXTH INTERNATIONAL CONFERENCE ON CLOUD COMPUTING, IEEE, 28 June 2013 (2013-06-28), pages 367 - 374, XP032525388, DOI: 10.1109/CLOUD.2013.123",ACTIVE
32,EP,A1,EP 3278538 A1,118-191-782-355-993,2018-02-07,2018,EP 16773630 A,2016-02-12,US 201514675439 A;;US 2016/0017772 W,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,,EMC CORP,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,,https://lens.org/118-191-782-355-993,Patent Application,yes,0,0,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,H04L29/06,,0,0,,,,ACTIVE
33,US,B2,US 10983961 B2,158-381-354-505-922,2021-04-20,2021,US 201816151726 A,2018-10-04,US 201816151726 A;;US 201514675425 A,2015-03-31,De-duplicating distributed file system using cloud-based object store,"Techniques to provide a de-duplicating distributed file system using a cloud-based object store are disclosed. In various embodiments, a request to store a file comprising a plurality of chunks of file data is received. A determination to store at least a subset of the plurality of chunks is made. The request is responded to at least in part by providing an indication to store two or more chunks comprising the at least a subset of the plurality of chunks comprising the file as a single stored object that includes the combined chunk data of said two or more chunks.",EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/158-381-354-505-922,Granted Patent,yes,49,1,6,6,0,G06F16/1752;;G06F16/1752;;G06F16/174;;G06F16/182,G06F16/174,,1,1,005-246-924-562-073,10.1109/cloud.2013.123,"RASHID FATEMA; MIRI ALI; WOUNGANG ISAAC: ""Secure Enterprise Data Deduplication in the Cloud"", 2013 IEEE SIXTH INTERNATIONAL CONFERENCE ON CLOUD COMPUTING, IEEE, 28 June 2013 (2013-06-28), pages 367 - 374, XP032525388, DOI: 10.1109/CLOUD.2013.123",ACTIVE
34,US,A1,US 2020/0082102 A1,189-921-972-567-679,2020-03-12,2020,US 201916687090 A,2019-11-18,US 201916687090 A;;US 201916360987 A;;US 201815885567 A;;US 201514675439 A,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,A combined object associated with a data chunk included in a request file is determined. An encryption key associated with the combined object and a corresponding chunk hash value associated with the data chunk are used to determine a corresponding chunk key associated with the data chunk. At least a locator to be used to retrieve the combined object and the corresponding chunk key associated with the data chunk are provided to a requesting system.,EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/189-921-972-567-679,Patent Application,yes,0,1,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/60;;G06F3/06;;G06F16/13;;G06F16/174;;G06F16/182;;G06F21/62,,0,0,,,,ACTIVE
35,US,A1,US 2016/0292429 A1,015-693-857-163-44X,2016-10-06,2016,US 201514675439 A,2015-03-31,US 201514675439 A,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,"Techniques to provide secure cloud-based storage of data shared across file system objects and clients are disclosed. In various embodiments, a primary encryption key is determined for an object associated with a plurality of component chunks of file system data. The primary encryption key is used to generate for each of said component chunks a corresponding chunk key, based at least in part on the primary encryption key and data comprising or otherwise associated with the chunk. The respective chunk keys are provided to a file system client configured to create and store the object at least in part by encrypting each chunk included in the plurality of component chunks using the chunk key provided for that chunk to generated encrypted chunk data, and combining the encrypted chunk data to create and store the object.",EMC CORP,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/015-693-857-163-44X,Patent Application,yes,3,89,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/60;;G06F17/30,,0,0,,,,ACTIVE
36,US,A1,US 2019/0050419 A1,040-748-509-894-133,2019-02-14,2019,US 201816151726 A,2018-10-04,US 201816151726 A;;US 201514675425 A,2015-03-31,DE-DUPLICATING DISTRIBUTED FILE SYSTEM USING CLOUD-BASED OBJECT STORE,"Techniques to provide a de-duplicating distributed file system using a cloud-based object store are disclosed. In various embodiments, a request to store a file comprising a plurality of chunks of file data is received. A determination to store at least a subset of the plurality of chunks is made. The request is responded to at least in part by providing an indication to store two or more chunks comprising the at least a subset of the plurality of chunks comprising the file as a single stored object that includes the combined chunk data of said two or more chunks.",EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/040-748-509-894-133,Patent Application,yes,0,0,6,6,0,G06F16/1752;;G06F16/1752;;G06F16/174;;G06F16/182,G06F17/30,,0,0,,,,ACTIVE
37,EP,B1,EP 3278538 B1,030-673-825-121-048,2021-01-13,2021,EP 16773630 A,2016-02-12,US 201514675439 A;;US 2016/0017772 W,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,,EMC CORP,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,,https://lens.org/030-673-825-121-048,Granted Patent,yes,4,0,14,14,0,G06F21/6218;;G06F21/6272;;G06F3/0608;;G06F3/0641;;G06F21/6227;;G06F2221/2107;;G06F16/1748;;G06F16/137;;G06F16/183;;G06F21/602;;G06F16/134;;G06F16/137;;G06F16/183;;G06F21/6218;;G06F21/6272;;G06F3/0608;;G06F3/0641;;G06F21/6227;;G06F2221/2107;;G06F16/1748;;G06F21/602,G06F21/62;;G06F3/06;;G06F16/13;;G06F16/174;;G06F16/182;;G06F21/60;;H04L29/06,,1,0,,,"RASHID FATEMA ET AL: ""Secure Enterprise Data Deduplication in the Cloud"", 2013 IEEE SIXTH INTERNATIONAL CONFERENCE ON CLOUD COMPUTING, IEEE, 28 June 2013 (2013-06-28), pages 367-374, XP032525388, DOI: 10.1109/CLOUD.2013.123 [retrieved on 2013-11-26]",ACTIVE
38,US,B2,US 11144651 B2,109-378-633-351-108,2021-10-12,2021,US 201916687090 A,2019-11-18,US 201916687090 A;;US 201916360987 A;;US 201815885567 A;;US 201514675439 A,2015-03-31,Secure cloud-based storage of data shared across file system objects and clients,A combined object associated with a data chunk included in a request file is determined. An encryption key associated with the combined object and a corresponding chunk hash value associated with the data chunk are used to determine a corresponding chunk key associated with the data chunk. At least a locator to be used to retrieve the combined object and the corresponding chunk key associated with the data chunk are provided to a requesting system.,EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/109-378-633-351-108,Granted Patent,yes,49,0,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/60;;G06F3/06;;G06F16/13;;G06F16/174;;G06F16/182;;G06F21/62,,1,1,005-246-924-562-073,10.1109/cloud.2013.123,"RASHID FATEMA; MIRI ALI; WOUNGANG ISAAC: ""Secure Enterprise Data Deduplication in the Cloud"", 2013 IEEE SIXTH INTERNATIONAL CONFERENCE ON CLOUD COMPUTING, IEEE, 28 June 2013 (2013-06-28), pages 367 - 374, XP032525388, DOI: 10.1109/CLOUD.2013.123",ACTIVE
39,US,B2,US 9916458 B2,190-002-992-070-801,2018-03-13,2018,US 201514675439 A,2015-03-31,US 201514675439 A,2015-03-31,Secure cloud-based storage of data shared across file system objects and clients,"Techniques to provide secure cloud-based storage of data shared across file system objects and clients are disclosed. In various embodiments, a primary encryption key is determined for an object associated with a plurality of component chunks of file system data. The primary encryption key is used to generate for each of said component chunks a corresponding chunk key, based at least in part on the primary encryption key and data comprising or otherwise associated with the chunk. The respective chunk keys are provided to a file system client configured to create and store the object at least in part by encrypting each chunk included in the plurality of component chunks using the chunk key provided for that chunk to generated encrypted chunk data, and combining the encrypted chunk data to create and store the object.",EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/190-002-992-070-801,Granted Patent,yes,24,3,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/60;;G06F17/30;;G06F21/62,,0,0,,,,ACTIVE
40,US,A1,US 2016/0292178 A1,099-752-185-191-003,2016-10-06,2016,US 201514675425 A,2015-03-31,US 201514675425 A,2015-03-31,DE-DUPLICATING DISTRIBUTED FILE SYSTEM USING CLOUD-BASED OBJECT STORE,"Techniques to provide a de-duplicating distributed file system using a cloud-based object store are disclosed. In various embodiments, a request to store a file comprising a plurality of chunks of file data is received. A determination to store at least a subset of the plurality of chunks is made. The request is responded to at least in part by providing an indication to store two or more chunks comprising the at least a subset of the plurality of chunks comprising the file as a single stored object that includes the combined chunk data of said two or more chunks.",EMC CORP,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/099-752-185-191-003,Patent Application,yes,10,52,6,6,0,G06F16/1752;;G06F16/1752;;G06F16/174;;G06F16/182,G06F17/30,,0,0,,,,ACTIVE
41,CN,A,CN 107615730 A,069-533-052-256-186,2018-01-19,2018,CN 201680024715 A,2016-02-12,US 201514675439 A;;US 2016/0017772 W,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,"Techniques to provide secure cloud-based storage of data shared across file system objects and clients are disclosed. In various embodiments, a primary encryption key is determined for an object associated with a plurality of component chunks of file system data. The primary encryption key is used to generate for each of said component chunks a corresponding chunk key, based at least in part on the primary encryption key and data comprising or otherwise associated with the chunk. The respective chunk keys are provided to a file system client configured to create and store the object at least in part by encrypting each chunk included in the plurality of component chunks using the chunk key provided for that chunk to generated encrypted chunk data, and combining the encrypted chunk data to create and store the object.",EMC CORP,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,,https://lens.org/069-533-052-256-186,Patent Application,no,4,8,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,H04L29/06,,1,1,005-246-924-562-073,10.1109/cloud.2013.123,"FATEMA RASHID ET.AL: ""Secure Enterprise Data Deduplication in the Cloud"", 《IEEE》",ACTIVE
42,US,A1,US 2019/0272380 A1,077-938-985-842-991,2019-09-05,2019,US 201916360987 A,2019-03-21,US 201916360987 A;;US 201815885567 A;;US 201514675439 A,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,"Techniques to provide secure cloud-based storage of data shared across file system objects and clients are disclosed. In various embodiments, a primary encryption key is determined for an object associated with a plurality of component chunks of file system data. The primary encryption key is used to generate for each of said component chunks a corresponding chunk key, based at least in part on the primary encryption key and data comprising or otherwise associated with the chunk. The respective chunk keys are provided to a file system client configured to create and store the object at least in part by encrypting each chunk included in the plurality of component chunks using the chunk key provided for that chunk to generated encrypted chunk data, and combining the encrypted chunk data to create and store the object.",EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/077-938-985-842-991,Patent Application,yes,0,1,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/60;;G06F3/06;;G06F16/13;;G06F16/174;;G06F16/182;;G06F21/62,,0,0,,,,ACTIVE
43,US,A1,US 2018/0157852 A1,015-331-450-945-986,2018-06-07,2018,US 201815885567 A,2018-01-31,US 201815885567 A;;US 201514675439 A,2015-03-31,SECURE CLOUD-BASED STORAGE OF DATA SHARED ACROSS FILE SYSTEM OBJECTS AND CLIENTS,"Techniques to provide secure cloud-based storage of data shared across file system objects and clients are disclosed. In various embodiments, a primary encryption key is determined for an object associated with a plurality of component chunks of file system data. The primary encryption key is used to generate for each of said component chunks a corresponding chunk key, based at least in part on the primary encryption key and data comprising or otherwise associated with the chunk. The respective chunk keys are provided to a file system client configured to create and store the object at least in part by encrypting each chunk included in the plurality of component chunks using the chunk key provided for that chunk to generated encrypted chunk data, and combining the encrypted chunk data to create and store the object.",EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/015-331-450-945-986,Patent Application,yes,0,1,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/60;;G06F17/30;;G06F21/62,,0,0,,,,ACTIVE
44,US,B1,US 10417194 B1,089-990-206-704-156,2019-09-17,2019,US 201514673071 A,2015-03-30,US 201514673071 A;;US 201462088427 P,2014-12-05,Site cache for a distributed file system,"A method, article of manufacture, and apparatus for providing a site cache in a distributed file system is discussed. Data objects may be written to a site cache prior to writing them to an authoritative object store. This provides performance benefits when a client writing the data has a better connection to the site cache than to the authoritative object store.",EMC IP HOLDING CO LLC,DESAI RAJIV;;JAVADEKAR SHRINAND;;PANGHAL VIJAY;;TOLIA NIRAJ,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/089-990-206-704-156,Granted Patent,yes,79,5,6,15,0,H04L67/1097;;G06F16/182;;H04L67/561;;H04L67/1097;;G06F16/182;;G06F16/1827;;G06F12/0833;;G06F12/121;;G06F2212/62;;H04L67/561,G06F12/00;;G06F12/0831;;G06F12/121;;G06F16/182,,64,0,,,"U.S. Appl. No. 14/671,740, filed Mar. 27, 2015, Rajiv Desai, et al.;;U.S. Appl. No. 15/199,599, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/199,617, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 15/199,624, filed Jun. 30, 2016, Rajiv Desai, et al.;;U.S. Appl. No. 14/671,675, filed Mar. 27, 2015, Rajiv Desai.;;U.S. Appl. No. 14/865,333, filed Sep. 25, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/864,399, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/864,425, filed Sep. 24, 2015, Vijay Panghal.;;U.S. Appl. No. 14/978,424, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,480, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/978,520, filed Dec. 22, 2015, Vijay Panghal, et al.;;U.S. Appl. No. 14/671,675, Dec. 14, 2016, Office Action.;;U.S. Appl. No. 14/865,333, Dec. 16, 2016, Office Action.;;U.S. Appl. No. 14/864,425, Dec. 29, 2016, Office Action.;;U.S. Appl. No. 14/864,399, Feb. 1, 2017, Office Action.;;U.S. Appl. No. 14/978,520, Mar. 13, 2017, Office Action.;;U.S. Appl. No. 15/388,805, filed Dec. 22, 2016, Shrinand Javadekar, et al.;;U.S. Appl. No. 14/865,333, Jun. 1, 2017, Final Office Action.;;U.S. Appl. No. 14/864,399, Jun. 15, 2017, Final Office Action.;;U.S. Appl. No. 14/864,425, Jun. 22, 2017, Final Office Action.;;U.S. Appl. No. 14/978,480, Jun. 23, 2017, Office Action.;;U.S. Appl. No. 14/671,675, Jun. 6, 2017, Final Office Action.;;U.S. Appl. No. 14/865,333, Aug. 25, 2017, Office Action.;;U.S. Appl. No. 14/978,520, Mar. 13, 2017, Final Office Action.;;U.S. Appl. No. 14/671,675, Oct. 6, 2017, Final Office Action.;;U.S. Appl. No. 14/864,425, Oct. 11, 2017, Notice of Allowance.;;U.S. Appl. No. 14/978,520, Sep. 20, 2017, Final Office Action.;;U.S. Appl. No. 14/671,740, Jul. 12, 2017, Office Action.;;U.S. Appl. No. 14/671,740, Dec. 6, 2017, Final Office Action.;;U.S. Appl. No. 14/864,399, Jan. 10, 2018, Office Action.;;U.S. Appl. No. 14/865,333, Feb. 27, 2018, Final Office Action.;;U.S. Appl. No. 14/978,424, Dec. 14, 2017, Office Action.;;U.S. Appl. No. 14/978,480, Dec. 5, 2017, Final Office Action.;;U.S. Appl. No. 14/978,520, Jan. 4, 2018, Office Action.;;U.S. Appl. No. 14/671,675, Mar. 13, 2018, Notice of Allowance.;;U.S. Appl. No. 14/978,480, Apr. 5, 2018, Office Action.;;U.S. Appl. No. 14/978,480, Nov. 27, 2018, Final Office Action.;;U.S. Appl. No. 14/865,333, Nov. 29, 2018, Final Office Action.;;U.S. Appl. No. 14/864,399, Dec. 13, 2018, Office Action.;;U.S. Appl. No. 14/978,424, Dec. 31, 2018, Office Action.;;U.S. Appl. No. 14/978,520, Jan. 11, 2018, Office Action.;;U.S. Appl. No. 15/199,617, Feb. 4, 2019, Final Office Action.;;U.S. Appl. No. 15/199,624, Feb. 6, 2019, Final Office Action.;;U.S. Appl. No. 16/031,775, filed Jul. 10, 2018, Rajiv Desai.;;U.S. Appl. No. 16/064,775, Aug. 27, 2018, Office Action.;;U.S. Appl. No. 15/199,617, Sep. 17, 2018, Office Action.;;U.S. Appl. No. 15/199,624, Sep. 5, 2018, Office Action.;;U.S. Appl. No. 14/864,399, Jul. 17, 2018, Final Office Action.;;U.S. Appl. No. 14/865,333, Jul. 25, 2018, Office Action.;;U.S. Appl. No. 14/671,740, Oct. 12, 2018, Office Action.;;U.S. Appl. No. 15/199,599, Oct. 5, 2018, Office Action.;;U.S. Appl. No. 14/978,424, Aug. 15, 2018, Final Office Action.;;U.S. Appl. No. 14/978,520, Sep. 18, 2018, Final Office Action.;;U.S. Appl. No. 15/388,805, Oct. 31, 2018, Office Action.;;U.S. Appl. No. 16/031,775, filed Mar. 26, 2019, Notice of Allowance.;;U.S. Appl. No. 14/865,333, filed Mar. 29, 2019, Office Action.;;U.S. Appl. No. 14/978,480, filed Apr. 22, 2019, Office Action.;;U.S. Appl. No. 15/388,805, filed Apr. 4, 2019, Final Office Action.;;U.S. Appl. No. 14/978,424, filed May 20, 2019, Notice of Allowance.;;U.S. Appl. No. 15/199,599, filed May 21, 2019, Notice of Allowance.;;U.S. Appl. No. 14/864,399, filed Jul. 22, 2019, Notice of Allowance.;;U.S. Appl. No. 15/199,624, filed Jul. 22, 2019, Office Action.;;U.S. Appl. No. 15/388,805, filed Jul. 25, 2019, Office Action.;;U.S. Appl. No. 14/978,520, filed Jul. 30, 2019, Notice of Allowance.",ACTIVE
45,US,B2,US 10515223 B2,018-047-509-878-249,2019-12-24,2019,US 201916360987 A,2019-03-21,US 201916360987 A;;US 201815885567 A;;US 201514675439 A,2015-03-31,Secure cloud-based storage of data shared across file system objects and clients,"Techniques to provide secure cloud-based storage of data shared across file system objects and clients are disclosed. In various embodiments, a primary encryption key is determined for an object associated with a plurality of component chunks of file system data. The primary encryption key is used to generate for each of said component chunks a corresponding chunk key, based at least in part on the primary encryption key and data comprising or otherwise associated with the chunk. The respective chunk keys are provided to a file system client configured to create and store the object at least in part by encrypting each chunk included in the plurality of component chunks using the chunk key provided for that chunk to generated encrypted chunk data, and combining the encrypted chunk data to create and store the object.",EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/018-047-509-878-249,Granted Patent,yes,36,0,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/60;;G06F3/06;;G06F16/13;;G06F16/174;;G06F16/182;;G06F21/62,,1,1,005-246-924-562-073,10.1109/cloud.2013.123,"RASHID FATEMA; MIRI ALI; WOUNGANG ISAAC: ""Secure Enterprise Data Deduplication in the Cloud"", 2013 IEEE SIXTH INTERNATIONAL CONFERENCE ON CLOUD COMPUTING, IEEE, 28 June 2013 (2013-06-28), pages 367 - 374, XP032525388, DOI: 10.1109/CLOUD.2013.123",ACTIVE
46,US,B2,US 10282556 B2,061-376-214-274-874,2019-05-07,2019,US 201815885567 A,2018-01-31,US 201815885567 A;;US 201514675439 A,2015-03-31,Secure cloud-based storage of data shared across file system objects and clients,"Techniques to provide secure cloud-based storage of data shared across file system objects and clients are disclosed. In various embodiments, a primary encryption key is determined for an object associated with a plurality of component chunks of file system data. The primary encryption key is used to generate for each of said component chunks a corresponding chunk key, based at least in part on the primary encryption key and data comprising or otherwise associated with the chunk. The respective chunk keys are provided to a file system client configured to create and store the object at least in part by encrypting each chunk included in the plurality of component chunks using the chunk key provided for that chunk to generated encrypted chunk data, and combining the encrypted chunk data to create and store the object.",EMC IP HOLDING CO LLC,MANVILLE THOMAS;;LOPEZ JULIO;;DESAI RAJIV;;ROSENBLUM NATHAN,EMC CORPORATION (2015-03-31);;EMC IP HOLDING COMPANY LLC (2016-09-01),https://lens.org/061-376-214-274-874,Granted Patent,yes,28,0,14,14,0,G06F21/602;;G06F21/602;;G06F3/0608;;G06F3/0608;;G06F3/0641;;G06F3/0641;;G06F16/134;;G06F16/137;;G06F16/137;;G06F16/1748;;G06F16/1748;;G06F16/183;;G06F16/183;;G06F21/6218;;G06F21/6218;;G06F21/6227;;G06F21/6227;;G06F21/6272;;G06F21/6272;;G06F2221/2107;;G06F2221/2107,G06F21/60;;G06F3/06;;G06F21/62,,1,1,005-246-924-562-073,10.1109/cloud.2013.123,"RASHID FATEMA; MIRI ALI; WOUNGANG ISAAC: ""Secure Enterprise Data Deduplication in the Cloud"", 2013 IEEE SIXTH INTERNATIONAL CONFERENCE ON CLOUD COMPUTING, IEEE, 28 June 2013 (2013-06-28), pages 367 - 374, XP032525388, DOI: 10.1109/CLOUD.2013.123",ACTIVE
47,US,B2,US 11771767 B2,041-746-837-237-850,2023-10-03,2023,US 202016992385 A,2020-08-13,US 202016992385 A;;US 201815770937 A;;US 2016/0058866 W;;US 201662351162 P;;US 201562246462 P,2015-10-26,Reduced and oxidized polysaccharides and methods of use thereof,"The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2016-12-20),https://lens.org/041-746-837-237-850,Granted Patent,yes,35,0,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K47/36;;A61K9/00;;A61K9/06;;A61K9/10;;A61K9/127;;A61K9/51;;A61K47/69;;C08B37/00;;C08L5/04,,15,13,019-320-775-234-842;;032-076-518-916-120;;027-826-055-662-863;;055-873-238-852-130;;073-103-221-858-781;;090-331-141-530-63X;;081-458-347-101-664;;017-218-438-380-298;;088-545-957-138-181;;152-149-742-353-444;;034-411-322-041-738;;054-735-500-349-468;;049-718-328-736-638,10.1007/s00289-015-1440-2;;10.1016/j.biomaterials.2004.10.005;;15626441;;15585248;;10.1016/j.biomaterials.2004.06.044;;19966309;;pmc2840452;;10.1073/pnas.0903875106;;10.1016/j.biomaterials.2015.01.048;;25736493;;23512290;;10.1002/mabi.201200409;;10.1039/c3cs60040h;;pmc3762890;;23609001;;10.1016/j.progpolymsci.2011.06.003;;pmc3223967;;22125349;;pmc3065812;;10.1155/2011/939851;;21490759;;10.1016/s0040-4039(97)00414-0;;28809210;;pmc5452316;;10.3390/ma6041285;;16827580;;10.1021/bm060099n;;18007275;;pmc6147732;;10.3390/10010006,"Hu et al., Polym. Bull. (2015) 72:2857-2869 (Year: 2015).;;Balakrishnan et al., Self-cross-linking biopolymers as injectable in situ forming biodegradable scaffolds. Biomaterials. Jun. 2005;26(18):3941-51.;;Boontheekul et al., Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials. May 2005;26(15):2455-65.;;Borselli et al., Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc Natl Acad Sci U S A. Feb. 23, 2010;107(8):3287-92.;;Desai et al., Versatile click alginate hydrogels crosslinked via tetrazine-norbornene chemistry. Biomaterials. May 2015;50:30-7.;;Khan et al., Polysaccharides and their derivatives for versatile tissue engineering application. Macromol Biosci. Apr. 2013;13(4):395-421.;;Kharkar et al., Designing degradable hydrogels for orthogonal control of cell microenvironments. Chem Soc Rev. Sep. 7, 2013;42(17):7335-72.;;Lee et al., Alginate: properties and biomedical applications. Prog Polym Sci. Jan. 2012;37(1):106-126.;;Mufamadi et al., A review on composite liposomal technologies for specialized drug delivery. J Drug Deliv. 2011;2011:939851. 19 pages.;;Ramachandran et al., Efficient Synthesis of Enantiomerically Pure C2-Symmetric Diols via the Allylboration of Appropriate Dialdehyde. Tetrahedron Letters. Apr. 7, 1997;38(14):2417-2420.;;Sun et al., Alginate-Based Biomaterials for Regenerative Medicine Applications. Materials (Basel). Mar. 26, 2013;6(4):1285-1309.;;Vold et al., A study of the chain stiffness and extension of alginates, in vitro epimerized alginates, and periodate-oxidized alginates using size-exclusion chromatography combined with light scattering and viscosity detectors. Biomacromolecules. Jul. 2006,7(7):2136-46.;;International Search Report and Written Opinion for Application No. PCT/US2016/058866, dated Jan. 25, 2017. 13 pages.;;Supplementary European Search Report for Application No. 16860689.5, dated Apr. 23, 2019, 16 pages.;;Coviello et al., Scleroglucan: a versatile polysaccharide for modified drug delivery. Molecules. Jan. 31, 2005;10(1):6-33.",ACTIVE
48,US,A1,US 2020/0368359 A1,190-908-188-182-141,2020-11-26,2020,US 202016992385 A,2020-08-13,US 202016992385 A;;US 201815770937 A;;US 2016/0058866 W;;US 201662351162 P;;US 201562246462 P,2015-10-26,REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,"The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2016-12-20),https://lens.org/190-908-188-182-141,Patent Application,yes,0,0,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K47/36;;A61K9/00;;A61K9/06;;A61K9/10;;A61K9/127;;A61K9/51;;A61K47/69;;C08B37/00;;C08L5/04,,1,1,019-320-775-234-842,10.1007/s00289-015-1440-2,"Hu et al., Polym. Bull. (2015) 72:2857-2869 (Year: 2015)",ACTIVE
49,US,B2,US 10780171 B2,131-709-361-211-080,2020-09-22,2020,US 201615770937 A,2016-10-26,US 201615770937 A;;US 201662351162 P;;US 201562246462 P;;US 2016/0058866 W,2015-10-26,Reduced and oxidized polysaccharides and methods of use thereof,"The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2016-12-20),https://lens.org/131-709-361-211-080,Granted Patent,yes,15,1,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K47/36;;A61K9/00;;A61K9/06;;A61K9/10;;A61K9/127;;A61K9/51;;A61K47/69;;C08B37/00;;C08L5/04,,13,11,032-076-518-916-120;;027-826-055-662-863;;055-873-238-852-130;;073-103-221-858-781;;090-331-141-530-63X;;081-458-347-101-664;;017-218-438-380-298;;088-545-957-138-181;;152-149-742-353-444;;034-411-322-041-738;;054-735-500-349-468,10.1016/j.biomaterials.2004.10.005;;15626441;;15585248;;10.1016/j.biomaterials.2004.06.044;;19966309;;pmc2840452;;10.1073/pnas.0903875106;;10.1016/j.biomaterials.2015.01.048;;25736493;;23512290;;10.1002/mabi.201200409;;10.1039/c3cs60040h;;pmc3762890;;23609001;;10.1016/j.progpolymsci.2011.06.003;;pmc3223967;;22125349;;pmc3065812;;10.1155/2011/939851;;21490759;;10.1016/s0040-4039(97)00414-0;;28809210;;pmc5452316;;10.3390/ma6041285;;16827580;;10.1021/bm060099n,"Supplementary European Search Report for Application No. 16860689.5, dated Apr. 23, 2019, 16 pages.;;Balakrishnan et al., Self-cross-linking biopolymers as injectable in situ forming biodegradable scaffolds. Biomaterials. Jun. 2005;26(18):3941-51.;;Boontheekul et al., Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials. May 2005;26(15):2455-65.;;Borselli et al., Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc Natl Acad Sci U S A. Feb. 23, 2010;107(8):3287-92.;;Desai et al., Versatile click alginate hydrogels crosslinked via tetrazine-norbornene chemistry. Biomaterials. May 2015;50:30-7.;;Khan et al., Polysaccharides and their derivatives for versatile tissue engineering application. Macromol Biosci. Apr. 2013;13(4):395-421.;;Kharkar et al., Designing degradable hydrogels for orthogonal control of cell microenvironments. Chem Soc Rev. Sep. 7, 2013;42(17):7335-72.;;Lee et al., Alginate: properties and biomedical applications. Prog Polym Sci. Jan. 2012;37(1):106-126.;;Mufamadi et al., A review on composite liposomal technologies for specialized drug delivery. J Drug Deliv. 2011;2011:939851. 19 pages.;;Ramachandran et al., Efficient Synthesis of Enantiomerically Pure C2-Symmetric Diols via the Allylboration of Appropriate Dialdehyde. Tetrahedron Letters. Apr. 7, 1997;38(14):2417-2420.;;Sun et al., Alginate-Based Biomaterials for Regenerative Medicine Applications. Materials (Basel). Mar. 26, 2013;6(4):1285-1309.;;Vold et al., A study of the chain stiffness and extension of alginates, in vitro epimerized alginates, and periodate-oxidized alginates using size-exclusion chromatography combined with light scattering and viscosity detectors. Biomacromolecules. Jul. 2006;7(7):2136-46.;;International Search Report and Written Opinion for Application No. PCT/US2016/058866, dated Jan. 25, 2017. 13 pages.",ACTIVE
50,CN,A,CN 111757879 A,164-737-967-756-275,2020-10-09,2020,CN 201980010709 A,2019-01-28,IN 201821003232 A;;IB 2019050668 W,2018-01-29,HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS,"Present invention relates to compounds of formula (1) its enantiomers, diastereomers, racemic mixtures and their pharmaceutically acceptable salts. This invention also directed to antibacterial drug compounds that are capable of treating bacterial infection which are hard to treat with existing drug compounds.",CADILA HEALTHCARE LTD,SHARMA RAJIV;;IYER PRAVIN;;DESAI JIGAR;;KUMAR SANJAY S,,https://lens.org/164-737-967-756-275,Patent Application,no,0,0,6,6,0,A61K31/5415;;A61K31/4709;;A61K31/4709;;A61K31/498;;A61K31/538;;A61K31/538;;A61K31/5415;;A61K45/06;;A61P31/04;;A61P31/06;;C07D405/14;;C07D405/14;;C07D405/14;;C07D413/14;;C07D413/14;;C07D413/14;;C07D417/14;;C07D417/14;;C07D417/14,C07D405/14;;A61K31/04;;A61K31/4704;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
51,KR,A,KR 20200115597 A,008-646-031-446-587,2020-10-07,2020,KR 20207024781 A,2019-01-28,IN 201821003232 A;;IB 2019050668 W,2018-01-29,항세균제로서 유용한 헤테로사이클릭 화합물,"본 발명은 하기 화학식 1의 화합물, 또는 이의 거울상 이성질체, 부분입체 이성질체, 라세미 혼합물 또는 약학적으로 허용되는 염에 관한 것이다. 본 발명은 또한 기존 약물 화합물로 치료하기 어려운 세균 감염을 치료할 수 있는 항세균성 약물 화합물에 관한 것이다: [화학식 1] TIFFpct00029.tif3662.",CADILA HEALTHCARE LTD,SHARMA RAJIV;;IYER PRAVIN;;DESAI JIGAR;;KUMAR SANJAY S,,https://lens.org/008-646-031-446-587,Patent Application,no,0,0,6,6,0,A61K31/5415;;A61K31/4709;;A61K31/4709;;A61K31/498;;A61K31/538;;A61K31/538;;A61K31/5415;;A61K45/06;;A61P31/04;;A61P31/06;;C07D405/14;;C07D405/14;;C07D405/14;;C07D413/14;;C07D413/14;;C07D413/14;;C07D417/14;;C07D417/14;;C07D417/14,C07D405/14;;A61K31/4709;;A61K31/538;;A61K31/5415;;A61K45/06;;A61P31/04;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
52,US,A1,US 2021/0092145 A1,179-738-018-688-409,2021-03-25,2021,US 201916698989 A,2019-11-28,IN 201941037953 A,2019-09-20,MALWARE PROPAGATION RISK ASSESSMENT IN SOFTWARE DEFINED NETWORKS,"Described herein are systems, methods, and software to identify propagation risk of threats in a computing environment. In one implementation, a management service may identify a connection tree for a computing environment based on forwarding rules for virtual nodes in the computing environment. The management service may further, for each connection in the connection tree, determine a threat value based at least on a protocol associated with the connection. The management service may also identify a threat to a virtual node of the virtual nodes and generate a threat propagation summary for the threat based on the one or more minimum or maximum spanning trees.",VMWARE INC,JAYSINGH BHALERAO ANAND;;DESAI ANERI RAJIV;;AJMANI DASHMEET KAUR,VMWARE INC (2019-10-18),https://lens.org/179-738-018-688-409,Patent Application,yes,11,0,2,2,0,H04L63/145;;H04L63/1425;;G06F9/45558;;G06F2009/45595;;H04L45/48;;H04L63/1433;;H04L45/48;;G06F2009/45595;;H04L63/1425;;G06F9/45558,H04L29/06;;G06F9/455;;H04L12/753,,2,1,057-445-830-734-194,10.1016/j.cose.2018.07.010,"Dourado et al, ""Design of connection networks with bounded number of non-terminal vertices"", (2014/4/9), Sociedade Brasileira de Matematica, Matematica Contemporanea, Vol 42, 39-48 (Year: 2014);;Tripathy et al, ""Risk based Security Enforcement in Software Defined Network"", (31 July 2018), Elsevier, ScienceDirect, Computers & Security 78, 321-335 (Year: 2018)",ACTIVE
53,US,A1,US 2018/0326073 A1,189-169-160-284-910,2018-11-15,2018,US 201615770937 A,2016-10-26,US 201615770937 A;;US 201662351162 P;;US 201562246462 P;;US 2016/0058866 W,2015-10-26,REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,"The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2016-12-20),https://lens.org/189-169-160-284-910,Patent Application,yes,0,8,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K47/36;;A61K9/127;;A61K9/51;;A61K47/69,,0,0,,,,ACTIVE
54,CN,A,CN 115073625 A,074-946-228-057-292,2022-09-20,2022,CN 202210460332 A,2016-10-26,CN 202210460332 A;;CN 201680062497 A;;US 201562246462 P;;US 201662351162 P;;US 2016/0058866 W,2015-10-26,Reduced and oxidized polysaccharides and methods of use thereof,"The present invention relates to reduced and highly oxidized polysaccharides, such as alginates, which can be used to encapsulate therapeutic or diagnostic agents, or lipid-based nanoparticles, such as liposomes or virosomes, encapsulating therapeutic or diagnostic agents (prior to their delivery into a subject), as well as methods of making and using them.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/074-946-228-057-292,Patent Application,no,4,0,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,C08B37/04;;A61K9/06;;A61K9/127;;A61K9/51;;A61K47/36;;A61P9/10;;A61P27/02;;A61P27/16;;C08J3/075;;C08L5/04,,1,1,019-320-775-234-842,10.1007/s00289-015-1440-2,"HU YAN: ""Preparation and characterization of composite hydrogel beads based on sodium alginate""",ACTIVE
55,EP,A4,EP 3368016 A4,050-573-184-014-732,2019-05-22,2019,EP 16860689 A,2016-10-26,US 201562246462 P;;US 201662351162 P;;US 2016/0058866 W,2015-10-26,REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,,HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/050-573-184-014-732,Search Report,no,7,0,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K9/16;;C08L5/04,,2,1,090-331-141-530-63X,23512290;;10.1002/mabi.201200409,"FERDOUS KHAN ET AL: ""Polysaccharides and Their Derivatives for Versatile Tissue Engineering Application : Polysaccharides and Their Derivatives for Versatile Tissue Engineering Application"", MACROMOLECULAR BIOSCIENCE, vol. 13, no. 4, 19 March 2013 (2013-03-19), DE, pages 395 - 421, XP055380163, ISSN: 1616-5187, DOI: 10.1002/mabi.201200409;;See also references of WO 2017075055A1",ACTIVE
56,WO,A1,WO 2019/145919 A1,191-116-585-927-056,2019-08-01,2019,IB 2019050668 W,2019-01-28,IN 201821003232 A,2018-01-29,HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS,"Present invention relates to compounds of formula (1) its enantiomers, diastereomers, racemic mixtures and their pharmaceutically acceptable salts. This invention also directed to antibacterial drug compounds that are capable of treating bacterial infection which are hard to treat with existing drug compounds.",CADILA HEALTHCARE LTD,SHARMA RAJIV;;IYER PRAVIN;;DESAI JIGAR;;KUMAR SANJAY S,,https://lens.org/191-116-585-927-056,Patent Application,yes,9,0,6,6,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;A61K31/4709;;A61K31/538;;A61K31/5415;;A61K45/06;;A61P31/04;;C07D413/14;;C07D417/14;;A61P31/06;;A61K31/4709;;A61K31/498;;A61K31/538;;A61K31/5415;;C07D405/14;;C07D413/14;;C07D417/14,C07D405/14;;A61K31/04;;A61K31/4704;;C07D413/14;;C07D417/14,,6,3,021-654-885-635-972;;093-757-551-295-203;;093-757-551-295-203,10.1016/b978-0-12-374194-3.00015-9;;22779424;;10.1021/jm300690s;;22779424;;10.1021/jm300690s,"PAOLA CIAPETTI AND BRUNO GIETHLEN ED - CAMILLE GEORGES WERMUTH: ""Chapter 15 - Molecular Variations Based on Isosteric Replacements"", 1 January 2008, THE PRACTICE OF MEDICINAL CHEMISTRY (THIRD EDIT, ELSEVIER, NL, PAGE(S) 290 - 342, ISBN: 978-0-12-374194-3, XP009142466;;G.A. JACOBY, CID, vol. 41, no. 2, 2005, pages SD120 - S126;;J ANTIMICROB CHEMOTHER, vol. 71, 2016, pages 1905 - 1913;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, 2014, pages 4889 - 4905;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 15, 2012, pages 6916;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, 2012, pages 6916 - 6933",PENDING
57,EP,A1,EP 3368016 A1,077-922-399-596-517,2018-09-05,2018,EP 16860689 A,2016-10-26,US 201562246462 P;;US 201662351162 P;;US 2016/0058866 W,2015-10-26,REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,,HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/077-922-399-596-517,Patent Application,yes,0,0,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K9/16;;C08L5/04,,0,0,,,,ACTIVE
58,EP,A1,EP 3821880 A1,146-799-539-967-624,2021-05-19,2021,EP 20201770 A,2016-10-26,US 201562246462 P;;US 201662351162 P;;EP 16860689 A;;US 2016/0058866 W,2015-10-26,OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,"The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.
",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/146-799-539-967-624,Patent Application,yes,44,0,19,19,6,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K9/16;;A61K9/127;;A61K9/50;;A61K47/36;;C08L5/04,,33,19,038-453-280-861-711;;014-523-979-262-456;;073-103-221-858-781;;089-511-071-398-110;;020-383-628-979-717;;058-504-564-469-706;;014-702-718-112-947;;103-208-470-324-673;;094-503-397-423-161;;020-277-467-522-783;;051-076-139-709-120;;106-794-448-070-391;;040-660-263-282-64X;;088-499-001-661-90X;;052-261-701-347-042;;009-392-028-195-798;;031-193-494-699-18X;;054-377-130-723-012;;098-515-979-374-914,10.1002/bit.260330111;;18587846;;21950520;;pmc3254257;;10.1021/bc200295y;;10.1016/j.biomaterials.2015.01.048;;25736493;;10.1021/bc8004446;;pmc2677645;;19053305;;pmc3623454;;10.1021/bm4000508;;23448682;;10.1016/s0040-4020(01)86295-5;;10.1021/jo00836a048;;5474325;;10.1021/ja00031a062;;10.1038/nbt0889-793;;0008001117;;10.1016/0092-8674(94)90068-x;;8001117;;pmc3082463;;10.1126/science.1151526;;18029452;;6375546;;10.1146/annurev.pa.24.040184.001215;;10.1146/annurev.pharmtox.24.1.199;;18570315;;10.1002/jbm.a.32134;;pmc2913724;;10.1016/j.carbpol.2014.06.045;;25129792;;10.1002/jbm.a.34701;;23505227;;10.1016/j.biomaterials.2004.02.018;;15207459;;10.1007/bf03219073;;10.1016/j.jconrel.2004.09.025;;15653130;;26806652;;10.1002/adhm.201500757;;pmc4849477,"MARTINSEN A. ET AL., BIOTECH. & BIOENG., vol. 33, 1989, pages 79 - 89;;KARVER ET AL., BIOCONJUGATE CHEM, vol. 22, no. 11, 2011, pages 2263 - 2270;;DESAI ET AL., BIOMATERIALS, vol. 50, 2015, pages 30 - 37;;DEVARAJ ET AL., BIOCONJUGATE CHEM, vol. 19, no. 12, 2008, pages 2297 - 2299;;ALGE ET AL., BIOMACROMOL, vol. 14, no. 4, 2013, pages 949 - 953;;""Harrison's Principles of Internal Medicine"", 1997, MEDICAL ECONOMICS CO.;;""Pharmacological Basis of Therapeutics"", 1990, UNITED STATES PHARMACOPEIA;;BEAUCAGE ET AL., TETRAHEDRON, vol. 49, no. 10, 1993, pages 1925;;LETSINGER, J. ORG. CHEM., vol. 35, 1970, pages 3800;;EGHOLM, J. AM. CHEM. SOC., vol. 114, 1992, pages 1895;;MEIER ET AL., CHEM. INT. ED. ENGL., vol. 31, 1992, pages 1008;;NIELSEN, NATURE, vol. 365, 1993, pages 566;;DIJKE ET AL.: ""Growth Factors for Wound Healing"", BIOLTECHNOLOGY, vol. 7, 1989, pages 793 - 798, XP000073312, DOI: 10.1038/nbt0889-793;;""Clinicians' Pocket Guide to Chronic Wound Repair"", 1998, SPRINGHOUSE CORPORATION, pages: 85;;ZIEGLER T.R.PIERCE, G.F.HERNDON, D.N.: ""International Symposium on Growth Factors and Wound Healing: Basic Science & Potential Clinical Applications"", 1995, SPRINGER VERLAG;;JONES ET AL., MOL. ENDOCRINOL., 1992, pages 611961;;SASAI ET AL., CELL, 1994, pages 791779 - 790;;FUKUI ET AL., DEVEL. BIOL., vol. 159, 1993, pages 1 - 31;;WANG ET AL., BIOL. CHEM., vol. 271, 1996, pages 44684476;;JUNYING YU, SCIENCE, vol. 318, 2007, pages 1917 - 1920;;TAKAHASHI K., CELL, vol. 131, 2007, pages 1 - 12;;""Trends in Biotechnology"", vol. 18, 2000, JOHN WILEY & SONS, INC., article ""Culture of Cells for Tissue Engineering"", pages: 17 - 19;;URQUHART ET AL., ANN. REV. PHARMACOL. TOXICOL., vol. 24, 1984, pages 199 - 236;;""Controlled Release of Pesticides and Pharmaceuticals"", 1981, PLENUM PRESS;;KS ANSETH, BIOMED. MATER. RES. A, vol. 90, 2009, pages 720 - 729;;PP KUNDU, CARBOHYDRATE POLYMERS, vol. 112, 2014, pages 627 - 637;;T. BAL, J. BIOMED. MATER. RES. PART A, vol. 102A, 2014, pages 487 - 495;;C. E. SCHMIDT, BIOMATERIALS, vol. 26, 2005, pages 125 - 135;;Y.M. LEE, MACROMOL. RESEARCH, vol. 14, 2006, pages 87 - 93;;C.P. COVAS, MAT. SCI. APP., vol. 2, 2011, pages 509 - 520;;W.F. MIELER, TRANS. AM. OPHTALMOL. SOC., vol. 106, 2008, pages 206 - 214;;W.M. TIAN, CONTROLLED RELEASE, vol. 102, 2005, pages 13 - 22;;KOSHY ET AL., ADVANCED HEALTHCARE MATERIALS, vol. 5, 2016, pages 541 - 547",PENDING
59,CN,A,CN 108430458 A,007-084-686-610-423,2018-08-21,2018,CN 201680062497 A,2016-10-26,US 201562246462 P;;US 201662351162 P;;US 2016/0058866 W,2015-10-26,REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,"The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/007-084-686-610-423,Patent Application,no,2,5,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K9/16;;C08L5/04,,0,0,,,,ACTIVE
60,US,A1,US 2021/0052597 A1,102-062-617-079-145,2021-02-25,2021,US 201916965475 A,2019-01-28,IN 201821003232 A;;IB 2019050668 W,2018-01-29,HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS,"Present invention relates to compounds of formula (1) its enantiomers, diastereomers, racemic mixtures and their pharmaceutically acceptable salts. This invention also directed to antibacterial drug compounds that are capable of treating bacterial infection which are hard to treat with existing drug compounds.",CADILA HEALTHCARE LTD,SHARMA RAJIV;;IYER PRAVIN;;DESAI JIGAR;;KUMAR SANJAY S,CADILA HEALTHCARE LIMITED (2020-08-05),https://lens.org/102-062-617-079-145,Patent Application,yes,0,2,6,6,0,A61K31/5415;;A61K31/4709;;A61K31/4709;;A61K31/498;;A61K31/538;;A61K31/538;;A61K31/5415;;A61K45/06;;A61P31/04;;A61P31/06;;C07D405/14;;C07D405/14;;C07D405/14;;C07D413/14;;C07D413/14;;C07D413/14;;C07D417/14;;C07D417/14;;C07D417/14,A61K31/5415;;A61K31/4709;;A61K31/498;;A61K31/538;;A61P31/06;;C07D405/14;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
61,ES,T3,ES 2846848 T3,097-092-803-270-101,2021-07-29,2021,ES 16860689 T,2016-10-26,US 201562246462 P;;US 201662351162 P;;US 2016/0058866 W,2015-10-26,Polisacáridos reducidos y oxidados y métodos de uso de los mismos,"Una composición que comprende un polisacárido reducido, en donde dicho polisacárido reducido (a) comprende menos de un 2% de aldehídos residuales; o (b) comprende menos de un 3% de aldehídos residuales; en donde dicho polisacárido reducido se produce haciendo reaccionar un polisacárido con un agente oxidante específico de diol, produciendo de este modo un polisacárido oxidado que contiene aldehídos que comprende 0,1% o más de oxidación en una base molar; continuando con una reacción de dicho polisacárido oxidado con un agente reductor específico de aldehído soluble en agua para reducir los restos de aldehído presentes en el polisacárido oxidado a restos de alcohol y producir dicho polisacárido reducido; en donde dicho agente reductor específico de aldehído soluble en agua no es borohidruro de sodio; y en donde dicho polisacárido se selecciona a partir del grupo que consiste en alginato, agarosa, pululano, escleroglucano, quitosano, elsinano, goma de xantano, manosa, gelano, levano, celulosa, ácido hialurónico, condroitín sulfato A, condroitín sulfato C, condroitín sulfato E y β-d-glucanos; opcionalmente en donde dicho polisacárido es alginato.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/097-092-803-270-101,Granted Patent,no,0,0,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K9/16;;C08L5/04,,0,0,,,,ACTIVE
62,WO,A9,WO 2017/075055 A9,101-996-755-669-170,2017-10-05,2017,US 2016/0058866 W,2016-10-26,US 201562246462 P;;US 201662351162 P,2015-10-26,REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,"The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/101-996-755-669-170,Search Report,yes,0,0,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K9/16;;C08L5/04,,0,0,,,,PENDING
63,EP,A1,EP 3746438 A1,161-231-455-618-373,2020-12-09,2020,EP 19709102 A,2019-01-28,IN 201821003232 A;;IB 2019050668 W,2018-01-29,HETEROCYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS,,CADILA HEALTHCARE LTD,SHARMA RAJIV;;IYER PRAVIN;;DESAI JIGAR;;KUMAR SANJAY S,,https://lens.org/161-231-455-618-373,Patent Application,yes,0,0,6,6,0,A61K31/5415;;A61K31/4709;;A61K31/4709;;A61K31/498;;A61K31/538;;A61K31/538;;A61K31/5415;;A61K45/06;;A61P31/04;;A61P31/06;;C07D405/14;;C07D405/14;;C07D405/14;;C07D413/14;;C07D413/14;;C07D413/14;;C07D417/14;;C07D417/14;;C07D417/14,C07D405/14;;A61K31/04;;A61K31/4704;;C07D413/14;;C07D417/14,,1,0,,,See references of WO 2019145919A1,DISCONTINUED
64,EP,B1,EP 3368016 B1,169-431-595-023-125,2020-10-21,2020,EP 16860689 A,2016-10-26,US 201562246462 P;;US 201662351162 P;;US 2016/0058866 W,2015-10-26,REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,,HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/169-431-595-023-125,Granted Patent,yes,11,0,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K9/16;;C08L5/04,,4,0,,,"FERDOUS KHAN ET AL: ""Polysaccharides and Their Derivatives for Versatile Tissue Engineering Application : Polysaccharides and Their Derivatives for Versatile Tissue Engineering Application"", MACROMOLECULAR BIOSCIENCE, vol. 13, no. 4, 19 March 2013 (2013-03-19) , pages 395-421, XP055380163, DE ISSN: 1616-5187, DOI: 10.1002/mabi.201200409;;KHAN ET AL.: 'Polysaccharides and Their Derivatives for Versatile Tissue Engineering Application' MACROMOLECULAR BIOSCIENCE 2013, pages 1 - 27, XP055380163;;RAMACHANDRAN ET AL.: 'Efficient Synthesis of Enantiometrically Pure C2-Symmetric Diols via the Allylboration of Appropriate Dialdehydes' TETRAHEDRON LETTERS vol. 38, 1997, pages 2417 - 2420, XP004056721;;MUFAMADI ET AL.: 'A Review on Composite Liposomal Technologies for Specialized Drug Delivery' JOURNAL OF DRUG DELIVERY 2011, pages 1 - 19, XP055089657",ACTIVE
65,WO,A1,WO 2017/075055 A1,124-823-710-606-685,2017-05-04,2017,US 2016/0058866 W,2016-10-26,US 201562246462 P;;US 201662351162 P,2015-10-26,REDUCED AND OXIDIZED POLYSACCHARIDES AND METHODS OF USE THEREOF,"The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.",HARVARD COLLEGE,MOONEY DAVID J;;STAFFORD ALEXANDER;;DESAI RAJIV;;MARTINICK KATHLEEN,,https://lens.org/124-823-710-606-685,Patent Application,yes,5,2,19,19,0,C08B37/0084;;C08J3/075;;A61K9/06;;A61K47/36;;A61K9/1271;;A61K9/5161;;A61K9/0046;;A61K9/0048;;A61P9/10;;A61P27/02;;A61P27/16;;C08J2305/04;;C08L5/04;;A61K9/0046;;A61K9/0048;;A61K9/06;;A61K9/10;;A61K9/127;;C08B37/0084;;A61K47/36;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/10;;A61K9/1652;;A61K9/5042;;A61K9/127;;A61K9/10;;A61K9/06;;C08L5/04;;A61K9/0046;;A61K9/0048;;C08B37/0084;;A61K47/36;;A61K47/6903;;A61K9/1271;;A61K9/5161,A61K9/16;;C08L5/04,,8,7,090-331-141-530-63X;;152-149-742-353-444;;088-545-957-138-181;;073-103-221-858-781;;089-511-071-398-110;;014-523-979-262-456;;020-383-628-979-717,23512290;;10.1002/mabi.201200409;;10.1016/s0040-4039(97)00414-0;;pmc3065812;;10.1155/2011/939851;;21490759;;10.1016/j.biomaterials.2015.01.048;;25736493;;10.1021/bc8004446;;pmc2677645;;19053305;;21950520;;pmc3254257;;10.1021/bc200295y;;pmc3623454;;10.1021/bm4000508;;23448682,"KHAN ET AL.: ""Polysaccharides and Their Derivatives for Versatile Tissue Engineering Application"", MACROMOLECULAR BIOSCIENCE, 2013, pages 1 - 27, XP055380163;;RAMACHANDRAN ET AL.: ""Efficient Synthesis of Enantiometrically Pure C2-Symmetric Diols via the Allylboration of Appropriate Dialdehydes"", TETRAHEDRON LETTERS, vol. 38, 1997, pages 2417 - 2420, XP004056721;;MUFAMADI ET AL.: ""A Review on Composite Liposomal Technologies for Specialized Drug Delivery"", JOURNAL OF DRUG DELIVERY, 2011, pages 1 - 19, XP055089657;;DESAI ET AL., BIOMATERIALS, vol. 50, 2015, pages 30 - 37;;DEVARAJ ET AL., BIOCONJUGATE CHEM., vol. 19, no. 12, 2008, pages 2297 - 2299;;KARVER ET AL., BIOCONJUGATE CHEM., vol. 22, no. 11, 2011, pages 2263 - 2270;;ALGE ET AL., BIOMACROMOL., vol. 14, no. 4, 2013, pages 949 - 953;;See also references of EP 3368016A4",PENDING
66,US,B2,US 11570193 B2,174-534-078-797-715,2023-01-31,2023,US 201916698989 A,2019-11-28,IN 201941037953 A,2019-09-20,Malware propagation risk assessment in software defined networks,"Described herein are systems, methods, and software to identify propagation risk of threats in a computing environment. In one implementation, a management service may identify a connection tree for a computing environment based on forwarding rules for virtual nodes in the computing environment. The management service may further, for each connection in the connection tree, determine a threat value based at least on a protocol associated with the connection. The management service may also identify a threat to a virtual node of the virtual nodes and generate a threat propagation summary for the threat based on the one or more minimum or maximum spanning trees.",VMWARE INC,BHALERAO ANAND JAYSINGH;;DESAI ANERI RAJIV;;AJMANI DASHMEET KAUR,VMWARE INC (2019-10-18),https://lens.org/174-534-078-797-715,Granted Patent,yes,14,0,2,2,0,H04L63/145;;H04L63/1425;;G06F9/45558;;G06F2009/45595;;H04L45/48;;H04L63/1433;;H04L45/48;;G06F2009/45595;;H04L63/1425;;G06F9/45558,H04L9/40;;G06F9/455;;H04L45/48,,2,1,057-445-830-734-194,10.1016/j.cose.2018.07.010,"Dourado et al, “Design of connection networks with bounded number of non-terminal vertices”, (Apr. 9, 2014), Sociedade Brasileira de Matematica, Matematica Contemporanea, vol. 42, 39-48 (Year: 2014).;;Tripathy et al, “Risk based Security Enforcement in Software Defined Network”, (Jul. 31, 2018), Elsevier, ScienceDirect, Computers & Security 78, 321-335 (Year: 2018).",ACTIVE
67,CN,A,CN 111212574 A,173-553-563-482-298,2020-05-29,2020,CN 201880066652 A,2018-10-11,US 201762572090 P;;EP 2018077761 W,2017-10-13,A METHOD OF PRODUCING FROZEN CONFECTION WITH PROTEIN AGGLOMERATION AND DELAYED SUCROSE ADDITION,"The invention relates to a method of producing a frozen confection product, the method comprising the steps of: providing an ingredient mix free from added sugar or comprises below 0.2 % wt, the composition comprising 3-17 wt. % fat, 3-17 wt. % milk solids non-fat, and 1-10 wt. % protein comprising casein and whey, the ingredient mix having a pH of 6.1- 6.4; homogenising the ingredient mix and subsequently pasteurizing the composition at a temperature of 80 DEG C-100 DEG C for a period of 0.5-3 min to form agglomerated protein comprising casein and whey, adding 3-25 wt. % of sugar to the ingredient mix; and freezing while optionally aerating the ingredient mix, to form a frozen confection product. The invention also relates to a product obtained with the method.",NESTEC SA,DESAI NILESH;;MARK STEPHEN;;VAGHELA MADANSINH;;DAVE RAJIV;;PANDYA NIRAV,,https://lens.org/173-553-563-482-298,Patent Application,no,7,0,7,7,0,A23G9/32;;A23G9/38;;A23G9/52;;A23G9/04;;A23G9/34;;A23G9/38;;A23G9/46,A23G9/32;;A23G9/38;;A23G9/52,,0,0,,,,PENDING
68,ES,T3,ES 2388684 T3,045-448-555-618-495,2012-10-17,2012,ES 06744545 T,2006-04-21,IN 505MU2005 A;;IB 2006000978 W,2005-04-25,Adyuvantes de vacunas,"Mycobacterium w inactivo para uso como adyuvante en el tratamiento profiláctico o terapéutico mediante vacunación, en donde dicho tratamiento comprende la administración a un mamífero de una vacuna que comprende Mycobacterium w mezclado, formulado, conjugado, cebado, fusionado y/o ligado con un antígeno, en donde dicho Mycobacterium w actúa como un adyuvante que potencia la inmunogenicidad de dicho antígeno.",CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH;;MODI INDRAVADAN;;MODI RAJIV;;GHOSH PRASANTA;;DESAI NIRAV,,https://lens.org/045-448-555-618-495,Granted Patent,no,0,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00;;A61K39/39,,0,0,,,,ACTIVE
69,WO,A1,WO 2019/072979 A1,160-418-759-681-551,2019-04-18,2019,EP 2018077761 W,2018-10-11,US 201762572090 P,2017-10-13,A METHOD OF PRODUCING FROZEN CONFECTION WITH PROTEIN AGGLOMERATION AND DELAYED SUCROSE ADDITION,"The invention relates to a method of producing a frozen confection product, the method comprising the steps of: providing an ingredient mix free from added sugar or comprises below 0.2 % wt, the composition comprising 3 - 17 wt. % fat, 3 - 17 wt. % milk solids non-fat, and 1 - 10 wt. % protein comprising casein and whey, the ingredient mix having a pH of 6.1 – 6.4; homogenising the ingredient mix and subsequently pasteurizing the composition at a temperature of 80°- 100°C for a period of 0.5 – 3 min to form agglomerated protein comprising casein and whey, adding 3 – 25 wt. % of sugar to the ingredient mix; and freezing while optionally aerating the ingredient mix, to form a frozen confection product. The invention also relates to a product obtained with the method.",NESTEC SA,DESAI NILESH;;MARK STEPHEN;;VAGHELA MADANSINH;;DAVE RAJIV;;PANDYA NIRAV,,https://lens.org/160-418-759-681-551,Patent Application,yes,6,0,7,7,0,A23G9/32;;A23G9/38;;A23G9/52;;A23G9/04;;A23G9/34;;A23G9/38;;A23G9/46,A23G9/32;;A23G9/38;;A23G9/52,,0,0,,,,PENDING
70,JP,A,JP 2016065098 A,137-970-072-241-846,2016-04-28,2016,JP 2016001660 A,2016-01-07,IN 464MU2010 A,2010-02-19,PHARMACEUTICAL COMPOSITION OF DEAD CELLS WITH SUBSTANTIALLY RETAINED IMMUNOGENICITY,"PROBLEM TO BE SOLVED: To prepare a stable composition of dead cells with substantially retained immunogenic properties.SOLUTION: This invention discloses a process for lyophilization of treated cells which comprises the use of a solution containing trehalose along with amphipathic polymer polyvinylpyrrolidone. Further, the invention discloses a process of treating, freezing, lyophilizing and reconstituting cancer cells. Immunomodulator treated dead, but intact cancerous cells are recovered, which can subsequently be used for cancer immunotherapy.SELECTED DRAWING: None",CADILA PHARMACEUTICALS LTD,BAKULESH MAFATLAL KHAMAR;;SATINDER SINGH;;NIRAV MANOJKUMAR DESAI;;RAJIV INDRAVADAN MODI,,https://lens.org/137-970-072-241-846,Patent Application,no,2,3,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,A61K39/00;;A61K39/39;;A61P35/00,,1,0,,,"INDIAN J BIOTECHNOL., VOL.4 P.106-114 (2005), JPN6014049585",ACTIVE
71,BR,A2,BR 112012020303 A2,158-791-680-867-349,2019-09-24,2019,BR 112012020303 A,2011-02-17,IB 2011050655 W;;IN 464MU2010 A,2010-02-19,"""composição estável de células mortas com propriedades imunogênicas substancialmente retidas, e, processo e método de preparação da composição.""","processo para preparar homo- ou copolímeros de isobuteno de alta reatividade, e, polímero de isobuteno. a invenção se refere à produção de homo- ou copolímeros de isobuteno altamente reativos tendo um conteúdo de ligações duplas de vinilideno por terminação da cadeia de poli-isobuteno de pelo menos 50% em moles e uma polidispersibilidade perferivelmente de 1,05 a menos do que 3,5, em que o isobuteno ou um mistura de monômeros contendo isobuteno são polimerizados na presença de um complexo doador de tri-halogeneto de aluminio atuando como um catalisador de polimerização, em particular um complexo doador de tricloreto de alumínio, compreendendo um composto orgânico tendo pelo menos uma função éter ou uma função éster de ácido carboxílico como o doador.",CADILA PHARMACEUTICALS LTD,BAKULESH MAFATLAL KHAMAR;;NIRAV MANOJKUMAR DESAI;;RAJIV INDRAVADAN MODI;;SATINDER SINGH,,https://lens.org/158-791-680-867-349,Patent Application,no,0,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574,,0,0,,,,DISCONTINUED
72,ES,T3,ES 2648139 T3,097-379-683-625-999,2017-12-28,2017,ES 11744341 T,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,Una composición farmacéutica de células muertas con inmunogenicidad sustancialmente retenida,"Un procedimiento para preparar una composición de células cancerosas muertas con propiedades inmunogénicas sustancialmente retenidas, que comprende a. Muerte de células cancerosas, b. tratar la composición obtenida a partir de la etapa a) con crioconservante intracelular trehalosa, c. tratar la composición obtenida de la etapa b) con povidona crioconservante extracelular (PVP), d. congelar instantáneamente la composición obtenida de la etapa c) con la formulación congelada antes de la liofilización, en la que la congelación rápida se realiza por debajo de -100ºC, y e. liofilización de la composición obtenida a partir de la etapa d).",CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/097-379-683-625-999,Granted Patent,no,0,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574;;A01N1/02;;A61K35/00;;A61K39/00,,0,0,,,,ACTIVE
73,WO,A3,WO 2009/001204 A3,069-630-638-786-824,2009-12-30,2009,IB 2008001675 W,2008-06-26,IN 1235MU2007 A,2007-06-28,MITOGEN ACTIVATED PROTEIN KINASE MODULATOR,The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.,CADILA PHARMACEUTICALS LTD;;MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,,https://lens.org/069-630-638-786-824,Search Report,yes,3,0,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,A61K35/74;;A01N63/02,,0,0,,,,PENDING
74,WO,A1,WO 2011/101796 A1,141-377-470-285-921,2011-08-25,2011,IB 2011050655 W,2011-02-17,IN 464MU2010 A,2010-02-19,A PHARMACEUTICAL COMPOSITION OF KILLED CELLS WITH SUBSTANTIALLY RETAINED IMMUNOGENICITY,"This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting, lmmunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.",CADILA PHARMACEUTICALS LTD;;KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/141-377-470-285-921,Patent Application,yes,18,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574,,8,4,106-101-300-099-361;;122-298-029-956-320;;009-511-849-416-294;;008-700-669-842-399,15892827;;10.1111/j.1464-410x.2005.05528.x;;10.1385/1592596886;;10.1016/j.bbamem.2006.12.007;;pmc1994664;;17239814;;10.1146/annurev.bb.03.060174.002013,"See also references of EP 2537030A4;;HARDEV S. PANDHA; DORTHE COOK; REBECCA GREENHALGH; ANGUS DALGLEISH, BJU INTERNATIONAL, vol. 95, 2005, pages 1336 - 1343;;D.B. LOWRIE; R.G. WHALEN: ""DNA Vaccines: Methods and Protocols"", 2000, HUMANA PRESS;;""Biochimica et Biophysica Acta (BBA"", BIOMEMBRANES, vol. 1768, no. 3, March 2007 (2007-03-01), pages 728 - 736;;ANNUAL REVIEW OF BIOPHYSICS AND BIOENGINEERING, vol. 3, pages 341 - 363;;INFECT IMMUN., vol. 21, no. 1, July 1978 (1978-07-01), pages 348;;DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol. 62, no. 2, October 2008 (2008-10-01), pages 133 - 141;;MORPHOLOGICAL FEATURES OF CELL DEATH. NEWS IN PHYSIOLOGICAL SCIENCES, vol. 19, no. 3, 2004, pages 124 - 128",PENDING
75,EP,A2,EP 2170083 A2,166-310-815-399-627,2010-04-07,2010,EP 08762971 A,2008-06-26,IB 2008001675 W;;IN 1235MU2007 A,2007-06-28,MITOGEN ACTIVATED PROTEIN KINASE MODULATOR,,CADILA PHARMACEUTICALS LTD,MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,,https://lens.org/166-310-815-399-627,Patent Application,yes,0,0,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,A61K35/74;;A61K38/54;;A61K38/00,,0,0,,,,DISCONTINUED
76,CN,A,CN 102753975 A,102-717-373-137-170,2012-10-24,2012,CN 201180009560 A,2011-02-17,IB 2011050655 W;;IN 464MU2010 A,2010-02-19,A pharmaceutical composition of killed cells with substantially retained immunogenicity,"This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting, lmmunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.",CADILA PHARMACEUTICALS LTD,MAFATLAL KHAMAR BAKULESH;;SATINDER SINGH;;MANOJKUMAR DESAI NIRAV;;INDRAVADAN MODI RAJIV,,https://lens.org/102-717-373-137-170,Patent Application,no,4,1,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574,,3,1,019-928-732-026-424,10.1002/jps.21409;;18399536,"ROY ET AL.: ""effect of pH on Stability of Recombinant Botulinum Serotype A Vaccine in Aqueous Solution and During Storage of Freeze-Dried Formulations"", 《JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 97, no. 12, 31 December 2008 (2008-12-31), pages 5132 - 5144, XP055094761, DOI: doi:10.1002/jps.21409;;KADAM ET AL: ""effect of excipients on product characteristics and structure of lyophilized lasota vacine"", 《INDIAN JOURNAL OF BIOTECHNOLOGY》, vol. 4, no. 1, 1 January 2005 (2005-01-01), pages 106 - 114;;李正丰等: ""口蹄疫病毒抗原保护剂的筛选和优化"", 《浙江农业科学》, no. 5, 31 May 2009 (2009-05-31), pages 1016 - 1020",ACTIVE
77,US,A1,US 2018/0042850 A1,151-734-159-335-24X,2018-02-15,2018,US 201715722511 A,2017-10-02,US 201715722511 A;;IN 464MU2010 A;;US 201113579607 A;;IB 2011050655 W,2010-02-19,Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity,"The present invention relates to a lyophilized composition comprising killed cancer cells with substantially retained immunogenicity and morphology, an intracellular cryopreservative such as trehalose and an extracellular cryopreservative such as polyvinylpyrrolidone. The present invention also relates to a process for the preparation of said lyophilized composition. The lyophilized composition of the present invention can be used for cancer immunotherapy.",CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,CADILA PHARMACEUTICALS LTD (2012-12-21),https://lens.org/151-734-159-335-24X,Patent Application,yes,3,0,1,18,0,A01N1/0221;;A61K35/13;;A61K39/0011;;A61K2039/5152;;C07H3/04;;A61K9/19;;A61K39/39;;A61K39/0011;;A61K47/26;;A61K47/32;;C08F26/10;;C12N1/20;;A61K2039/5152;;G01N2333/36;;C07H3/04;;A61K47/36;;A61K35/13;;A01N1/0221,A61K9/19;;A61K39/00;;A61K39/39;;A61K47/26;;A61K47/32;;A61K47/36;;C12N1/20,,0,0,,,,DISCONTINUED
78,GB,A,GB 2463434 A,146-705-313-067-092,2010-03-17,2010,GB 201000933 A,2008-06-26,IB 2008001675 W;;IN 1235MU2007 A,2007-06-28,Mitogen activated protein kinase modulator,The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacteritum w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.,CADILA PHARMACEUTICALS LTD,MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATIAL,,https://lens.org/146-705-313-067-092,Patent Application,no,3,0,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,C07K14/35;;A61K35/74;;A61K39/04,,0,0,,,,INACTIVE
79,EP,A1,EP 2537030 A1,003-634-689-305-940,2012-12-26,2012,EP 11744341 A,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,A PHARMACEUTICAL COMPOSITION OF KILLED CELLS WITH SUBSTANTIALLY RETAINED IMMUNOGENICITY,,CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/003-634-689-305-940,Patent Application,yes,0,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574;;A01N1/02;;A61K35/00;;A61K39/00,,0,0,,,,ACTIVE
80,CA,C,CA 2789915 C,179-813-542-613-742,2018-05-01,2018,CA 2789915 A,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,A PHARMACEUTICAL COMPOSITION OF KILLED CELLS WITH SUBSTANTIALLY RETAINED IMMUNOGENICITY,"This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting, lmmunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.",CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/179-813-542-613-742,Granted Patent,no,0,0,17,18,0,A61K35/13;;A61K2039/5152;;A01N1/00;;A61K39/0011;;A61P35/00;;A61P37/04;;A61K35/13;;A61K2039/5152;;A01N1/00;;A61K39/0011,,,0,0,,,,ACTIVE
81,US,B2,US 9795659 B2,049-283-669-547-341,2017-10-24,2017,US 201113579607 A,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,Pharmaceutical composition of killed cells with substantially retained immunogenicity,"This invention discloses the process for lyophilization of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.",KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN;;CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,CADILA PHARMACEUTICALS LTD (2012-12-21),https://lens.org/049-283-669-547-341,Granted Patent,yes,2,2,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,A61K35/13;;A01N1/00;;A61K39/00,,1,0,,,"International Search Report and Written Opinion issued by the PCT on Jun. 24, 2011.",ACTIVE
82,CA,A1,CA 2789915 A1,102-383-586-449-912,2011-08-25,2011,CA 2789915 A,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,A PHARMACEUTICAL COMPOSITION OF KILLED CELLS WITH SUBSTANTIALLY RETAINED IMMUNOGENICITY,"This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting, lmmunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.",CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/102-383-586-449-912,Patent Application,no,0,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574,,0,0,,,,ACTIVE
83,CA,A1,CA 2691702 A1,156-379-441-903-288,2008-12-31,2008,CA 2691702 A,2008-06-26,IN 1235MU2007 A;;IB 2008001675 W,2007-06-28,MITOGEN ACTIVATED PROTEIN KINASE MODULATOR,The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.,CADILA PHARMACEUTICALS LTD,DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL;;BHARDWAJ DEVESH;;MODI RAJIV INDRAVADAN,,https://lens.org/156-379-441-903-288,Patent Application,no,0,0,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,A61K39/04;;A61K35/74,,0,0,,,,DISCONTINUED
84,EA,B1,EA 027915 B1,196-438-283-315-357,2017-09-29,2017,EA 201290786 A,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,METHOD OF PREPARING A COMPOSITION OF KILLED CELLS WITH SUBSTANTIALLY RETAINED IMMUNOGENICITY,"This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing trehalose along with amphipathic polymer polyvinylpyrrolidone. Further the invention discloses the process of treating cancer cells, freezing, lyophilizing and reconstituting, wherein immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.",CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/196-438-283-315-357,Granted Patent,no,4,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574,,0,0,,,,ACTIVE
85,EP,B1,EP 2537030 B1,041-608-788-332-345,2017-08-30,2017,EP 11744341 A,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,A PHARMACEUTICAL COMPOSITION OF KILLED CELLS WITH SUBSTANTIALLY RETAINED IMMUNOGENICITY,,CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/041-608-788-332-345,Granted Patent,yes,1,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574;;A01N1/02;;A61K35/00;;A61K39/00,,1,1,106-101-300-099-361,15892827;;10.1111/j.1464-410x.2005.05528.x,"HARDEV S. PANDHA ET AL: ""Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy"", BJU INTERNATIONAL, vol. 95, no. 9, 1 June 2005 (2005-06-01), GB, pages 1336 - 1343, XP055348070, ISSN: 1464-4096, DOI: 10.1111/j.1464-410X.2005.05528.x",ACTIVE
86,US,A1,US 2012/0308605 A1,161-151-315-387-382,2012-12-06,2012,US 201113579607 A,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,Pharmaceutical Composition of Killed Cells with Substantially Retained Immunogenicity,"This invention discloses the process for lyophilisation of the treated cells which comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator treated dead, but intact cancerous cells were recovered, which can subsequently be used for cancer immunotherapy.",KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN;;CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,CADILA PHARMACEUTICALS LTD (2012-12-21),https://lens.org/161-151-315-387-382,Patent Application,yes,2,4,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,A61K39/00;;A61P35/00;;A61P37/04,424/277.1,0,0,,,,ACTIVE
87,WO,A2,WO 2009/001204 A2,178-872-377-756-099,2008-12-31,2008,IB 2008001675 W,2008-06-26,IN 1235MU2007 A,2007-06-28,MITOGEN ACTIVATED PROTEIN KINASE MODULATOR,The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.,CADILA PHARMACEUTICALS LTD;;MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,,https://lens.org/178-872-377-756-099,Patent Application,yes,0,1,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,A61K39/04,,0,0,,,,PENDING
88,EP,A4,EP 2537030 A4,108-925-852-009-955,2014-02-12,2014,EP 11744341 A,2011-02-17,IN 464MU2010 A;;IB 2011050655 W,2010-02-19,A PHARMACEUTICAL COMPOSITION OF KILLED CELLS WITH SUBSTANTIALLY RETAINED IMMUNOGENICITY,,CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/108-925-852-009-955,Search Report,no,0,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574;;A01N1/02;;A61K35/00;;A61K39/00,,5,3,019-928-732-026-424;;081-771-926-748-594;;109-755-476-339-308,10.1002/jps.21409;;18399536;;pmc2781091;;20046674;;10.4161/org.5.3.9583;;12818211;;10.1016/s0011-2240(03)00046-4,"SHOUVIK ROY ET AL: ""Effect of pH on stability of recombinant botulinum serotype A vaccine in aqueous solution and during storage of freeze-dried formulations"", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 97, no. 12, 1 December 2008 (2008-12-01), pages 5132 - 5146, XP055094761, ISSN: 0022-3549, DOI: 10.1002/jps.21409;;S S KADAM ET AL: ""Effect of excipients on product characteristics and structure of lyophilized lasota vaccine"", INDIAN JOURNAL OF BIOTECHNOLOGY, vol. 4, no. 1, 1 January 2005 (2005-01-01), pages 106 - 114, XP055094735, ISSN: 0972-5849, Retrieved from the Internet <URL:http://nopr.niscair.res.in/bitstream/123456789/5624/1/IJBT 4(1) 106-114.pdf> [retrieved on 20140103];;BAKHACH, JOSEPH: ""The cryopreservation of composite tissues"", ORGANOGENESIS, vol. 5, no. 3, 1 July 2009 (2009-07-01) - 30 September 2009 (2009-09-30), pages 119 - 126, XP055094703, ISSN: 1555-8592, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2781091/pdf/org0503_0119.pdf> [retrieved on 20140102], DOI: 10.4161/org.5.3.9583;;HUBÁLEK Z: ""Protectants used in the cryopreservation of microorganisms"", CRYOBIOLOGY, ACADEMIC PRESS INC, US, vol. 46, no. 3, 1 June 2003 (2003-06-01), pages 205 - 229, XP002373087, ISSN: 0011-2240, DOI: 10.1016/S0011-2240(03)00046-4;;See also references of WO 2011101796A1",ACTIVE
89,GB,B,GB 2463434 B,134-180-545-893-938,2013-01-30,2013,GB 201000933 A,2008-06-26,IB 2008001675 W;;IN 1235MU2007 A,2007-06-28,Mitogen activated protein kinase modulator,,CADILA PHARMACEUTICALS LTD,MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,,https://lens.org/134-180-545-893-938,Granted Patent,no,8,0,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,C07K14/35;;A61K35/74;;A61K39/04,,0,0,,,,INACTIVE
90,EP,A4,EP 2170083 A4,016-203-901-118-171,2011-09-28,2011,EP 08762971 A,2008-06-26,IB 2008001675 W;;IN 1235MU2007 A,2007-06-28,MITOGEN ACTIVATED PROTEIN KINASE MODULATOR,,CADILA PHARMACEUTICALS LTD,MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,,https://lens.org/016-203-901-118-171,Search Report,no,5,0,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,A61K38/54;;A61K35/74;;A61K38/00,,0,0,,,,DISCONTINUED
91,AU,A1,AU 2008/269427 A1,112-400-120-760-64X,2008-12-31,2008,AU 2008/269427 A,2008-06-26,IN 1235MU2007 A;;IB 2008001675 W,2007-06-28,Mitogen activated protein kinase modulator,,CADILA PHARMACEUTICALS LTD,BHARDWAJ DEVESH;;MODI RAJIV INDRAVADAN;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,,https://lens.org/112-400-120-760-64X,Patent Application,no,0,0,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,A61K39/04,,0,0,,,,DISCONTINUED
92,CN,B,CN 102753975 B,026-481-538-132-472,2015-05-20,2015,CN 201180009560 A,2011-02-17,IB 2011050655 W;;IN 464MU2010 A,2010-02-19,A pharmaceutical composition of killed cells with substantially retained immunogenicity,,CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;SINGH SATINDER;;DESAI NIRAV MANOJKUMAR;;MODI RAJIV INDRAVADAN,,https://lens.org/026-481-538-132-472,Granted Patent,no,0,0,17,18,0,A61K39/0011;;A61K39/0011;;A01N1/00;;A01N1/00;;A61K35/13;;A61K35/13;;A61K2039/5152;;A61K2039/5152;;A61P35/00;;A61P37/04,G01N33/574,,0,0,,,,ACTIVE
93,US,A1,US 2010/0209394 A1,139-545-195-204-522,2010-08-19,2010,US 66685208 A,2008-06-26,IN 1235MU2007 A;;IB 2008001675 W,2007-06-28,MITOGEN ACTIVATED PROTEIN KINASE MODULATOR,The present invention describes the method of modulating MAPK pathways. Further more the invention describes the use of Mycobacterium w for modulation of MAPK pathway intermediates for treatment of MAPK mediated conditions.,CADILA PHARMACEUTICALS LTD,MODI RAJIV INDRAVADAN;;BHARDWAJ DEVESH;;DESAI NIRAV M;;KHAMAR BAKULESH MAFATLAL,CADILA PHARMACEUTICALS LTD (2011-02-21);;CADILA PHARMACEUTICALS LIMITED (2010-01-01),https://lens.org/139-545-195-204-522,Patent Application,yes,3,1,12,12,0,A61K35/74;;A61P29/00;;A61P37/02;;A61P43/00;;A61K35/74;;A61K39/04;;C07K14/35;;A61K35/74,A61P29/00;;A61K35/74;;A61P43/00;;C12N1/20,424/93.4;;435/253.1,0,0,,,,DISCONTINUED
94,US,B2,US 10365949 B2,038-703-750-845-556,2019-07-30,2019,US 201715828068 A,2017-11-30,US 201715828068 A;;US 201762549914 P,2017-08-24,Large-scale asynchronous event processor,"A large-scale asynchronous processor of events in a distributed and parallel processing environment. The processor includes a plurality of processes executing on a plurality of interconnected processors. The plurality of processes including a frontend process, a plurality of dispatcher processes, a plurality of job queues, and a plurality of worker processes. The frontend process is for receiving event notification remote procedure calls from one or more event sources and for publishing event notifications, based on the received calls, to topics of a distributed streaming platform. The plurality of dispatcher process are for consuming event notifications from the topics and for en-queuing jobs, based on the consumed event notifications, to the plurality of job queues. The plurality of worker process are for pulling jobs from the plurality of job queues and for the processing the jobs.",DROPBOX INC,SENAPATY SHASHANK;;AL-RAWI BASHAR;;KANG PENG;;DESAI RAJIV;;ZHOU DAISY LUO,DROPBOX INC (2018-02-12),https://lens.org/038-703-750-845-556,Granted Patent,yes,4,0,2,2,0,G06F9/4881;;G06F9/542;;G06F9/5088;;G06F9/542,G06F9/54;;G06F9/48;;G06F9/50,,0,0,,,,ACTIVE
95,US,A1,US 2024/0028498 A1,001-554-209-563-332,2024-01-25,2024,US 202217965846 A,2022-10-14,IN 202241041950 A,2022-07-22,DYNAMICALLY CAPTURING DEBUG LOGS DURING RUNTIME,"Systems and methods are described herein for dynamic debug logging during application runtime. In an example, a wrapper can be added to the code for functions of the application. During runtime, the wrapper can cause the functions to retain certain debug data. In one example, a function call graph can be constructed, which can include all the possible function call paths for the application. When an error occurs, if the application does not have a stack trace tool or API available, the application can use the function call graph to determine all possible function call paths between the entrant function and the errored function. If an application does have a stack trace tool or API, then the application can retrieve the actual function call path that led to the error. The application can enable a debug flag in the wrapper for each function in the function call path, which can cause those functions to log runtime debug data.",VMWARE INC,DESAI ANERI RAJIV;;PAREKH MANISHA GAMBHIR;;BHALERAO ANAND JAYSINGH;;SANGODKAR AMIT RATNAPAL,VMWARE INC (2022-08-17),https://lens.org/001-554-209-563-332,Patent Application,yes,0,0,1,1,0,G06F8/427;;G06F11/364;;G06F11/366;;G06F11/3636;;G06F11/366;;G06F11/364;;G06F8/427,G06F11/36;;G06F8/41,,0,0,,,,PENDING
96,US,A1,US 2024/0028497 A1,107-389-588-190-202,2024-01-25,2024,US 202217965808 A,2022-10-14,IN 202241041949 A,2022-07-22,DYNAMICALLY CAPTURING DEBUG LOGS DURING RUNTIME,"Systems and methods are described herein for dynamic debug logging during application runtime. In an example, a wrapper can be added to the code for functions of the application. During runtime, the wrapper can cause the functions to retain certain debug data. In one example, a function call graph can be constructed, which can include all the possible function call paths for the application. When an error occurs, if the application does not have a stack trace tool or API available, the application can use the function call graph to determine all possible function call paths between the entrant function and the errored function. If an application does have a stack trace tool or API, then the application can retrieve the actual function call path that led to the error. The application can enable a debug flag in the wrapper for each function in the function call path, which can cause those functions to log runtime debug data.",VMWARE INC,DESAI ANERI RAJIV;;PAREKH MANISHA GAMBHIR;;BHALERAO ANAND JAYSINGH;;SANGODKAR AMIT RATNAPAL,VMWARE INC (2022-08-17),https://lens.org/107-389-588-190-202,Patent Application,yes,3,0,1,1,0,G06F8/427;;G06F11/366;;G06F11/3636;;G06F8/427;;G06F11/366,G06F11/36;;G06F8/41,,0,0,,,,PENDING
97,US,B1,US 6789170 B1,091-442-424-335-322,2004-09-07,2004,US 92310301 A,2001-08-04,US 92310301 A,2001-08-04,System and method for customizing cached data,"
    A system and methods are provided for enabling a cache system, operating on behalf of a data server (e.g., web server, application server, database server), to cache and customize one set of data (e.g., a web page) in different ways for different requests (e.g., to include a client's name, account information, a special logo). An application that generates or produces the data on the data server embeds or includes special tags or markers in customizable data, to identify where custom data should be inserted or substituted. The custom data may be included in client requests or retrieved from the cache system, data server or elsewhere. When the cache system receives a new request for cached data that is customizable, the data is retrieved from cache, the custom data is retrieved and inserted at the corresponding tags and the customized data is served. 
",ORACLE INT CORP,JACOBS LAWRENCE;;LIU XIANG;;NAKHODA SHEHZAAD;;MISHRA RAJIV;;ZENG ZHENG;;DESAI SACHIN,ORACLE INTERNATIONAL CORPORATION (2003-02-06);;ORACLE CORPORATION (2001-08-27),https://lens.org/091-442-424-335-322,Granted Patent,yes,9,108,1,1,0,G06F16/9574;;G06F16/9574,G06F12/00;;G06F17/30,711/133;;709/203;;709/227,13,2,033-987-008-034-789;;100-169-422-750-135,10.1145/375663.375736;;10.1007/3-540-45559-0_2,"Candan, et al., Enabling Dynamic Content Caching for Database-Driven Web Sites. ACM SIGMOD 2001 May 21-24, Santa Barbara, CA, Copyright 2001 ACM.;;Challenger, et al., A Scalable System for Consistently Caching Dynamic Web Data. IBM Research, Yorktown Heights, NY.;;Challenger, et al., A Publishing System for Efficiently Creating Dynamic Web Content. IBM Research, Yorktown Heights, NY.;;Datta, et al., A Comparative Study of Alternative Middle Tier Caching Solutions to Support Dynamic Web Content Acceleration. Proceedings of the 27<th >VLDB Conference, Roma, Italy, 2001.;;Degenaro, et al., A Middleware System Which Intelligently Caches Query Results. IBM Research, Yorktown Heights, NY, Copyright 2000, Springer-Verlag.;;Wessels, et al., ICP and the Squid Web Cache, pp. 1-25. Aug. 13, 1997.;;Wessels, et al., Internet Cache Protocol (ICP), version 2, pp. 1-9. National Laboratory for Applied Network Research/UCSD, Sep. 1997.;;Akamai white paper: Turbo-Charging Dynamic Web Sites with Akamai EdgeSuite, pp. 1-16. www.akamai.com, Sep. 23, 2002. Copyright 2001, Akamai Technologies, Inc.;;Edge Sides Includes (ESI) Overview, pp. 1-7. www.esi.org, Sep. 23, 2002. Copyright 2001, Oracle Corporation, Akamai Technologies, Inc.;;Tsimelzon, et al., Edge Sides Includes ESI-Accelerating E-Business Applications: Language Specification 1.0, pp. 1-12. www.esi.org/language_spec_1-0,html, Sep. 23, 2002. Copyright 2001, Akamai Technologies, Oracle Corporation.;;Nottingham, et al., Edge Side Includes ESI-Accelerating E-Business Applications: Edge Architecture Specification, pp. 1-6. ww.esi.org/architecture_spec_1-0.html, Sep. 23, 2002. Copyright 2001, Akamai Technologies, Oracle Corporation.;;Jacobs, et al., Edge Side Includes ESI-Accelerating E-Business Applications: ESI Invalidation Protocol 1.0, pp. 1-13. www.esi.org/invalidation_protocol_1-0.html, Sep. 23, 2002. Copyright 2001, Oracle Corporation.;;Basu, et al., Edge Side Includes ESI-Accelerating E-Business Applications: JESI Tag Library 1.0 Specification: Tags for Edge-Side Includes in JSP, pp. 1-19. www.esi.org/jesit_tag_lib_1-0.html, Sep. 23, 2002. Copyright 2001, Oracle Corporation, Akamai Technologies, Inc.",EXPIRED
98,US,B1,US 7103714 B1,094-645-954-278-336,2006-09-05,2006,US 92310201 A,2001-08-04,US 92310201 A,2001-08-04,System and method for serving one set of cached data for differing data requests,"A system and method for enabling a cache system, operating on behalf of a data server (e.g., web server, application server, database server), to serve one set of data in response to multiple requests that differ in content or form. In particular, the requests may include different session identifiers for identifying different users, clients or sessions, but they target the same basic set of data (e.g., a web page). When a set of data is cached in response to a request having one session identifier, it can also be served in response to another request having a second session identifier because the session identifiers are deleted, masked, replaced or otherwise ignored when searching the cache system for data responsive to the second request. Also, the cache system may include a requestor's session identifier as part of a data identifier (e.g., URI, hyperlink) within data served to the requester.",ORACLE INT CORP,JACOBS LAWRENCE;;LIU XIANG;;NAKHODA SHEHZAAD;;MISHRA RAJIV;;ZENG ZHENG;;DESAI SACHIN,ORACLE INTERNATIONAL CORPORATION (2003-02-06);;ORACLE CORPORATION (2001-08-27),https://lens.org/094-645-954-278-336,Granted Patent,yes,17,88,1,1,0,H04L67/02;;H04L67/142;;G06F16/9574;;G06F16/9574;;H04L67/142;;H04L67/02,G06F12/00,711/113;;709/228;;709/229;;711/130;;711/133,17,2,033-987-008-034-789;;100-169-422-750-135,10.1145/375663.375736;;10.1007/3-540-45559-0_2,"Candan, et al., Enabling Dynamic Content Caching for Database-Driven Web Sites. ACM SIGMOD May 21-24, 2001, Santa Barbara, CA, Copyright 2001 ACM.;;Challenger, et al., A Scalable System for Consistently Caching Dynamic Web Data. IBM Research, Yorktown Heights, NY.;;Challenger, et al., A Publishing System for Efficiently Creating Dynamic Web Content. IBM Research, Yorktown Heights, NY.;;Datta, et al., A Comparative Study of Alternative Middle Tier Caching Solutions to Support Dynamic Web Content Acceleration. Proceedings of the 27<SUP>th </SUP>VLDB Conference, Roma, Italy, 2001.;;Degenaro, et al., A Middleware System Which Intelligently Caches Query Results. IBM Research, Yorktown Heights, NY, Copyright 2000, Springer-Verlag.;;Wessels, et al., ICP and the Squid Web Cache, pp. 1-25. Aug. 13, 1997.;;Wessels, et al., Internet Cache Protocol (ICP), version 2, pp. 1-9. National Laboratory for Applied Network Research/UCSD, Sep. 1997.;;Kantor, et al., Network News Transfer Protocol: A Proposed Standard for the Stream-Based Transmission of News, pp. 1-27. Feb. 1986.;;Akamai white paper: Turbo-Charging Dynamic Web Sites with Akamai EdgeSuite, pp. 1-16. www.akamai.com, Sep. 23, 2002. Copyright 2001, Akamai Technologies, Inc.;;A Distributed Infrastructure for e-Business-Real Benefits, Measurable Returns, pp. 1-28. www.akamai.com, Sep. 23, 2002. Copyright 2000 and 2001, Akamai Technologies, Inc.;;Edge Sides Includes (ESI) Overview, pp. 1-7. www.esi.org, Sep. 23, 2002. Copyright 2001, Oracle Corporation, Akamai Technologies, Inc.;;Tsimelzon, et al., Edge Sides Includes ESI-Accelerating E-Business Applications: Language Specification 1.0, pp. 1-12. www.esi.org/language<SUB>-</SUB>spec<SUB>-</SUB>1-0.html, Sep. 23, 2002. Copyright 2001, Akamai Technologies, Oracle Corporation.;;Nottingham, et al., Edge Side Includes ESI-Accelerating E-Business Applications: Edge Architecture Specification, pp. 1-6. www.esi.org/architecture<SUB>-</SUB>spec<SUB>-</SUB>1-0.html, Sep. 23, 2002. Copyright 2001, Akamai Technologies, Oracle Corporation.;;Jacobs, et al., Edge Side Includes ESI-Accelerating E-Business Applications: ESI Invalidation Protocol 1.0, pp. 1-13. www.esi.org/invalidation<SUB>-</SUB>protocol<SUB>-</SUB>1-0.html, Sep. 23, 2002. Copyright 2001, Oracle Corporation.;;Basu, et al., Edge Side Includes ESI-Accelerating E-Business Applications: JESI Tag Library 1.0 Specification: Tags for Edge-Side Includes in JSP, pp. 1-19. www.esi.org/jesit<SUB>-</SUB>tag<SUB>-</SUB>lib<SUB>-</SUB>1-0.html, Sep. 23, 2002. Copyright 2001, Oracle Corporation, Akamai Technologies, Inc.;;Challenger, et al., A Publishing System for Efficiently Creating Dynamic Web Content. (1999) Proceedings of the 18<SUP>th </SUP>Annual Joint Conference of the IEEE Computer and Communications Societies.;;Challenger, et al., A Scalable System for Consistently Caching Dynamic Web Data. INFOCOMM, 2000.",EXPIRED
99,US,A1,US 2019/0065246 A1,122-788-263-800-721,2019-02-28,2019,US 201715828068 A,2017-11-30,US 201715828068 A;;US 201762549914 P,2017-08-24,LARGE-SCALE ASYNCHRONOUS EVENT PROCESSOR,"A large-scale asynchronous processor of events in a distributed and parallel processing environment. The processor includes a plurality of processes executing on a plurality of interconnected processors. The plurality of processes including a frontend process, a plurality of dispatcher processes, a plurality of job queues, and a plurality of worker processes. The frontend process is for receiving event notification remote procedure calls from one or more event sources and for publishing event notifications, based on the received calls, to topics of a distributed streaming platform. The plurality of dispatcher process are for consuming event notifications from the topics and for en-queuing jobs, based on the consumed event notifications, to the plurality of job queues. The plurality of worker process are for pulling jobs from the plurality of job queues and for the processing the jobs.",DROPBOX INC,SENAPATY SHASHANK;;AL-RAWI BASHAR;;KANG PENG;;DESAI RAJIV;;ZHOU DAISY LUO,DROPBOX INC (2018-02-12),https://lens.org/122-788-263-800-721,Patent Application,yes,0,8,2,2,0,G06F9/4881;;G06F9/542;;G06F9/5088;;G06F9/542,G06F9/48;;G06F9/50;;G06F9/54,,0,0,,,,ACTIVE
100,US,A1,US 2021/0128790 A1,060-319-654-708-501,2021-05-06,2021,US 202017022062 A,2020-09-15,US 202017022062 A;;US 201615301466 A;;US 2015/0024523 W;;US 201461975375 P,2014-04-04,CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE,The present disclosure provides click-crosslinked hydrogels and methods of use.,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2016-12-20),https://lens.org/060-319-654-708-501,Patent Application,yes,0,1,11,11,5,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L27/52;;A61L27/20;;A61L27/22;;A61L27/26;;A61L27/38;;A61L27/54;;C07D237/26;;C07K14/78;;C08B37/00,,0,0,,,,PENDING
101,US,B2,US 8048434 B2,083-066-704-508-391,2011-11-01,2011,US 58373108 A,2008-02-19,IN 505MU2005 A;;IB 2006000978 W,2005-04-25,Vaccine adjuvants,"The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.",CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;MODI RAJIV INDRAVADAN;;MODI INDRAVADAN AMBALAL;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,CADILA PHARMACEUTICALS LTD (2007-12-27),https://lens.org/083-066-704-508-391,Granted Patent,yes,3,3,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,A61K39/04;;A61K39/00;;A61K39/02,424/248.1;;424/9.1;;424/9.2;;424/130.1;;424/184.1;;424/185.1;;424/234.1;;435/4;;435/7.1;;435/7.2,0,0,,,,INACTIVE
102,CA,A1,CA 3078830 A1,085-076-704-953-294,2019-04-18,2019,CA 3078830 A,2018-10-11,US 201762572090 P;;EP 2018077761 W,2017-10-13,A METHOD OF PRODUCING FROZEN CONFECTION WITH PROTEIN AGGLOMERATION AND DELAYED SUCROSE ADDITION,"CA 03078830 2020-04-09 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1 11111 1 111111 11 111111 1 11 11111 1 111 1111 1 1 11 111111 111 1 111 111111 111 1111 11111111111 1 11 1111 International Bureau (10) International Publication Number (43) International Publication Date WO 2019/072979 Al 18 April 2019 (18.04.2019) WIPO I PCT (51) International Patent Classification: Gene; 32 Lolupe Lane, Unit Q204, Kihei, HI Hawaii A23G 9/32 (2006.01) A23G 9/52 (2006.01) 96'753 (US). VAGHELA, Madansinh, Nathusinh; 8958 A23G 9/38 (2006.01) Chinaberry Cir North, Macedonia, OH Ohio 44056 (US). DAVE, Rajiv, Indravadan; 11605 Regarse Drive, BAK-(21) International Application Number: ERSF1ELD, CA California 93311 (US). PANDYA, Nirav, PCT/EP2018/077761 Chandrakant; 9103 Coney Island Drive, BAKERSFIELD, (22) International Filing Date: CA California 93311 (US). 11 October 2018 (11.10.2018) (74) Agent: ELLEBY, Gudrun; Centre de Recherche Nestlé (25) Filing Language: English Vers-Chez-les-Blanc, Case Postale 44, 1000 Lausanne 26 (CH). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/572,090 13 October 201'7 (13.10.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (71) Applicant: NESTEC S.A. [CH/CH]; Avenue Nestlé 55, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 1800 VEVEY (CH). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ED, EL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (72) Inventors: DESAI, Nilesh; 12203 Timberpointe Dr, Bak- KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, ersfield, CA California 93312 (US). MARK, Stephen, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (54) Title: A METHOD OF PRODUCING FROZEN CONFECTION WITH PROTEIN AGGLOMERATION AND DELAYED SU-= CROSE ADDITION Mix Making Fiow Diagram Liquid Dairy Blend Tank = __ Sugared Egg Yolks Homogenization 1500 + 500 psi (2000 psi total) Pasteurization 1809F for 90 Seconds Pasteurized Sucrose Cooling (<45 F) = ______________________________ Solution Mix Tank Temp: <45 F Max Storage: 72 hours Fig. 1 (57) Abstract: The invention relates to a method of producing a frozen confection product, the method comprising the steps of: providing r=ll an ingredient mix free from added sugar or comprises below 0.2 % wt, the composition comprising 3 - 1'7 wt. % fat, 3 - 1'7 wt. % 1--"" milk solids non-fat, and 1 - 10 wt. % protein comprising casein and whey, the ingredient mix having a pH of 6.1 ¨ 6.4; homogenising the ingredient mix and subsequently pasteurizing the composition at a temperature of 80 - 100 C for a period of 0.5 ¨ 3 min to form agglomerated protein comprising casein and whey, adding 3 ¨ 25 wt. % of sugar to the ingredient mix; and freezing while optionally aerating the ingredient mix, to form a frozen confection product. The invention also relates to a product obtained with the method. C.) [Continued on next page] CA 03078830 2020-04-09 WO 2019/072979 Al I11111 RINI II lIllIl 11111 11111 3E111 I O 10 1110 lll 01111111 lll11 01111111111111111111 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): AREPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: ¨ as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) ¨ as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) ¨ of inventorship (Rule 4.17(iv)) Published: ¨ with international search report (Art. 21(3))",NESTLE SA,DESAI NILESH;;MARK STEPHEN GENE;;VAGHELLA MADANSINH NATHUSINH;;DAVE RAJIV INDRAVADAN;;PANDYA NIRAV CHANDRAKANT,,https://lens.org/085-076-704-953-294,Patent Application,no,0,0,7,7,0,A23G9/32;;A23G9/38;;A23G9/52;;A23G9/04;;A23G9/34;;A23G9/38;;A23G9/46,A23G9/04;;A23G9/32;;A23G9/34;;A23G9/38;;A23G9/46,,0,0,,,,PENDING
103,PL,T3,PL 1948782 T3,105-919-969-661-912,2013-01-31,2013,PL 06744545 T,2006-04-21,IN 505MU2005 A;;EP 06744545 A;;IB 2006000978 W,2005-04-25,VACCINE ADJUVANTS,,CADILA PHARMACEUTICALS LTD,MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV;;KHAMAR BAKULESH MAFATIAL,,https://lens.org/105-919-969-661-912,Patent Application,no,0,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00;;A61K39/39,,0,0,,,,PENDING
104,EP,B1,EP 1948782 B1,039-261-603-226-481,2012-08-01,2012,EP 06744545 A,2006-04-21,IB 2006000978 W;;IN 505MU2005 A,2005-04-25,VACCINE ADJUVANTS,,CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/039-261-603-226-481,Granted Patent,yes,2,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00;;A61K39/39,,5,0,,,"GORMUS BOBBY J ET AL: ""Under-explored experimental topics related to integral mycobacterial vaccines for leprosy"" EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 2, no. 6, 1 December 2003 (2003-12-01), pages 791-804, XP009115719 ISSN: 1476-0584;;STILLS HAROLD F JR: ""Adjuvants and antibody production: Dispelling the myths associated with Freund's complete and other adjuvants"" ILAR JOURNAL, vol. 46, no. 3, 1 January 2005 (2005-01-01), pages 280-293, XP001539142 ISSN: 1084-2020;;SUR PRABIR KUMAR ET AL: ""Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer)."" JOURNAL OF THE INDIAN MEDICAL ASSOCIATION FEB 2003, vol. 101, no. 2, February 2003 (2003-02), page 118 , 120, XP009115704 ISSN: 0019-5847;;SHARMA P ET AL: ""Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment."" LEPROSY REVIEW JUN 2000, vol. 71, no. 2, June 2000 (2000-06), pages 179-192, XP009115711 ISSN: 0305-7518;;PETROVSKY N.: 'Vaccine Adjuvants: Current State and Future Trends' IMMUNOLOGY AND CELL BIOLOGY vol. 82, 2004, pages 488 - 496, XP009078668",ACTIVE
105,EP,A1,EP 3694338 A1,019-359-129-552-684,2020-08-19,2020,EP 18789574 A,2018-10-11,US 201762572090 P;;EP 2018077761 W,2017-10-13,A METHOD OF PRODUCING FROZEN CONFECTION WITH PROTEIN AGGLOMERATION AND DELAYED SUCROSE ADDITION,,NESTLE SA,DESAI NILESH;;MARK STEPHEN GENE;;VAGHELA MADANSINH NATHUSINH;;DAVE RAJIV INDRAVADAN;;PANDYA NIRAV CHANDRAKANT,,https://lens.org/019-359-129-552-684,Patent Application,yes,0,0,7,7,0,A23G9/32;;A23G9/38;;A23G9/52;;A23G9/04;;A23G9/34;;A23G9/38;;A23G9/46,A23G9/32;;A23G9/38;;A23G9/52,,0,0,,,,PENDING
106,GB,A,GB 2442408 A,037-953-350-026-303,2008-04-02,2008,GB 0801474 A,2006-04-21,IB 2006000978 W;;IN 505MU2005 A,2005-04-25,Vaccine adjuvants,"The invention relates. to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition, e.g. immune na¬ve or preimmunised status.",CADILA PHARMACEUTICALS LTD;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAI,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAI,,https://lens.org/037-953-350-026-303,Patent Application,no,2,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,A61K39/04;;A61K35/74;;A61K39/00;;A61K39/395;;A61P35/00;;A61P37/04,,1,1,054-154-380-125-957,15479434;;10.1111/j.0818-9641.2004.01272.x,"Immunol Cell Biol; Vol 82, pp 488-496 (2004). Petrovsky. ""Vaccine adjuvants: current state and future trends""",INACTIVE
107,CA,A1,CA 2632353 A1,107-479-481-533-219,2006-11-02,2006,CA 2632353 A,2006-04-21,IN 505MU2005 A;;IB 2006000978 W,2005-04-25,VACCINE ADJUVANTS,,GHOSH PRASANTA;;KHAMAR BAKULESH;;MODI RAJIV INDRAVADAN;;MODI INDRAVADN;;DESAI NIRAV,GHOSH PRASANTA KUMAR;;KHAMAR BAKULESH MAFATLAL;;MODI RAJIV INDRAVADAN;;MODI INDRAVADAN AMBALAL;;DESAI NIRAV,,https://lens.org/107-479-481-533-219,Patent Application,no,0,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00,,0,0,,,,INACTIVE
108,GB,B,GB 2442408 B,106-169-100-265-952,2010-06-30,2010,GB 0801474 A,2006-04-21,IB 2006000978 W;;IN 505MU2005 A,2005-04-25,Mycobacterium W as an adjuvant,,CADILA PHARMACEUTICALS LTD;;MODI INDRAVADN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/106-169-100-265-952,Granted Patent,no,2,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,A61K39/04;;A61K35/74;;A61K39/00;;A61K39/395;;A61P35/00;;A61P37/04,,4,4,054-154-380-125-957;;113-631-614-503-947;;082-189-439-186-275;;107-977-001-261-94X,15479434;;10.1111/j.0818-9641.2004.01272.x;;12841498;;10920613;;10.5935/0305-7518.20000020;;15953835;;10.1093/ilar.46.3.280,"Immunol Cell Biol; Vol 82, pp 488-496 (2004). Petrovsky. ""Vaccine adjuvants: current state and future trends"";;J Ind Med Assoc; Vol 101, pp 118-120 (2003). Sur et al. ""Role of mycobacterium w as adjuvant treatment of lung cancer...."";;Lepr Rev; Vol 71, pp 179-192 (2000). Sharma et al. ""Mycobacterium w vaccine, a useful adjuvant to multidrug therapy...."";;ILAR J; Vol 46, pp 280-293 (2005). Stills. ""Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants""",INACTIVE
109,US,B2,US 8277778 B2,183-676-846-149-893,2012-10-02,2012,US 201113242909 A,2011-09-23,US 201113242909 A;;IN 505MU2005 A;;US 58373108 A;;IB 2006000978 W,2005-04-25,Vaccine adjuvants,"The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen(s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen(s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunized status.",KHAMAR BAKULESH MAFATLAL;;MODI RAJIV INDRAVADAN;;MODI INDRAVADAN AMBALAL;;GHOSH PRASANTA KUMAR;;DESAI NIRAV;;CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;MODI RAJIV INDRAVADAN;;MODI INDRAVADAN AMBALAL;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/183-676-846-149-893,Granted Patent,yes,3,2,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,A61K49/00;;A61K39/00;;A61K39/04;;G01N33/53,424/9.2;;424/9.1;;424/130.1;;424/184.1;;424/185.1;;424/234.1;;424/248.1;;435/4;;435/7.1;;435/7.2,1,1,054-154-380-125-957,15479434;;10.1111/j.0818-9641.2004.01272.x,"Petrovsky N, Vaccine adjuvants: Current state and future trends; Immunology and Cell Biology (2004) 82, 488-496.",INACTIVE
110,CA,C,CA 2632353 C,000-079-441-040-230,2018-02-20,2018,CA 2632353 A,2006-04-21,IN 505MU2005 A;;IB 2006000978 W,2005-04-25,VACCINE ADJUVANTS COMPRISING MYCOBATERIUM,"The invention relates. to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition, e.g. immune naÊve or preimmunised status.",KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/000-079-441-040-230,Granted Patent,no,0,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00,,0,0,,,,INACTIVE
111,EP,B1,EP 3125960 B1,031-984-537-878-112,2020-06-03,2020,EP 15772786 A,2015-04-06,US 201461975375 P;;US 2015/0024523 W,2014-04-04,CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE,,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,,https://lens.org/031-984-537-878-112,Granted Patent,yes,8,0,11,11,0,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L24/00;;A61L15/60;;A61L27/52;;C07D237/26,,4,0,,,"D.L. ALGE ET. AL.: ""Synthetically Tractable Click Hydrogels for Three Dimensional Cell Culture Formed Using Tetrazine-Norbornene Chemistry"", BIOMACROMOLECULES, vol. 14, 1 March 2013 (2013-03-01), pages 949-953, XP055069977, DOI: 10.1021/bm4000508;;Y. JIANG ET. AL.: ""Click hydrogels, microgels and nanogels: Emerging platforms for drug delivery and tissue engineering."", BIOMATERIALS, vol. 35, 24 March 2014 (2014-03-24), pages 4969-4985, XP055125853, DOI: 10.1016/j.biomaterials.2014.03.001;;I. A. BARKER ET. AL.: ""Tetrazine-Norbornene Click Reactions to Functionalize Degradable Polymers Derived from Lactide"", MACROMOLECULAR RAPID COMMUNICATIONS, vol. 32, 1 June 2011 (2011-06-01), XP055069714, DOI: 10.1002/marc.201100324;;C. F. HANSELL ET. AL.: ""Additive-Free Clicking for Polymer Functionalization and Coupling by Tetrazine-Norbornene Chemistry"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 133, 5 August 2011 (2011-08-05), pages 13828-13831, XP055037383, DOI: 10.1021/ja203957h",ACTIVE
112,AU,A1,AU 2006/238906 A1,069-989-488-327-622,2006-11-02,2006,AU 2006/238906 A,2006-04-21,IN 505MU2005 A;;IB 2006000978 W,2005-04-25,Vaccine adjuvants,,BAKULESH KHAMAR;;INDRAVADN MODI;;RAJIV MODI;;PRASANTA GHOSH;;DESAI NIRAV,KHAMAR BAKULESH MAFATLAL;;GHOSH PRASANTA KUMAR;;DESAI NIRAV;;MODI RAJIV INDRAVADAN;;MODI INDRAVADN AMBALAL,CADILA PHARMACEUTICALS LTD. (2013-10-10),https://lens.org/069-989-488-327-622,Patent Application,no,0,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00,,0,0,,,,INACTIVE
113,US,A1,US 2008/0131458 A1,087-420-652-788-807,2008-06-05,2008,US 58373108 A,2008-02-19,IN 505MU2005 A;;IB 2006000978 W,2005-04-25,Vaccine Adjuvants,"The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.",CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;MODI RAJIV INDRAVADAN;;MODI INDRAVADAN ARNBALAL;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,CADILA PHARMACEUTICALS LTD (2007-12-27),https://lens.org/087-420-652-788-807,Patent Application,yes,0,4,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,A61K39/12;;A61K39/00;;A61K39/02;;A61K39/04;;A61K39/35;;A61K45/00;;C12M1/20,424/204.1;;424/248.1;;424/282.1;;424/234.1;;424/275.1;;424/277.1;;435/253.1,0,0,,,,INACTIVE
114,EP,B8,EP 1948782 B8,114-054-365-729-548,2012-09-12,2012,EP 06744545 A,2006-04-21,IB 2006000978 W;;IN 505MU2005 A,2005-04-25,VACCINE ADJUVANTS,,CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/114-054-365-729-548,Amended Patent,yes,2,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00;;A61K39/39,,5,0,,,"GORMUS BOBBY J ET AL: ""Under-explored experimental topics related to integral mycobacterial vaccines for leprosy"" EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 2, no. 6, 1 December 2003 (2003-12-01), pages 791-804, XP009115719 ISSN: 1476-0584;;STILLS HAROLD F JR: ""Adjuvants and antibody production: Dispelling the myths associated with Freund's complete and other adjuvants"" ILAR JOURNAL, vol. 46, no. 3, 1 January 2005 (2005-01-01), pages 280-293, XP001539142 ISSN: 1084-2020;;SUR PRABIR KUMAR ET AL: ""Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer)."" JOURNAL OF THE INDIAN MEDICAL ASSOCIATION FEB 2003, vol. 101, no. 2, February 2003 (2003-02), page 118 , 120, XP009115704 ISSN: 0019-5847;;SHARMA P ET AL: ""Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment."" LEPROSY REVIEW JUN 2000, vol. 71, no. 2, June 2000 (2000-06), pages 179-192, XP009115711 ISSN: 0305-7518;;PETROVSKY N.: 'Vaccine Adjuvants: Current State and Future Trends' IMMUNOLOGY AND CELL BIOLOGY vol. 82, 2004, pages 488 - 496, XP009078668",ACTIVE
115,WO,A8,WO 2006/114680 A8,070-972-330-678-881,2008-08-14,2008,IB 2006000978 W,2006-04-21,IN 505MU2005 A,2005-04-25,VACCINE ADJUVANTS,"The invention relates. to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition, e.g. immune naÊve or preimmunised status.",KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/070-972-330-678-881,Patent Application,no,0,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00,,0,0,,,,PENDING
116,AU,B2,AU 2006/238906 B2,034-364-674-928-114,2013-04-11,2013,AU 2006/238906 A,2006-04-21,IN 505MU2005 A;;IB 2006000978 W,2005-04-25,Vaccine adjuvants,The invention relates. to a novel adjuvant,DESAI NIRAV;;GHOSH PRASANTA KUMAR;;KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADN AMBALAL;;MODI RAJIV INDRAVADAN,KHAMAR BAKULESH MAFATLAL;;GHOSH PRASANTA KUMAR;;MODI INDRAVADN AMBALAL;;MODI RAJIV INDRAVADAN;;DESAI NIRAV,CADILA PHARMACEUTICALS LTD. (2013-10-10),https://lens.org/034-364-674-928-114,Granted Patent,no,3,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00,,3,3,113-631-614-503-947;;001-238-456-415-711;;082-189-439-186-275,12841498;;14711362;;10.1586/14760584.2.6.791;;10920613;;10.5935/0305-7518.20000020,"SUR, P.K. et al., Journal of the Indian Medical Association, 2003, Vol. 101, No. 2, pages 118-120;;GORMUS, B.J. et al., Expert Reviews of Vaccines, 2003, Vol. 2, pages 791-804;;SHARMA, P. et al., Leprosy Review, 2000, Vol. 71, pages 179-192",INACTIVE
117,US,B2,US 11758921 B2,071-902-436-651-68X,2023-09-19,2023,US 201816754163 A,2018-10-11,US 201816754163 A;;US 201762572090 P;;EP 2018077761 W,2017-10-13,Method of producing frozen confection with protein agglomeration and delayed sucrose addition,"The invention relates to a method of producing a frozen confection product, the method comprising the steps of: providing an ingredient mix free from added sugar or comprises below 0.2% wt, the composition comprising 3-17 wt. % fat, 3-17 wt. % milk solids non-fat, and 1-10 wt. % protein comprising casein and whey, the ingredient mix having a pH of 6.1-6.4; homogenising the ingredient mix and subsequently pasteurizing the composition at a temperature of 80°-100° C. for a period of 0.5-3 min to form agglomerated protein comprising casein and whey, adding 3-25 wt. % of sugar to the ingredient mix; and freezing while optionally aerating the ingredient mix, to form a frozen confection product. The invention also relates to a product obtained with the method.",NESTLE SA,DESAI NILESH;;MARK STEPHEN GENE;;VAGHELA MADANSINH NATHUSINH;;DAVE RAJIV INDRAVADAN;;PANDYA NIRAV CHANDRAKANT,SOCIETE DES PRODUITS NESTLE S.A (2019-05-28);;NESTEC S.A (2017-10-27),https://lens.org/071-902-436-651-68X,Granted Patent,yes,8,0,7,7,0,A23G9/32;;A23G9/38;;A23G9/52;;A23G9/04;;A23G9/34;;A23G9/38;;A23G9/46,A23G9/38;;A23G9/04;;A23G9/34;;A23G9/46,,1,0,,,"Chinese Office Action for Appl No. 201880066652.1 dated Nov. 3, 2022.",ACTIVE
118,US,A1,US 2017/0189581 A1,191-054-667-324-856,2017-07-06,2017,US 201515301466 A,2015-04-06,US 201515301466 A;;US 201461975375 P;;US 2015/0024523 W,2014-04-04,CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE,The present disclosure provides click-crosslinked hydrogels and methods of use.,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2015-05-04),https://lens.org/191-054-667-324-856,Patent Application,yes,4,18,11,11,5,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L27/52;;A61L27/20;;A61L27/22;;A61L27/26;;A61L27/38;;A61L27/54;;C07K14/78;;C08B37/00,,13,8,020-383-628-979-717;;004-118-621-232-189;;003-600-340-570-893;;017-218-438-380-298;;089-279-105-495-397;;081-458-347-101-664;;069-912-547-173-198;;069-912-547-173-198,pmc3623454;;10.1021/bm4000508;;23448682;;24887284;;10.1016/j.actbio.2014.05.023;;10.1002/macp.201000108;;10.1016/j.progpolymsci.2011.06.003;;pmc3223967;;22125349;;10.1021/bm0700800;;17523655;;10.1039/c3cs60040h;;pmc3762890;;23609001;;21819063;;10.1021/ja203957h;;21819063;;10.1021/ja203957h,"Matrix Scientific 2010, cited in the Office action mailed on 9/28/17;;Alge Biomacromolecules, 2013, cited in the Office action mailed on 9/28/17;;Kharkar Chem. Soc. Rev., 2013, cited in the Office action mailed on 9/28/17;;Lee Prog Polymer Sci, 2012, cited in the Office action mailed on 9/28/17;;Alge et al., Biomacromolecules, 14, pages 949-953. (Year: 2013);;Lee et al., Acta Biomaterialia, 10, pages 4167-4174. (Year: 2014);;Sanyal, Macromol. Chem. Phys. 211, 1417-1425. (Year: 2010);;Lee et al., Prog Polym Sci, 37(1), pages 106-126. (Year: 2012);;Matrix Scientific, MSDS for 1-Bicyclo[2.2.1]hept-5-en-2-ylmethanamine, pages 1-3. (Year: 2010);;Crescenzi et al., Biomacromolecules, 8, pages 1844-1850. (Year: 2007);;Kharkar et al., Chem. Soc. Rev., 42 pages 7335-7372 (Year: 2013);;Hansell et al., J. Am. Chem. Soc., 2011, 133, 13828-13831 and S1-S20.;;Hansell et al., J. Am. Chem. Soc., 2011, 133, 13828-13831 and S1-S20.",ACTIVE
119,ES,T3,ES 2951908 T3,055-467-579-249-192,2023-10-25,2023,ES 20176544 T,2015-04-06,US 201461975375 P,2014-04-04,Hidrogeles reticulados por química clic y métodos de uso,"La presente divulgación proporciona hidrogeles reticulados por clic y métodos de uso. (Traducción automática con Google Translate, sin valor legal)",HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,,https://lens.org/055-467-579-249-192,Granted Patent,no,0,0,11,11,0,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L24/00;;A61L15/60;;A61L27/52;;C07D237/26,,0,0,,,,ACTIVE
120,US,A1,US 2012/0014985 A1,140-115-683-475-300,2012-01-19,2012,US 201113242909 A,2011-09-23,US 201113242909 A;;IN 505MU2005 A;;US 58373108 A;;IB 2006000978 W,2005-04-25,Vaccine Adjuvants,"The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.",KHAMAR BAKULESH MAFATLAL;;MODI RAJIV INDRAVADAN;;MODI INDRAVADAN AMBALAL;;GHOSH PRASANTA KUMAR;;DESAI NIRAV;;CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;MODI RAJIV INDRAVADAN;;MODI INDRAVADAN AMBALAL;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/140-115-683-475-300,Patent Application,yes,0,2,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,A61K39/385;;A61K39/00;;A61K39/04;;A61K39/12;;A61P37/00,424/193.1;;424/204.1;;424/248.1,0,0,,,,INACTIVE
121,US,A1,US 2021/0195916 A1,158-813-784-880-470,2021-07-01,2021,US 201816754163 A,2018-10-11,US 201816754163 A;;US 201762572090 P;;EP 2018077761 W,2017-10-13,A METHOD OF PRODUCING FROZEN CONFECTION WITH PROTEIN AGGLOMERATION AND DELAYED SUCROSE ADDITION,"The invention relates to a method of producing a frozen confection product, the method comprising the steps of: providing an ingredient mix free from added sugar or comprises below 0.2% wt, the composition comprising 3-17 wt. % fat, 3-17 wt. % milk solids non-fat, and 1-10 wt. % protein comprising casein and whey, the ingredient mix having a pH of 6.1-6.4; homogenising the ingredient mix and subsequently pasteurizing the composition at a temperature of 80°-100° C. for a period of 0.5-3 min to form agglomerated protein comprising casein and whey, adding 3-25 wt. % of sugar to the ingredient mix; and freezing while optionally aerating the ingredient mix, to form a frozen confection product. The invention also relates to a product obtained with the method.",NESTLE SA,DESAI NILESH;;MARK STEPHEN GENE;;VAGHELA MADANSINH NATHUSINH;;DAVE RAJIV INDRAVADAN;;PANDYA NIRAV CHANDRAKANT,SOCIETE DES PRODUITS NESTLE S.A (2019-05-28);;NESTEC S.A (2017-10-27),https://lens.org/158-813-784-880-470,Patent Application,yes,2,0,7,7,0,A23G9/32;;A23G9/38;;A23G9/52;;A23G9/04;;A23G9/34;;A23G9/38;;A23G9/46,A23G9/38;;A23G9/04;;A23G9/34;;A23G9/46,,0,0,,,,ACTIVE
122,EP,A1,EP 3730160 A1,000-628-522-891-431,2020-10-28,2020,EP 20176544 A,2015-04-06,US 201461975375 P;;EP 15772786 A;;US 2015/0024523 W,2014-04-04,CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE,The present disclosure provides click-crosslinked hydrogels and methods of use.,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,,https://lens.org/000-628-522-891-431,Patent Application,yes,4,0,11,11,5,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L24/00;;A61L15/60;;A61L27/52;;C07D237/26,,9,9,020-383-628-979-717;;144-198-873-357-104;;002-466-182-127-747;;069-912-547-173-198;;027-493-288-859-744;;020-383-628-979-717;;089-511-071-398-110;;014-523-979-262-456;;020-383-628-979-717,pmc3623454;;10.1021/bm4000508;;23448682;;10.1016/j.biomaterials.2014.03.001;;24674460;;25867900;;10.1002/marc.201100324;;21819063;;10.1021/ja203957h;;22955625;;10.1038/nature11409;;pmc3642868;;pmc3623454;;10.1021/bm4000508;;23448682;;10.1021/bc8004446;;pmc2677645;;19053305;;21950520;;pmc3254257;;10.1021/bc200295y;;pmc3623454;;10.1021/bm4000508;;23448682,"D.L. ALGE ET. AL.: ""Synthetically Tractable Click Hydrogels for Three Dimensional Cell Culture Formed Using Tetrazine-Norbornene Chemistry"", BIOMACROMOLECULES, vol. 14, 1 March 2013 (2013-03-01), pages 949 - 953, XP055069977, DOI: 10.1021/bm4000508;;Y. JIANG ET. AL.: ""Click hydrogels, microgels and nanogels: Emerging platforms for drug delivery and tissue engineering."", BIOMATERIALS, vol. 35, 24 March 2014 (2014-03-24), pages 4969 - 4985, XP055125853, DOI: 10.1016/j.biomaterials.2014.03.001;;I. A. BARKER ET. AL.: ""Tetrazine-Norbornene Click Reactions to Functionalize Degradable Polymers Derived from Lactide"", MACROMOLECULAR RAPID COMMUNICATIONS, vol. 32, 1 June 2011 (2011-06-01), XP055069714, DOI: 10.1002/marc.201100324;;C. F. HANSELL ET. AL.: ""Additive-Free Clicking for Polymer Functionalization and Coupling by Tetrazine-Norbornene Chemistry"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 133, 5 August 2011 (2011-08-05), pages 13828 - 13831, XP055037383, DOI: 10.1021/ja203957h;;SUN ET AL.: ""Highly stretchable and tough hydrogels"", NATURE, vol. 489, no. 7414, 2013, pages 133 - 136, XP055377727, DOI: 10.1038/nature11409;;ALGE ET AL.: ""Synthetically Tractable Click Hydrogels for Three-Dimensional Cell Culture Formed Using Tetrazine-Norbornene Chemistry"", BIOMACROMOLECULES, vol. 14, no. 4, 2013, pages 949 - 953, XP055069977, DOI: 10.1021/bm4000508;;DEVARAJ ET AL., BIOCONJUGATE CHEM., vol. 19.12, 2008, pages 2297 - 2299;;KARVER ET AL., BIOCONJUGATE CHEM., vol. 22.11, 2011, pages 2263 - 2270;;ALGE ET AL., BIOMACROMOL., vol. 14.4, 2013, pages 949 - 953",ACTIVE
123,EP,B1,EP 3730160 B1,022-526-429-497-342,2023-06-07,2023,EP 20176544 A,2015-04-06,US 201461975375 P;;EP 15772786 A;;US 2015/0024523 W,2014-04-04,CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE,,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,,https://lens.org/022-526-429-497-342,Granted Patent,yes,0,0,11,11,0,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L24/00;;A61L15/60;;A61L27/52;;C07D237/26,,4,0,,,"D.L. ALGE ET. AL.: ""Synthetically Tractable Click Hydrogels for Three Dimensional Cell Culture Formed Using Tetrazine-Norbornene Chemistry"", BIOMACROMOLECULES, vol. 14, 1 March 2013 (2013-03-01), pages 949-953, XP055069977, DOI: 10.1021/bm4000508;;Y. JIANG ET. AL.: ""Click hydrogels, microgels and nanogels: Emerging platforms for drug delivery and tissue engineering."", BIOMATERIALS, vol. 35, 24 March 2014 (2014-03-24), pages 4969-4985, XP055125853, DOI: 10.1016/j.biomaterials.2014.03.001;;I. A. BARKER ET. AL.: ""Tetrazine-Norbornene Click Reactions to Functionalize Degradable Polymers Derived from Lactide"", MACROMOLECULAR RAPID COMMUNICATIONS, vol. 32, 1 June 2011 (2011-06-01), XP055069714, DOI: 10.1002/marc.201100324;;C. F. HANSELL ET. AL.: ""Additive-Free Clicking for Polymer Functionalization and Coupling by Tetrazine-Norbornene Chemistry"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 133, 5 August 2011 (2011-08-05), pages 13828-13831, XP055037383, DOI: 10.1021/ja203957h",ACTIVE
124,EP,A4,EP 3125960 A4,103-138-652-375-622,2017-12-27,2017,EP 15772786 A,2015-04-06,US 201461975375 P;;US 2015/0024523 W,2014-04-04,CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE,,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,,https://lens.org/103-138-652-375-622,Search Report,no,0,0,11,11,0,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L24/00;;A61L15/60;;A61L27/52;;C07D237/26,,4,4,020-383-628-979-717;;144-198-873-357-104;;002-466-182-127-747;;069-912-547-173-198,pmc3623454;;10.1021/bm4000508;;23448682;;10.1016/j.biomaterials.2014.03.001;;24674460;;25867900;;10.1002/marc.201100324;;21819063;;10.1021/ja203957h,"D.L. ALGE ET. AL.: ""Synthetically Tractable Click Hydrogels for Three Dimensional Cell Culture Formed Using Tetrazine-Norbornene Chemistry"", BIOMACROMOLECULES, vol. 14, 1 March 2013 (2013-03-01), pages 949 - 953, XP055069977, DOI: 10.1021/bm4000508;;Y. JIANG ET. AL.: ""Click hydrogels, microgels and nanogels: Emerging platforms for drug delivery and tissue engineering."", BIOMATERIALS, vol. 35, 24 March 2014 (2014-03-24), pages 4969 - 4985, XP055125853, DOI: 10.1016/j.biomaterials.2014.03.001;;I. A. BARKER ET. AL.: ""Tetrazine-Norbornene Click Reactions to Functionalize Degradable Polymers Derived from Lactide"", MACROMOLECULAR RAPID COMMUNICATIONS, vol. 32, 1 June 2011 (2011-06-01), XP055069714, DOI: 10.1002/marc.201100324;;C. F. HANSELL ET. AL.: ""Additive-Free Clicking for Polymer Functionalization and Coupling by Tetrazine-Norbornene Chemistry"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 133, 5 August 2011 (2011-08-05), pages 13828 - 13831, XP055037383, DOI: 10.1021/ja203957h",ACTIVE
125,EP,A1,EP 3125960 A1,131-191-523-060-171,2017-02-08,2017,EP 15772786 A,2015-04-06,US 201461975375 P;;US 2015/0024523 W,2014-04-04,CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE,,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,,https://lens.org/131-191-523-060-171,Patent Application,yes,0,0,11,11,5,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L24/00;;A61L15/60;;A61L27/52,,0,0,,,,ACTIVE
126,US,B2,US 10821208 B2,016-891-187-942-690,2020-11-03,2020,US 201515301466 A,2015-04-06,US 201515301466 A;;US 201461975375 P;;US 2015/0024523 W,2014-04-04,Click-crosslinked hydrogels and methods of use,The present disclosure provides click-crosslinked hydrogels and methods of use.,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2015-05-04),https://lens.org/016-891-187-942-690,Granted Patent,yes,10,0,11,11,5,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L27/52;;A61L27/20;;A61L27/22;;A61L27/26;;A61L27/38;;A61L27/54;;C07D237/26;;C07K14/78;;C08B37/00,,11,9,069-912-547-173-198;;020-383-628-979-717;;081-458-347-101-664;;017-218-438-380-298;;004-118-621-232-189;;089-279-105-495-397;;003-600-340-570-893;;002-466-182-127-747;;144-198-873-357-104,21819063;;10.1021/ja203957h;;pmc3623454;;10.1021/bm4000508;;23448682;;10.1039/c3cs60040h;;pmc3762890;;23609001;;10.1016/j.progpolymsci.2011.06.003;;pmc3223967;;22125349;;24887284;;10.1016/j.actbio.2014.05.023;;10.1021/bm0700800;;17523655;;10.1002/macp.201000108;;25867900;;10.1002/marc.201100324;;10.1016/j.biomaterials.2014.03.001;;24674460,"Hansell et al., J. Am. Chem. Soc., 2011, 133, 13828-13831 and S1-S20.;;Alge et al., Biomacromolecules, 14, pp. 949-953. (Year: 2013).;;Kharkar et al., Chem. Soc. Rev., 42 pages 7335-7372 (Year: 2013).;;Lee et al., Prog Polym Sci, 37(1), pp. 106-126. (Year: 2012).;;Matrix Scientific, MSDS for 1-Bicyclo[2.2.1]hept-5-en-2-ylmethanamine, pp. 1-3. (Year: 2010).;;Lee et al., Acta Biomaterialia, 10, pp. 4167-4174. (Year: 2014).;;Crescenzi et al., Biomacromolecules, 8, pp. 1844-1850. (Year: 2007).;;Sanyal, Macromol. Chem. Phys. 211, 1417-1425. (Year: 2010).;;International Search Report and Written Opinion for Application No. PCT/US2015/024523, dated Jun. 25, 2015. 8 pages.;;Barker et al., Tetrazine-norbomene click reactions to functionalize degradable polymers derived from lactide. Macromol. Rapid Commun. Sep. 1, 2011;32(17):1362-6.;;Jiang et al., Click hydrogels, microgels and nanogels: emerging platforms for drug delivery and tissue engineering. Biomaterials Jun. 2014;35(18):4969-85.",ACTIVE
127,WO,A1,WO 2015/154078 A1,059-266-034-220-896,2015-10-08,2015,US 2015/0024523 W,2015-04-06,US 201461975375 P,2014-04-04,CLICK-CROSSLINKED HYDROGELS AND METHODS OF USE,The present disclosure provides click-crosslinked hydrogels and methods of use.,HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,,https://lens.org/059-266-034-220-896,Patent Application,yes,12,50,11,11,5,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L15/60;;A61L24/00;;A61L27/52,,2,2,027-493-288-859-744;;014-523-979-262-456,22955625;;10.1038/nature11409;;pmc3642868;;21950520;;pmc3254257;;10.1021/bc200295y,"SUN ET AL.: ""Highly stretchable and tough hydrogels"", NATURE, vol. 489, no. 7414, 2013, pages 133 - 136, XP055377727, doi:10.1038/nature11409;;KARVER ET AL., BIOCONJUGATE CHEM., vol. 22, 2011, pages 2263 - 2270",PENDING
128,AU,A1,AU 2018/350144 A1,111-594-443-565-20X,2020-04-23,2020,AU 2018/350144 A,2018-10-11,US 201762572090 P;;EP 2018077761 W,2017-10-13,A method of producing frozen confection with protein agglomeration and delayed sucrose addition,"The invention relates to a method of producing a frozen confection product, the method comprising the steps of: providing an ingredient mix free from added sugar or comprises below 0.2 % wt, the composition comprising 3 - 17 wt. % fat, 3 - 17 wt. % milk solids non-fat, and 1 - 10 wt. % protein comprising casein and whey, the ingredient mix having a pH of 6.1 – 6.4; homogenising the ingredient mix and subsequently pasteurizing the composition at a temperature of 80°- 100°C for a period of 0.5 – 3 min to form agglomerated protein comprising casein and whey, adding 3 – 25 wt. % of sugar to the ingredient mix; and freezing while optionally aerating the ingredient mix, to form a frozen confection product. The invention also relates to a product obtained with the method.",NESTLE SA,DESAI NILESH;;MARK STEPHEN GENE;;VAGHELA MADANSINH NATHUSINH;;DAVE RAJIV INDRAVADAN;;PANDYA NIRAV CHANDRAKANT,,https://lens.org/111-594-443-565-20X,Patent Application,no,0,0,7,7,0,A23G9/32;;A23G9/38;;A23G9/52;;A23G9/04;;A23G9/34;;A23G9/38;;A23G9/46,A23G9/32;;A23G9/38;;A23G9/52,,0,0,,,,DISCONTINUED
129,ES,T3,ES 2811301 T3,042-020-392-168-218,2021-03-11,2021,ES 15772786 T,2015-04-06,US 201461975375 P;;US 2015/0024523 W,2014-04-04,Hidrogeles reticulados por química clic y métodos de uso,"Un hidrogel que comprende un primer polímero y un segundo polímero, en el que el primer polímero y el segundo polímero son el mismo polímero, y en el que el primer polímero está conectado con el segundo polímero mediante enlazadores de fórmula (A): **(Ver fórmula)** en donde el enlace --- es un enlace simple o doble; R1 es -alquil C0-C6-NH-, -alquil C0-C6-O- o -alquil C0-C3-C(O)-; R2 es un enlace, arilo o heteroarilo, en donde el arilo y el heteroarilo están sustituidos opcionalmente con halógeno, hidroxi, alquilo C1-C6, alcoxi C1-C6, (alquil C1-C6)amino o di(alquil C1-C6)amino; R3 es -alquil C0-C6-NH-, -alquil C0-C6-O- o -alquil C0-C3-C(O)-; y R4 es hidrógeno, alquilo C1-C6, arilo o heteroarilo, en donde el arilo y el heteroarilo están sustituidos opcionalmente con halógeno, hidroxi, alquilo C1-C6, alcoxi C1-C6, (alquil C1-C6)amino o di(alquil C1-C6)amino.",HARVARD COLLEGE,DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J;;KOSHY SANDEEP T;;STAFFORD ALEXANDER G,,https://lens.org/042-020-392-168-218,Granted Patent,no,0,0,11,11,0,A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/26;;A61L2300/256;;A61L2300/414;;C07D237/26;;A61L27/52;;A61L27/20;;A61L27/222;;A61L27/3886;;A61L27/54;;A61L2300/22;;A61L2300/23;;A61L2300/252;;A61L2300/258;;A61L2300/64;;A61L2400/06;;A61L2400/18;;C07K14/78;;C08B37/0084,A61L24/00;;A61L15/60;;A61L27/52;;C07D237/26,,0,0,,,,ACTIVE
130,EP,A4,EP 1948782 A4,060-595-862-857-529,2009-06-17,2009,EP 06744545 A,2006-04-21,IB 2006000978 W;;IN 505MU2005 A,2005-04-25,VACCINE ADJUVANTS,,CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/060-595-862-857-529,Search Report,no,0,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00;;A61K39/39,,5,4,001-238-456-415-711;;107-977-001-261-94X;;113-631-614-503-947;;082-189-439-186-275,14711362;;10.1586/14760584.2.6.791;;15953835;;10.1093/ilar.46.3.280;;12841498;;10920613;;10.5935/0305-7518.20000020,"GORMUS BOBBY J ET AL: ""Under-explored experimental topics related to integral mycobacterial vaccines for leprosy"", EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 2, no. 6, 1 December 2003 (2003-12-01), pages 791 - 804, XP009115719, ISSN: 1476-0584;;STILLS HAROLD F JR: ""Adjuvants and antibody production: Dispelling the myths associated with Freund's complete and other adjuvants"", ILAR JOURNAL, vol. 46, no. 3, 1 January 2005 (2005-01-01), pages 280 - 293, XP001539142, ISSN: 1084-2020;;SUR PRABIR KUMAR ET AL: ""Role of mycobacterium w as adjuvant treatment of lung cancer (non-small cell lung cancer)."", JOURNAL OF THE INDIAN MEDICAL ASSOCIATION FEB 2003, vol. 101, no. 2, February 2003 (2003-02-01), pages 118 , 120, XP009115704, ISSN: 0019-5847;;SHARMA P ET AL: ""Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment."", LEPROSY REVIEW JUN 2000, vol. 71, no. 2, June 2000 (2000-06-01), pages 179 - 192, XP009115711, ISSN: 0305-7518;;See also references of WO 2006114680A2",ACTIVE
131,EP,A2,EP 1948782 A2,184-928-826-698-38X,2008-07-30,2008,EP 06744545 A,2006-04-21,IB 2006000978 W;;IN 505MU2005 A,2005-04-25,VACCINE ADJUVANTS,,CADILA PHARMACEUTICALS LTD,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADAN AMBALAL;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/184-928-826-698-38X,Patent Application,yes,0,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00;;A61K39/39,,0,0,,,,ACTIVE
132,WO,A3,WO 2014/111903 A3,011-361-279-765-134,2014-10-23,2014,IB 2014058437 W,2014-01-21,IN 184MU2013 A,2013-01-21,"A PROCESS FOR THE PREPARATION OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE- 2-CARBALDEHYDE","The present invention relates to a process for ihe preparation of 6-f!uoro-3,4-dihydro- 2H-chromene-2-carbaidehyde which is useful as an Intermediate in the synthesis of Nebivolol or its pharmaceutical acceptable salts.",CADILA PHARMACEUTICALS LTD,MODI RAJIV INDRAVADAN;;ISMAILI AMINMAHAMAD NASIRUDDIN;;RAUT DIPAK BHIKANRAO;;MANSURI JAVEDHUSEN KARIMBHAI;;DESAI CHAITANYA CHHOTUBHAI,,https://lens.org/011-361-279-765-134,Search Report,yes,1,0,2,2,0,C07D311/58;;C07D311/66,C07D311/58;;C07D311/66,,0,0,,,,PENDING
133,WO,A3,WO 2006/114680 A3,024-072-534-355-847,2007-08-23,2007,IB 2006000978 W,2006-04-21,IN 505MU2005 A,2005-04-25,VACCINE ADJUVANTS,"The invention relates. to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition, e.g. immune naÊve or preimmunised status.",KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADN AMBALAL CADILA;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADN AMBALAL CADILA;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/024-072-534-355-847,Search Report,yes,2,0,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,C12N1/20;;A61K39/00,,1,1,054-154-380-125-957,15479434;;10.1111/j.0818-9641.2004.01272.x,"PETROVSKY N.: ""Vaccine Adjuvants: Current State and Future Trends"", IMMUNOLOGY AND CELL BIOLOGY, vol. 82, 2004, pages 488 - 496, XP009078668",PENDING
134,WO,A2,WO 2006/114680 A2,083-301-628-313-708,2006-11-02,2006,IB 2006000978 W,2006-04-21,IN 505MU2005 A,2005-04-25,VACCINE ADJUVANTS,"The invention relates. to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition, e.g. immune naÊve or preimmunised status.",KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADN AMBALAL CADILA;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,KHAMAR BAKULESH MAFATLAL;;MODI INDRAVADN AMBALAL CADILA;;MODI RAJIV INDRAVADAN;;GHOSH PRASANTA KUMAR;;DESAI NIRAV,,https://lens.org/083-301-628-313-708,Patent Application,yes,13,13,22,22,0,A61K39/39;;A61K2039/55594;;A61P35/00;;A61P37/00;;A61P37/04;;Y02A50/30;;A61K35/74;;A61K39/04;;A61K39/39558;;A61K39/39;;A61K2039/55594,A61K39/00,,6,5,144-681-635-203-96X;;001-238-456-415-711;;107-977-001-261-94X;;113-631-614-503-947;;082-189-439-186-275,10.1016/s0264-410x(98)00465-4;;10392627;;14711362;;10.1586/14760584.2.6.791;;15953835;;10.1093/ilar.46.3.280;;12841498;;10920613;;10.5935/0305-7518.20000020,"VACCINE, vol. 17, 1999, pages 2446 - 2452;;GORMUS BOBBY J ET AL., EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON GB, vol. 2, no. 6, 2003, pages 791 - 804;;STILLS HAROLD F JR, ILAR JOURNAL, vol. 46, no. 3, 2005, pages 280 - 293;;SUR PRABIR KUMAR ET AL., JOURNAL OF THE INDIAN MEDICAL ASSOCIATION, vol. 101, no. 2, 2003, pages 118,120;;SHARMA P ET AL., LEPROSY REVIEW, vol. 71, no. 2, 2000, pages 179 - 192;;See also references of EP 1948782A4",PENDING
135,WO,A2,WO 2014/111903 A2,116-627-815-892-405,2014-07-24,2014,IB 2014058437 W,2014-01-21,IN 184MU2013 A,2013-01-21,"A PROCESS FOR THE PREPARATION OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE- 2-CARBALDEHYDE","The present invention relates to a process for ihe preparation of 6-f!uoro-3,4-dihydro- 2H-chromene-2-carbaidehyde which is useful as an Intermediate in the synthesis of Nebivolol or its pharmaceutical acceptable salts.",CADILA PHARMACEUTICALS LTD,MODI RAJIV INDRAVADAN;;ISMAILI AMINMAHAMAD NASIRUDDIN;;RAUT DIPAK BHIKANRAO;;MANSURI JAVEDHUSEN KARIMBHAI;;DESAI CHAITANYA CHHOTUBHAI,,https://lens.org/116-627-815-892-405,Patent Application,yes,4,2,2,2,0,C07D311/58;;C07D311/66,C07D311/58,,0,0,,,,PENDING
136,ES,T3,ES 2871029 T3,157-843-763-424-08X,2021-10-28,2021,ES 15773877 T,2015-04-06,US 201461975443 P;;US 201462085898 P;;US 2015/0024540 W,2014-04-04,Dispositivos de liberación de fármacos recargables y procedimientos de uso de los mismos,"Un sistema de liberación de fármacos recargable que comprende un dispositivo de liberación de fármacos y una recarga de fármacos, en el que el dispositivo de liberación de fármacos comprende un hidrogel y una molécula de reconocimiento de la diana y es adecuado para implantación en una localización deseable dentro de un sujeto; en el que la recarga de fármacos comprende una composición farmacéutica unida a una molécula diana por medio de un conector escindible y la recarga de fármacos es adecuada para la administración posterior al sujeto; en el que la recarga de fármacos es móvil dentro del sujeto hasta que la molécula diana en la recarga de fármacos se une a la molécula de reconocimiento de la diana en el dispositivo de liberación de fármacos en la localización deseable dentro del sujeto; y la molécula diana y la molécula de reconocimiento de la diana forman un par de unión de dos componentes; en el que, tras la unión de la molécula diana a la molécula de reconocimiento de la diana, el conector escindible se escinde y la recarga de fármacos suministra la composición farmacéutica al dispositivo de liberación de fármacos, recargando de este modo el dispositivo de liberación de fármacos; en el que el conector escindible comprende una unión seleccionada del grupo que consiste en una unión hidrazona, una unión acetal, una unión cetal, una unión oxima, una unión imina y una unión disulfuro y en el que la molécula diana comprende un grupo funcional bioortogonal y la molécula de reconocimiento de la diana comprende un grupo funcional complementario, en el que el grupo funcional bioortogonal puede reaccionar mediante química clic con el grupo funcional complementario para formar un enlace covalente.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL;;MOONEY DAVID,,https://lens.org/157-843-763-424-08X,Granted Patent,no,0,0,12,16,0,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K9/00,,0,0,,,,ACTIVE
137,US,A1,US 2018/0117171 A1,192-267-206-765-611,2018-05-03,2018,US 201615563878 A,2016-04-01,US 201615563878 A;;US 201562145053 P;;US 201562141684 P;;US 2016/0025717 W,2015-04-01,IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS,"The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.",HARVARD COLLEGE,MOONEY DAVID J;;SANDS ROGER WARREN;;STERN JOEL;;LI AILEEN W;;DESAI RAJIV;;LU BEVERLY YING,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2016-08-10),https://lens.org/192-267-206-765-611,Patent Application,yes,0,38,2,2,30,A61K45/06;;C07H21/00;;A61K39/0008;;A61K39/0011;;A61K2039/55522;;A61K2039/55561;;A61K2039/55566;;A61K2039/55572;;A61K2039/60;;A61K2039/6018;;A61K2039/6025;;A61K47/543;;A61K47/549;;A61K47/554;;A61K47/64;;A61K47/643;;A61K47/646;;A61P17/10;;A61P37/00;;A61P17/06;;A61P3/08;;A61P31/00;;A61P11/06;;A61P37/06;;A61P17/00;;A61P19/02;;A61P37/08;;A61P1/00;;A61P25/00;;A61P29/00;;A61P35/00;;A61K45/06;;A61K39/00;;C07H21/00;;A61K2039/60;;A61K2039/55566;;A61K39/0011;;A61K47/643;;A61K2039/6025;;A61K2039/55572;;A61K2039/55522;;A61K47/554;;A61K47/543;;A61K39/0008;;A61K2039/6018;;A61K2039/55561;;A61K47/549;;A61K47/64;;A61K47/646;;A61K47/6957;;A61P17/10;;A61P37/00;;A61P17/06;;A61P3/08;;A61P31/00;;A61P11/06;;A61P37/06;;A61P17/00;;A61P19/02;;A61P37/08;;A61P1/00;;A61P25/00;;A61P29/00;;A61P35/00;;A61L27/227;;A61L27/28;;A61L27/54;;A61L2300/416;;A61L2300/426;;A61L2300/43;;A61L2300/432;;A61L2300/45;;A61L2300/606;;A61L2430/02,A61K47/64;;A61K45/06;;A61K47/69;;A61L27/22;;A61L27/28;;A61L27/54;;A61P1/00;;A61P3/08;;A61P11/06;;A61P17/00;;A61P17/06;;A61P17/10;;A61P19/02;;A61P25/00;;A61P29/00;;A61P31/00;;A61P35/00;;A61P37/00;;A61P37/06;;A61P37/08,,0,0,,,,DISCONTINUED
138,WO,A1,WO 2016/161372 A1,099-793-598-389-780,2016-10-06,2016,US 2016/0025717 W,2016-04-01,US 201562145053 P;;US 201562141684 P,2015-04-01,IMMUNOCONJUGATES FOR PROGRAMMING OR REPROGRAMMING OF CELLS,"The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.",HARVARD COLLEGE,MOONEY DAVID J;;SANDS ROGER WARREN;;STERN JOEL N H;;LI WEIWEI AILEEN;;DESAI RAJIV;;LU BEVERLY YING,,https://lens.org/099-793-598-389-780,Patent Application,yes,2,40,2,2,30,A61K45/06;;C07H21/00;;A61K39/0008;;A61K39/0011;;A61K2039/55522;;A61K2039/55561;;A61K2039/55566;;A61K2039/55572;;A61K2039/60;;A61K2039/6018;;A61K2039/6025;;A61K47/543;;A61K47/549;;A61K47/554;;A61K47/64;;A61K47/643;;A61K47/646;;A61P17/10;;A61P37/00;;A61P17/06;;A61P3/08;;A61P31/00;;A61P11/06;;A61P37/06;;A61P17/00;;A61P19/02;;A61P37/08;;A61P1/00;;A61P25/00;;A61P29/00;;A61P35/00;;A61K45/06;;A61K39/00;;C07H21/00;;A61K2039/60;;A61K2039/55566;;A61K39/0011;;A61K47/643;;A61K2039/6025;;A61K2039/55572;;A61K2039/55522;;A61K47/554;;A61K47/543;;A61K39/0008;;A61K2039/6018;;A61K2039/55561;;A61K47/549;;A61K47/64;;A61K47/646;;A61K47/6957;;A61P17/10;;A61P37/00;;A61P17/06;;A61P3/08;;A61P31/00;;A61P11/06;;A61P37/06;;A61P17/00;;A61P19/02;;A61P37/08;;A61P1/00;;A61P25/00;;A61P29/00;;A61P35/00;;A61L27/227;;A61L27/28;;A61L27/54;;A61L2300/416;;A61L2300/426;;A61L2300/43;;A61L2300/432;;A61L2300/45;;A61L2300/606;;A61L2430/02,A61K48/00;;A61K9/00;;A61K39/00;;A61K45/06;;A61P37/04;;C07H21/00,,0,0,,,,PENDING
139,EP,A1,EP 3125866 A1,145-993-538-019-57X,2017-02-08,2017,EP 15773877 A,2015-04-06,US 201461975443 P;;US 201462085898 P;;US 2015/0024540 W,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,,HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,,https://lens.org/145-993-538-019-57X,Patent Application,yes,0,0,12,16,30,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K9/00,,0,0,,,,ACTIVE
140,WO,A8,WO 2015/154082 A8,016-544-723-583-040,2016-03-24,2016,US 2015/0024540 W,2015-04-06,US 201462085898 P;;US 201461975443 P,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,"The present invention provides refillable drug delivery devices. The invention is based in part on the development of systemically administered drug payloads that home to and refill resident, e.g., previously administered/implanted, drug delivery systems, e.g., hydrogel drug delivery systems. In one aspect, the drug delivery depots of the invention are systemically administered, e.g., enterally administered or parenterally administered. The invention provides a method of nanotherapeutic drug delivery, e.g., a DNA nanotechnology-based approach for blood-based drug refilling of intra-tumor drug depots.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,,https://lens.org/016-544-723-583-040,Amended Application,yes,0,0,12,16,0,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K9/00,,0,0,,,,PENDING
141,EP,A4,EP 3125866 A4,074-737-063-235-001,2017-11-15,2017,EP 15773877 A,2015-04-06,US 201461975443 P;;US 201462085898 P;;US 2015/0024540 W,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,,HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,,https://lens.org/074-737-063-235-001,Search Report,no,1,0,12,16,0,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K9/00,,0,0,,,,ACTIVE
142,WO,A1,WO 2015/154082 A1,085-394-778-840-069,2015-10-08,2015,US 2015/0024540 W,2015-04-06,US 201462085898 P;;US 201461975443 P,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,"The present invention provides refillable drug delivery devices. The invention is based in part on the development of systemically administered drug payloads that home to and refill resident, e.g., previously administered/implanted, drug delivery systems, e.g., hydrogel drug delivery systems. In one aspect, the drug delivery depots of the invention are systemically administered, e.g., enterally administered or parenterally administered. The invention provides a method of nanotherapeutic drug delivery, e.g., a DNA nanotechnology-based approach for blood-based drug refilling of intra-tumor drug depots.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,,https://lens.org/085-394-778-840-069,Patent Application,yes,40,23,12,16,0,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K9/00,,54,48,004-515-598-141-332;;021-625-325-400-515;;015-053-586-513-35X;;108-051-768-708-329;;073-818-437-080-787;;096-668-408-953-925;;016-766-003-829-43X;;013-358-880-267-705;;012-494-305-062-316;;043-693-070-677-637;;004-515-598-141-332;;021-625-325-400-515;;015-053-586-513-35X;;025-890-439-540-56X;;076-236-419-580-015;;001-930-100-899-429;;005-253-527-443-068;;017-828-032-710-953;;064-444-260-593-463;;024-279-957-179-302;;000-782-039-824-584;;093-840-684-282-884;;016-138-634-837-113;;033-699-267-863-323;;025-977-229-632-687;;031-134-227-154-118;;074-143-292-410-776;;076-509-804-969-853;;062-434-708-328-288;;118-298-036-524-740;;023-025-970-300-828;;047-474-503-831-747;;013-991-500-734-628;;015-841-302-546-641;;043-576-552-032-302;;007-427-337-722-840;;056-600-377-438-979;;012-533-621-393-108;;053-908-879-659-781;;060-984-021-882-18X;;107-902-146-226-858;;068-631-867-983-723;;040-261-931-800-484;;024-283-506-616-544;;053-889-383-854-435;;038-692-303-174-905;;007-250-238-076-256;;051-193-415-266-438,23618965;;10.1016/j.ijpharm.2013.04.025;;pmc3754779;;23852409;;10.1039/c3nr02049e;;10.3390/s100504381;;22399885;;pmc3292124;;10.1073/pnas.1413027111;;pmc4156738;;25139997;;20195268;;10.1038/nrcardio.2010.14;;10.1248/bpb.b12-01102;;23649331;;19384084;;10.1097/crd.0b013e318199e9b7;;10.1006/jmcc.2000.1329;;11181008;;15173038;;10.1161/01.cir.0000128595.79378.fa;;10.1038/nmat3758;;24150418;;23618965;;10.1016/j.ijpharm.2013.04.025;;pmc3754779;;23852409;;10.1039/c3nr02049e;;10.3390/s100504381;;22399885;;pmc3292124;;10.2147/vhrm.2005.1.4.263;;pmc1993957;;17315599;;10.1161/circinterventions.109.891192;;20716758;;25162537;;10.1016/j.actbio.2014.08.019;;10.1002/adhm.201400095;;24862232;;pmc4227916;;10.1038/nmat3776;;24150417;;19458720;;pmc2688462;;10.1038/nature08016;;10.1038/nature11075;;pmc4238960;;22660323;;22512362;;10.1021/la204863s;;10.1073/pnas.0900717106;;19273855;;pmc2660766;;24141539;;10.1038/nnano.2013.209;;pmc333706;;10.1093/nar/19.4.747;;1850122;;9916931;;pmc1853442;;10.1016/s0002-9440(10)65263-7;;8382790;;pmc309076;;10.1093/nar/21.1.145;;2188993;;10.1016/0165-022x(90)90084-p;;10.1073/pnas.0707090104;;pmc2040404;;17942682;;pmc3687584;;23642228;;10.1021/bc300621n;;23081905;;10.1002/anie.201206703;;20391522;;10.1002/anie.200906294;;pmc2811415;;19538051;;10.1089/cbr.2008.0626;;10.1002/1521-3773(20010601)40:11<2004::aid-anie2004>3.0.co;2-5;;10.1002/1521-3773(20010601)40:11<2004::aid-anie2004>3.3.co;2-x;;11433435;;10.1177/155698450600100501;;10.1097/01.imi.0000240673.14388.fc;;22436750;;10.1073/pnas.1211516109;;pmc3511752;;23150549;;10.1073/pnas.072699999;;pmc122734;;11929981;;10.1002/adma.200305406;;10.1002/1520-6777(2001)20:2<157::aid-nau18>3.0.co;2-a;;11170190;;20570346;;10.1016/j.biomaterials.2010.05.017;;pmc3001248;;10.1177/088391159501000102;;10.1021/nn205073n;;22650310;;pmc3057607;;20217810;;10.1002/adma.200902895;;pmc2895069;;20534561;;10.1073/pnas.1001367107;;20231381;;10.1083/jcb.200910104;;pmc2845077;;10.1073/pnas.0610298104;;17215365;;pmc1783417;;10.1038/nmat3049;;pmc3361766;;21685903;;10.1007/s11095-006-9173-4;;17191092;;10.1016/j.biomaterials.2009.10.052;;19906422;;pmc2813952,"GUO ET AL.: ""Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy"", INT J PHARM., vol. 451, no. 1-2, 22 April 2013 (2013-04-22), pages 1 - 11, XP028556769;;PARK ET AL.: ""Replenishable dendrimer-nanoparticle hybrid membranes for sustained release of therapeutics"", NANOSCALE, vol. 5, no. 17, 7 September 2013 (2013-09-07), pages 7805 - 780, XP055229945;;GAWEL ET AL.: ""Responsive Hydrogels for Label-Free Signal Transduction within Biosensors"", SENSORS, vol. 10, 30 April 2010 (2010-04-30), pages 4381 - 4409, XP002697114;;BRUDNO ET AL.: ""Refilling drug delivery depots through the blood"", PROC NATL ACAD SCI USA, vol. 111, no. 35, 19 August 2014 (2014-08-19), pages 12722 - 12727, XP055229948;;SIMARD T ET AL., THE CANADIAN JOURNAL OF CARDIOLOGY, 2013;;WESSELY R, NATURE REVIEWS. CARDIOLOGY, vol. 7, no. 4, 2010, pages 194 - 203;;IWAMOTO T, BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 36, no. 5, 2013, pages 715 - 718;;ATTANASIO SSNELL J, CARDIOLOGY IN REVIEW, vol. 17, no. 3, 2009, pages 115 - 120;;FREEDMAN SISNER J, JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 33, no. 3, 2001, pages 379 - 393;;LOSORDO DDIMMELER S, CIRCULATION, vol. 109, no. 21, 2004, pages 2487 - 2491;;KEARNEY CMOONEY D, NATURE MATERIALS, vol. 12, no. 11, 2013, pages 1004 - 1017;;GUO ET AL., INT. J. PHARM., vol. 451, no. 1-2, 2013, pages 1 - 11;;PARK ET AL., NANOSCALE, vol. 5, no. 17, 2013, pages 7805 - 7808;;GAWEL ET AL.: ""Responsive Hydrogels for Label-Free Signal Transduction within Biosensors"", SENSORS, vol. 10, 2010, pages 4381 - 4409, XP002697114, doi:10.3390/s100504381;;HTAY ET AL., VASC. HEALTH RISK MANAG., vol. 1.4, 2005, pages 263 - 76;;ABIZAID ET AL., CIRCULATION: CARDIOVASCULAR INTERVENTIONS, vol. 3, 2010, pages 384 - 93;;ONETO ET AL., ACTA BIOMATERIALIA, vol. 10, 2014, pages 5099 - 5105;;CEZAR ET AL., ADVANCED HEALTHCARE MATERIALS, 2014;;ZHAO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 108, 2011, pages 67;;MURA ET AL., NAT. MATERIALS, vol. 12, 2013, pages 991;;DOUGLAS S ET AL., NATURE, vol. 459, no. 7245, 2009, pages 414 - 418;;WEI BDAI MYIN P, NATURE, vol. 485, no. 7400, 2012, pages 623 - 626;;ONOE H ET AL., LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS, vol. 28, no. 21, 2012, pages 8120 - 8126;;GARTNER ZBERTOZZI C, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 106, no. 12, 2009, pages 4606 - 4610;;ZHANG YLU FYAGER KVAN DER LELIE DGANG O, NATURE NANOTECHNOLOGY, vol. 8, no. 11, 2013, pages 865 - 872;;SHAW JKENT KBIRD JFISHBACK JFROEHLER B, NUCLEIC ACIDS RESEARCH, vol. 19, no. 4, 1991, pages 747 - 750;;FLOEGE J ET AL., THE AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 1, 1999, pages 169 - 179;;GAMPER H ET AL., NUCLEIC ACIDS RESEARCH, vol. 21, no. 1, 1993, pages 145 - 150;;CAMPBELL JBACON TWICKSTROM E, JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 20, no. 3, 1990, pages 259 - 267;;BASKIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 16793;;ONETO ET AL., ACTA BIOMATERILIA, 2014;;NEVES ET AL., BIOCONJUGATE CHEMISTRY, vol. 24, 2013, pages 934;;KOO ET AL., ANGEWANDTE CHEMIE, vol. 51, 2012, pages 1 1836;;ROSSIN ET AL., ANGEWANDTE CHEMIE, vol. 49, 2010, pages 3375;;NWE KBRECHBIEL MW, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 24, no. 3, 2009, pages 289 - 302;;KOLB HC ET AL., ANGEW. CHEM. INT. ED., vol. 40, 2001, pages 2004 - 2021;;OTA ET AL., INNOVATIONS, vol. 1, 2006, pages 227 - 231;;BENCHERIF ET AL., PROC. NATL. ACAD. SCI. USA, 2012, pages 19590 - 5;;LEE ET AL., CHEM. REV., vol. 7, pages 1869 - 1879;;HARTGERINK ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 99, 2002, pages 5133 - 5138;;LEE ET AL., ADV. MAT., vol. 15, 2003, pages 1828 - 1832;;NEUROUROLOGY AND URODYNAMICS, vol. 20, no. 2, 2001, pages 157 - 165;;ZHAO LWEIR MXU H, BIOMATERIALS, vol. 31, no. 25, 2010, pages 6502 - 6510;;AL-SHAMKHANI ADUNCAN R, JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, vol. 10, no. 1, 1995, pages 4 - 13;;KODIYAN ASILVA EKIM JAIZENBERG MMOONEY D, ACS NANO, vol. 6, no. 6, 2012, pages 4796 - 4805;;PARK J-H ET AL., ADVANCED MATERIALS (DEERFIELD BEACH, FLA., vol. 22, no. 8, 2010, pages 880 - 885;;PERRAULT SCHAN W, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, no. 25, 2010, pages 11194 - 11199;;RUOSLAHTI EBHATIA SSAILOR M, THE JOURNAL OF CELL BIOLOGY, vol. 188, no. 6, 2010, pages 759 - 768;;SIMBERG D ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 3, 2007, pages 932 - 936;;MALTZAHN G ET AL., NATURE MATERIALS, vol. 10, no. 7, 2011, pages 545 - 552;;RINDERKNECHT ET AL., J. BIOL. CHEM., vol. 253, pages 2768 - 2776;;CHEN ET AL., J. PHARMACEUTICAL RESEARCH, vol. 24, 2006, pages 258;;SILVA ET AL., J. BIOMATERIALS, vol. 31, 2010, pages 1235;;See also references of EP 3125866A4",PENDING
143,JP,A,JP 2017081904 A,154-886-981-117-652,2017-05-18,2017,JP 2016197945 A,2016-10-06,US 201514878578 A,2015-10-08,REFILLABLE DRUG DELIVERY DEVICE AND METHOD OF USING SAME,"PROBLEM TO BE SOLVED: To provide more sustained and controlled release systems of pharmaceutical compositions over a time scale of days, weeks, months or years.SOLUTION: Disclosed is a system comprising a drug delivery device and a drug replenisher, wherein the drug delivery device comprises a carrier and a target recognition moiety and suitable for transplantation in a desired position within a subject body; the drug replenisher contains a pharmaceutical composition and a target; the target and the target recognition moiety form a binary binding pair; the drug replenisher is movable until the target on the drug replenisher binds the target recognition moiety on the drug delivery device; the drug replenisher directly delivers the pharmaceutical composition to the drug delivery device when the target binds the target recognition moiety; and thereby the drug delivery device is replenished. The pharmaceutical composition contains a small molecule or a biological formulation and is bound to the target through a cleavable linker or is directly bound to the target.SELECTED DRAWING: None",HARVARD COLLEGE,YEVGENY BRUDNO;;CATHAL J KEARNEY;;EDUARDO SILVA;;MICHAEL AIZENBERG;;BRIAN KWEE;;RAJIV DESAI;;NEEL S JOSHI;;MOONEY DAVID J,,https://lens.org/154-886-981-117-652,Patent Application,no,1,3,3,16,26,A61K9/0024;;A61K9/06;;A61K47/36;;A61K31/704;;A61P35/00;;A61P35/02;;A61P43/00,A61K9/00;;A61K9/06;;A61K31/704;;A61K45/00;;A61K47/06;;A61K47/10;;A61K47/16;;A61K47/34;;A61K47/36;;A61K47/42;;A61K47/50;;A61P35/00;;A61P35/02;;A61P43/00;;C12N15/09,,2,1,049-245-643-865-862,24198488;;pmc3781713;;10.2147/nsa.s23605,"AL-DUBAI H ET AL.: ""Biocompatible medical implant materials with binding sites for a biodegradable drug-delivery system"", NANOTECHNOLOGY, SCIENCE AND APPLICATIONS, vol. 4, JPN6019010212, 2011, pages 87 - 94, ISSN: 0004321968;;DRUG DELIVERY SYSTEM, vol. Vol. 28, Issue 5, JPN6021036736, 2013, pages 406 - 411, ISSN: 0004595275",PENDING
144,US,A1,US 2016/0114046 A1,041-506-539-435-012,2016-04-28,2016,US 201514878578 A,2015-10-08,US 201514878578 A;;US 2015/0024540 W;;US 201461975443 P;;US 201462085898 P,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,"The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2016-04-12),https://lens.org/041-506-539-435-012,Patent Application,yes,3,18,12,16,26,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K47/36;;A61K9/00;;A61K31/704,,2,1,014-004-161-773-773,10.1177/1078155209355847;;20015925,"LACY et al (Drug Information Handbook (2000), pg. 344-345).;;AL-KOFIDE et al (Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010 Dec;16(4):245-50).",DISCONTINUED
145,EP,B1,EP 3153155 B1,049-780-850-584-515,2021-03-03,2021,EP 16191732 A,2016-09-30,US 201514878578 A,2015-10-08,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,,HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,,https://lens.org/049-780-850-584-515,Granted Patent,yes,3,0,3,16,0,A61K9/0024;;A61K9/06;;A61K47/36;;A61K31/704;;A61P35/00;;A61P35/02;;A61P43/00,A61K9/00;;A61K9/06;;A61K31/00;;A61K47/36,,5,4,108-051-768-708-329;;026-968-967-231-369;;012-000-610-347-251;;049-245-643-865-862,10.1073/pnas.1413027111;;pmc4156738;;25139997;;10.1039/c2cc36589h;;23320254;;10.1002/cmdc.201402527;;25704998;;24198488;;pmc3781713;;10.2147/nsa.s23605,"Y. BRUDNO, E. A. SILVA, C. J. KEARNEY, S. A. LEWIN, A. MILLER, K. D. MARTINICK, M. AIZENBERG, D. J. MOONEY: ""Refilling drug delivery depots through the blood"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 35, 2 September 2014 (2014-09-02), pages 12722 - 12727, XP055229947, ISSN: 0027-8424, DOI: 10.1073/pnas.1413027111;;SANDRA BINAULD, MARTINA H. STENZEL: ""Acid-degradable polymers for drug delivery: a decade of innovation"", CHEMICAL COMMUNICATIONS, ROYAL SOCIETY OF CHEMISTRY, UK, vol. 49, no. 21, 1 January 2013 (2013-01-01), UK , pages 2082 - 2102, XP055232425, ISSN: 1359-7345, DOI: 10.1039/c2cc36589h;;BRUDNO YEVGENY, DESAI RAJIV M., KWEE BRIAN J., JOSHI NEEL S., AIZENBERG MICHAEL, MOONEY DAVID J.: ""In Vivo Targeting through Click Chemistry"", CHEMMEDCHEM COMMUNICATIONS, WILEY-VCH, DE, vol. 10, no. 4, 1 April 2015 (2015-04-01), DE , pages 617 - 620, XP055890488, ISSN: 1860-7179, DOI: 10.1002/cmdc.201402527;;HAIFA AL-DUBAI, GISELA PITTNER, FRANZ GABOR: ""Biocompatible medical implant materials with binding sites for a biodegradable drug-delivery system"", NANOTECHNOLOGY, SCIENCE AND APPLICATIONS, vol. 2011, no. 4, pages 87 - 94, XP055300987, DOI: 10.2147/NSA.S23605;;RON M. VERSTEEGEN, RAFFAELLA ROSSIN, WOLTER TEN HOEVE, HENK M. JANSSEN, MARC S. ROBILLARD: ""Click to Release: Instantaneous Doxorubicin Elimination upon Tetrazine Ligation"", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, ¬VERLAG CHEMIE| :, vol. 52, no. 52, 23 December 2013 (2013-12-23), pages 14112 - 14116, XP055105238, ISSN: 14337851, DOI: 10.1002/anie.201305969",INACTIVE
146,EP,B1,EP 3125866 B1,044-011-855-436-652,2021-03-03,2021,EP 15773877 A,2015-04-06,US 201461975443 P;;US 201462085898 P;;US 2015/0024540 W,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,,HARVARD COLLEGE,KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J;;BRUDNO YEVGENY,,https://lens.org/044-011-855-436-652,Granted Patent,yes,4,0,12,16,0,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K9/00,,3,2,077-681-889-128-586;;001-930-100-899-429,21141861;;pmc3016050;;10.1021/ja1083909;;25162537;;10.1016/j.actbio.2014.08.019,"JANEK SZYCHOWSKI ET AL: ""Cleavable Biotin Probes for Labeling of Biomolecules via Azide-Alkyne Cycloaddition"", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, no. 51, 29 December 2010 (2010-12-29), pages 18351 - 18360, XP055029467, ISSN: 0002-7863, DOI: 10.1021/ja1083909;;ENRIQUE LALLANA OZORES ET AL: ""Click Chemistry with Polymers, Dendrimers, and Hydrogels for Drug Delivery Methods for the simplification of the NMR of complex mixtures and pseudo separations View project Dendrimers for biomedical applications View project"", 25 January 2012 (2012-01-25), XP055598051, Retrieved from the Internet <URL:file:///C:/Users/HS51195/Downloads/art3A10.10072Fs11095-012-0683-y.pdf> [retrieved on 20190619], DOI: 10.1007/s11095-012-0683-y.Source:;;JOS? M. MEJ?A ONETO ET AL: ""Implantable biomaterial based on click chemistry for targeting small molecules"", ACTA BIOMATERIALIA, vol. 10, no. 12, 24 August 2014 (2014-08-24), AMSTERDAM, NL, pages 5099 - 5105, XP055301001, ISSN: 1742-7061, DOI: 10.1016/j.actbio.2014.08.019",ACTIVE
147,WO,A1,WO 2021/181360 A1,056-893-747-811-091,2021-09-16,2021,IB 2021052090 W,2021-03-12,IN 202021010832 A,2020-03-13,NOVEL SALTS OF QUINOLONE COMPOUNDS,The present invention relates to novel pharmaceutically acceptable salts of formula (Ia). The invention is also related to process for the preparation of the said novel salts and pharmaceutical composition of the same. Compounds of the present invention are prolyl hydroxylase inhibitors and are suitable for the treatment of anemia.,CADILA HEALTHCARE LTD,SHARMA RAJIV;;NAIR RANJEET;;SHAH KALPESH A;;CHAUHAN RAKESH;;CHAUBEY VIPIN;;PANDYA VRAJESH;;DESAI RANJIT;;JAIN MUKUL;;JOHARAPURKAR AMIT,,https://lens.org/056-893-747-811-091,Patent Application,yes,4,1,2,2,0,C07D215/58;;C07D207/16;;A61P7/06;;C07C279/26;;C07C275/02,C07D215/00;;A61K31/33;;A61K31/395;;C07D215/58;;C07D215/60,,1,1,090-824-007-877-021,31112954;;10.1159/000500232,"PARMAR DEVEN V.ET AL.: ""Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study"", AMERICAN JOURNAL OF NEPHROLOGY, vol. 49, no. 6, 21 May 2019 (2019-05-21), pages 470 - 478, DOI: 10.1159/000500232",PENDING
148,US,A1,US 2016/0220686 A1,101-489-952-390-48X,2016-08-04,2016,US 201615097092 A,2016-04-12,US 201615097092 A;;US 201514878578 A;;US 2015/0024540 W;;US 201461975443 P;;US 201462085898 P,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,"The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2016-04-12),https://lens.org/101-489-952-390-48X,Patent Application,yes,3,10,12,16,26,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K47/48;;A61K9/00;;A61K31/704,,1,0,,,"provisional application 61/836,800 (06/19/2013)",DISCONTINUED
149,ES,T3,ES 2874930 T3,181-971-668-342-314,2021-11-05,2021,ES 16191732 T,2016-09-30,US 201514878578 D,2015-10-08,Dispositivos recargables de administración de fármacos y procedimientos de uso de los mismos,"Un sistema que comprende un dispositivo de administración de fármacos y una recarga de fármaco, en el que el dispositivo de administración de fármacos comprende un vehículo y un resto de reconocimiento de la diana y es adecuado para su implantación en una localización deseable dentro de un sujeto; en el que la recarga de fármaco comprende una composición farmacéutica y una diana, en el que la composición farmacéutica se une a la diana por medio de un conector escindible que se puede escindir dentro del sujeto; en el que la diana y el resto de reconocimiento de la diana forman un par de unión de dos componentes; en el que la recarga de fármaco es móvil hasta que la diana en la recarga de fármaco se une al resto de reconocimiento de la diana en el dispositivo de administración de fármacos; en el que tras la unión de la diana al resto de reconocimiento de la diana, la recarga de fármaco administra la composición farmacéutica directamente al dispositivo de administración de fármacos, recargando de este modo el dispositivo de administración de fármacos; y en el que la composición farmacéutica se libera en la localización deseable dentro del sujeto de manera controlada sobre una escala de tiempo de días, semanas, meses o años, tras la escisión del conector escindible.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,,https://lens.org/181-971-668-342-314,Granted Patent,no,0,0,1,1,0,,A61K9/00;;A61K9/06;;A61K31/00;;A61K47/36,,0,0,,,,ACTIVE
150,US,A1,US 2017/0119892 A1,183-361-298-262-257,2017-05-04,2017,US 201515300880 A,2015-04-06,US 201515300880 A;;US 201461975443 P;;US 201462085898 P;;US 2015/0024540 W,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,"The present invention provides refillable drug delivery devices. The invention is based in part on the development of systemically administered drug payloads that home to and refill resident, e.g., previously administered/implanted, drug delivery systems, e.g., hydrogel drug delivery systems. In one aspect, the drug delivery depots of the invention are systemically administered, e.g., enterally administered or parenterally administered. The invention provides a method of nanotherapeutic drug delivery, e.g., a DNA nanotechnology-based approach for blood-based drug refilling of intra-tumor drug depots.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2015-05-04),https://lens.org/183-361-298-262-257,Patent Application,yes,3,4,12,16,30,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61B10/00;;A61K9/06;;A61K31/704;;A61K49/00;;C12N15/113,,7,6,017-301-508-377-64X;;048-028-500-416-78X;;000-715-235-416-254;;057-899-534-485-601;;118-298-036-524-740;;049-245-643-865-862,16928810;;10.1158/1535-7163.mct-06-0141;;22154931;;10.1016/j.jconrel.2011.11.031;;pmc3878823;;10699706;;10.1016/s0378-5173(99)00409-3;;12877480;;10.1039/b304251k;;23081905;;10.1002/anie.201206703;;24198488;;pmc3781713;;10.2147/nsa.s23605,"Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Molecular cancer therapeutics. 2006 Aug;5(8):1909-17. (Year: 2006);;Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. Journal of controlled release. 2012 Apr 10;159(1):14-26. (Year: 2012);;Coester, C., et al. ""Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA)."" International journal of pharmaceutics 196.2 (2000): 147-149.;;Gillies, Elizabeth R., and Jean MJ Fréchet. ""A new approach towards acid sensitive copolymer micelles for drug delivery."" Chemical Communications 14 (2003): 1640-1641.;;Koo, Heebeom, et al. ""Bioorthogonal Copper‐Free Click Chemistry In Vivo for Tumor‐Targeted Delivery of Nanoparticles."" Angewandte Chemie International Edition 51.47 (2012): 11836-11840.;;Al-Dubai, Haifa, et al. ""Biocompatible medical implant materials with binding sites for a biodegradable drug-delivery system."" Nanotechnology, science and applications 4 (2011): 87.;;Johansson, Henrik, and Daniel Sejer Pedersen. ""Azide‐and Alkyne‐Derivatised α‐Amino Acids."" European Journal of Organic Chemistry 2012.23 (2012): 4267-4281.",PENDING
151,EP,A1,EP 3153155 A1,168-501-930-964-171,2017-04-12,2017,EP 16191732 A,2016-09-30,US 201514878578 A,2015-10-08,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,"The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.
",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL S;;MOONEY DAVID J,,https://lens.org/168-501-930-964-171,Patent Application,yes,4,1,3,16,26,A61K9/0024;;A61K9/06;;A61K31/704;;A61K47/36;;A61P35/00;;A61P35/02;;A61P43/00,A61K9/00;;A61K9/06;;A61K31/00;;A61K47/36,,46,42,049-245-643-865-862;;004-515-598-141-332;;029-109-750-662-882;;073-818-437-080-787;;096-668-408-953-925;;016-766-003-829-43X;;013-358-880-267-705;;012-494-305-062-316;;043-693-070-677-637;;015-841-302-546-641;;043-576-552-032-302;;026-144-573-593-998;;055-437-037-993-534;;060-984-021-882-18X;;107-902-146-226-858;;005-253-527-443-068;;017-828-032-710-953;;064-444-260-593-463;;024-279-957-179-302;;000-782-039-824-584;;093-840-684-282-884;;016-138-634-837-113;;033-699-267-863-323;;025-977-229-632-687;;031-134-227-154-118;;074-143-292-410-776;;076-509-804-969-853;;062-434-708-328-288;;118-298-036-524-740;;023-025-970-300-828;;047-474-503-831-747;;013-991-500-734-628;;033-699-267-863-323;;024-876-489-911-376;;008-432-033-930-280;;012-982-014-480-684;;093-605-874-287-838;;054-773-061-022-099;;007-250-238-076-256;;051-193-415-266-438;;026-968-967-231-369;;049-245-643-865-862,24198488;;pmc3781713;;10.2147/nsa.s23605;;23618965;;10.1016/j.ijpharm.2013.04.025;;24286961;;10.1016/j.cjca.2013.09.012;;20195268;;10.1038/nrcardio.2010.14;;10.1248/bpb.b12-01102;;23649331;;19384084;;10.1097/crd.0b013e318199e9b7;;10.1006/jmcc.2000.1329;;11181008;;15173038;;10.1161/01.cir.0000128595.79378.fa;;10.1038/nmat3758;;24150418;;10.1177/155698450600100501;;10.1097/01.imi.0000240673.14388.fc;;22436750;;10.1073/pnas.1211516109;;pmc3511752;;23150549;;10.1021/bm0257412;;12857069;;17126395;;10.1016/j.biomaterials.2006.11.002;;10.1177/088391159501000102;;10.1021/nn205073n;;22650310;;10.1002/adhm.201400095;;24862232;;pmc4227916;;10.1038/nmat3776;;24150417;;19458720;;pmc2688462;;10.1038/nature08016;;10.1038/nature11075;;pmc4238960;;22660323;;22512362;;10.1021/la204863s;;10.1073/pnas.0900717106;;19273855;;pmc2660766;;24141539;;10.1038/nnano.2013.209;;pmc333706;;10.1093/nar/19.4.747;;1850122;;9916931;;pmc1853442;;10.1016/s0002-9440(10)65263-7;;8382790;;pmc309076;;10.1093/nar/21.1.145;;2188993;;10.1016/0165-022x(90)90084-p;;10.1073/pnas.0707090104;;pmc2040404;;17942682;;pmc3687584;;23642228;;10.1021/bc300621n;;23081905;;10.1002/anie.201206703;;20391522;;10.1002/anie.200906294;;pmc2811415;;19538051;;10.1089/cbr.2008.0626;;10.1002/1521-3773(20010601)40:11<2004::aid-anie2004>3.0.co;2-5;;10.1002/1521-3773(20010601)40:11<2004::aid-anie2004>3.3.co;2-x;;11433435;;pmc333706;;10.1093/nar/19.4.747;;1850122;;10699287;;10.1016/s0168-3659(99)00248-5;;11587588;;10.1021/bp010070p;;10.1016/s0142-9612(01)00003-5;;11519782;;10.1021/nn202070n;;21967065;;pmc3445465;;10.1371/journal.pone.0045191;;23028839;;10.1007/s11095-006-9173-4;;17191092;;10.1016/j.biomaterials.2009.10.052;;19906422;;pmc2813952;;10.1039/c2cc36589h;;23320254;;24198488;;pmc3781713;;10.2147/nsa.s23605,"HAIFA AL-DUBAI ET AL: ""Biocompatible medical implant materials with binding sites for a biodegradable drug-delivery system"", NANOTECHNOLOGY, SCIENCE AND APPLICATIONS, 1 October 2011 (2011-10-01), pages 87, XP055300987, DOI: 10.2147/NSA.S23605;;GUO HUA ET AL: ""Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 451, no. 1, 22 April 2013 (2013-04-22), pages 1 - 11, XP028556769, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2013.04.025;;SIMARD T ET AL., THE CANADIAN JOURNAL OF CARDIOLOGY, vol. 30, no. 1, 2014, pages 34 - 45;;WESSELY R, NATURE REVIEWS CARDIOLOGY, vol. 7, no. 4, 2010, pages 194 - 203;;IWAMOTO T, BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 36, no. 5, 2013, pages 715 - 718;;ATTANASIO S; SNELL J, CARDIOLOGY REV, vol. 17, no. 3, 2009, pages 115 - 120;;FREEDMAN S; ISNER J, JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 33, no. 3, 2001, pages 379 - 393;;LOSORDO D; DIMMELER S, CIRCULATION, vol. 109, no. 21, 2004, pages 2487 - 2491;;KEARNEY C; MOONEY D, NATURE MATERIALS, vol. 12, no. 11, 2013, pages 1004 - 1017;;OTA ET AL., INNOVATIONS, vol. 1, 2006, pages 227 - 231;;BENCHERIF ET AL., PROC. NATL. ACAD. SCI. USA, vol. 109.48, 2012, pages 19590 - 5;;WT BRINKMAN ET AL., BIOMACROMOLECULES, vol. 4, no. 4, 2003, pages 890 - 895;;W. RYU ET AL., BIOMATERIALS, vol. 28, no. 6, 2007, pages 1174 - 1184;;WRIGHT, PAUL K.: ""21st Century manufacturing"", 2001, PRENTICE-HALL INC.;;C. CHOI, NEW SCIENTIST, vol. 25, 2003, pages V2379;;AL-SHAMKHANI A; DUNCAN R, JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, vol. 10, no. 1, 1995, pages 4 - 13;;KODIYAN A ET AL., ACS NANO, vol. 6, no. 6, 2012, pages 4796 - 4805;;CEZAR ET AL., ADVANCED HEALTHCARE MATERIALS, 2014;;ZHAO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 108, 2011, pages 67;;MURA ET AL., NAT. MATERIALS, vol. 12, 2013, pages 991;;DOUGLAS S ET AL., NATURE, vol. 459, no. 7245, 2009, pages 414 - 418;;WEI B; DAI M; YIN P, NATURE, vol. 485, no. 7400, 2012, pages 623 - 626;;ONOE H ET AL., LANGMUIR, vol. 28, no. 21, 2012, pages 8120 - 8126;;GARTNER Z; BERTOZZI C, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 106, no. 12, 2009, pages 4606 - 4610;;ZHANG Y ET AL., NATURE NANOTECHNOLOGY, vol. 8, no. 11, 2013, pages 865 - 872;;SHAW J ET AL., NUCLEIC ACIDS RESEARCH, vol. 19, no. 4, 1991, pages 747 - 750;;FLOEGE J ET AL., THE AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 1, 1999, pages 169 - 179;;GAMPER H ET AL., NUCLEIC ACIDS RESEARCH, vol. 21, no. 1, 1993, pages 145 - 150;;CAMPBELL J ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 20, no. 3, 1990, pages 259 - 267;;BASKIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 16793;;ONETO ET AL., ACTA BIOMATERILIA, 2014;;NEVES ET AL., BIOCONJUGATE CHEMISTRY, vol. 24, 2013, pages 934;;KOO ET AL., ANGEWANDTE CHEMIE, vol. 51, 2012, pages 11836;;ROSSIN ET AL., ANGEWANDTE CHEMIE, vol. 49, 2010, pages 3375;;NWE K; BRECHBIEL MW, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 24, no. 3, 2009, pages 289 - 302;;KOLB HC ET AL., ANGEW. CHEM. INT. ED., vol. 40, 2001, pages 2004 - 2021;;SHAW J; KENT K; BIRD J; FISHBACK J; FROEHLER B, NUCLEIC ACIDS RESEARCH, vol. 19, no. 4, 1991, pages 747 - 750;;MAEDA H; WU J; SAWA T; MATSUMURA Y; & HORI K, JOURNAL OF CONTROLLED RELEASE: OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY, vol. 65, no. 1-2, 2000, pages 271 - 284;;BOUHADIR K ET AL., BIOTECHNOLOGY PROGRESS, vol. 17, no. 5, 2001, pages 945 - 950;;BOUHADIR K; ALSBERG E; MOONEY D, BIOMATERIALS, vol. 22, no. 19, 2001, pages 2625 - 2633;;CHOI K ET AL., ACS NANO, vol. 5, no. 11, 2011, pages 8591 - 8599;;TIEN J; TRUSLOW J; NELSON C, PLOS ONE, vol. 7, no. 9, 2012;;CHEN ET AL., J. PHARMACEUTICAL RESEARCH, vol. 24, 2006, pages 258;;SILVA ET AL., J. BIOMATERIALS, vol. 31, 2010, pages 1235;;SANDRA BINAULD ET AL: ""Acid-degradable polymers for drug delivery: a decade of innovation"", CHEMICAL COMMUNICATION, vol. 49, no. 21, 1 January 2013 (2013-01-01), pages 2082, XP055232425;;HAIFA AL-DUBAI ET AL: ""Biocompatible medical implant materials with binding sites for a biodegradable drug-delivery system"", NANOTECHNOLOGY, SCIENCE AND APPLICATIONS, vol. 2011, no. 4, 1 October 2011 (2011-10-01), pages 87, XP055300987",INACTIVE
152,WO,A1,WO 2024/028795 A1,056-928-989-725-820,2024-02-08,2024,IB 2023057846 W,2023-08-03,IN 202221044573 A,2022-08-04,HETEROBICYCLIC COMPOUNDS AS ORAL GLP1R AGONISTS,"The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon like peptide 1 receptor.",ZYDUS LIFESCIENCES LTD,MAITI PRANAB;;SHARMA RAJIV;;NAGASWAMY KUMARAGURUBARAN;;KANDRE SHIVAJI SADASHIV;;SONI KRUNAL GIRISHBHAI;;BAROT JAYMINKUMAR;;RAVANI ANKITA;;DESAI JIGAR;;KUMAR SANJAY,,https://lens.org/056-928-989-725-820,Patent Application,yes,1,0,1,1,0,A61K31/4184;;A61P3/04;;A61P3/10;;C07D401/04;;C07D401/14;;C07D413/14;;C07D471/04,A61K31/4184;;A61P3/04;;A61P3/10;;C07D401/04;;C07D401/14;;C07D413/14;;C07D471/04,,0,0,,,,PENDING
153,TW,A,TW 202200547 A,004-854-644-796-484,2022-01-01,2022,TW 110108938 A,2021-03-12,IN 202021010832 A,2020-03-13,Novel salts of quinolone compounds,Present invention relates to novel pharmaceutically acceptable salts of formula (Ia). Invention is also related to process for the preparation of the said novel salts and pharmaceutical composition of the same. Compounds and of the present invention are prolyl hydroxylase inhibitors and are suitable for the treatment of anemia.,CADILA HEALTHCARE LTD,SHARMA RAJIV;;NAIR RANJEET;;SHAH KALPESH A;;CHAUHAN RAKESH;;CHAUBEY VIPIN;;PANDYA VRAJESH;;DESAI RANJIT C;;JAIN MUKUL R;;JOHARAPURKAR AMIT,,https://lens.org/004-854-644-796-484,Patent of Addition,no,0,0,2,2,0,C07D215/58;;C07D207/16;;A61P7/06;;C07C279/26;;C07C275/02,C07D215/60;;A61K31/47;;A61P7/06,,0,0,,,,PENDING
154,US,A1,US 2019/0359574 A1,138-594-965-617-759,2019-11-28,2019,US 201916421671 A,2019-05-24,IN 201821019633 A;;IN 201821049821 A,2018-05-25,PROCESS FOR THE PREPARATION OF QUINOLONE BASED COMPOUNDS,The present invention relates to an improved process for the preparation of quinolone based compounds of general formula (I) using intermediate compound of general formula (XII). Invention also provides an improved process for the preparation of compound of formula (I-a) using intermediate compound of formula (XII-a) and some novel impurities generated during process. Compounds prepared using this process can be used to treat anemia.,CADILA HEALTHCARE LTD,DESAI RANJIT C;;SHARMA RAJIV;;PANDYA VRAJESH;;SHAH KALPESH;;PATEL SUNIL;;CHAUHAN RAKESH;;NAIR RANJEET;;JOSHI VIVEK;;PATEL MANOJ;;SHUKLA MRIGENDRA,ZYDUS LIFESCIENCES LIMITED (2019-05-27),https://lens.org/138-594-965-617-759,Patent Application,yes,0,8,2,2,0,C07D215/56;;C07D215/58;;C07C229/56;;C07C291/02;;C07C291/04;;C07C239/20;;C07C2601/02;;C07C235/74;;C07C233/54;;C07D215/56;;C07D215/58,C07D215/58;;C07D215/56,,0,0,,,,ACTIVE
155,US,B2,US 10899713 B2,198-351-668-567-660,2021-01-26,2021,US 201916421671 A,2019-05-24,IN 201821019633 A;;IN 201821049821 A,2018-05-25,Process for the preparation of quinolone based compounds,The present invention relates to an improved process for the preparation of quinolone based compounds of general formula (I) using intermediate compound of general formula (XII). Invention also provides an improved process for the preparation of compound of formula (I-a) using intermediate compound of formula (XII-a) and some novel impurities generated during process. Compounds prepared using this process can be used to treat anemia.,CADILA HEALTHCARE LTD,DESAI RANJIT C;;SHARMA RAJIV;;PANDYA VRAJESH;;SHAH KALPESH;;PATEL SUNIL;;CHAUHAN RAKESH;;NAIR RANJEET;;JOSHI VIVEK;;PATEL MANOJ;;SHUKLA MRIGENDRA,ZYDUS LIFESCIENCES LIMITED (2019-05-27),https://lens.org/198-351-668-567-660,Granted Patent,yes,4,0,2,2,0,C07D215/56;;C07D215/58;;C07C229/56;;C07C291/02;;C07C291/04;;C07C239/20;;C07C2601/02;;C07C235/74;;C07C233/54;;C07D215/56;;C07D215/58,C07D215/58;;C07D215/56,,0,0,,,,ACTIVE
156,US,A1,US 2020/0197526 A1,149-603-547-206-691,2020-06-25,2020,US 201916705672 A,2019-12-06,US 201916705672 A;;US 201615097092 A;;US 201514878578 A;;US 2015/0024540 W;;US 201461975443 P;;US 201462085898 P,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,"The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO ALEXANDRE BARROS E;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2015-05-04),https://lens.org/149-603-547-206-691,Patent Application,yes,0,0,12,16,26,A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61P17/02;;A61P31/00;;A61P35/00;;A61P35/02;;A61P9/00;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K47/54;;A61K9/00;;A61K9/06;;A61K31/704;;A61K47/36;;A61K47/69;;A61K49/00;;C12N15/113,,0,0,,,,DISCONTINUED
157,US,A1,US 2022/0401562 A1,172-319-514-362-79X,2022-12-22,2022,US 202217569720 A,2022-01-06,US 202217569720 A;;US 201916705672 A;;US 201615097092 A;;US 201514878578 A;;US 2015/0024540 W;;US 201461975443 P;;US 201462085898 P,2014-04-04,REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF,"The present invention provides refillable drug delivery systems, as well as methods of refilling the systems, and methods of using them to treat diseases.",HARVARD COLLEGE,BRUDNO YEVGENY;;KEARNEY CATHAL J;;SILVA EDUARDO ALEXANDRE BARROS E;;AIZENBERG MICHAEL;;KWEE BRIAN;;DESAI RAJIV;;JOSHI NEEL SATISH;;MOONEY DAVID J,PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2015-05-04),https://lens.org/172-319-514-362-79X,Patent Application,yes,0,0,1,16,26,A61K31/704;;A61K9/06;;A61K47/61;;A61K47/6903;;A61K47/555;;A61K9/0024;;A61K9/06;;A61K47/549;;A61K47/555;;A61K47/6903;;A61K47/36;;A61K31/704;;A61K49/0021;;A61K49/0054;;C12N15/113;;C12N2310/113;;C12N2310/315;;C12N2310/351;;C12N2320/32,A61K47/54;;A61K9/00;;A61K9/06;;A61K31/704;;A61K47/36;;A61K47/69;;A61K49/00;;C12N15/113,,0,0,,,,PENDING
